目次

2.7.4 臨床的安全性 3
2.7.4.1 医薬品への曝露 3
2.7.4.2 有害事象 14
2.7.4.3 臨床検査値の評価 43
2.7.4.4 バイタルサイン、身体的所見及び安全性に関連する他の観察項目 43
2.7.4.5 特別な患者集団及び状況下における安全性 46
2.7.4.6 市販後データ 49
2.7.4.7 付録 50

Confidential

表 2.7.4-1. 臨床的安全性の概要で用いた略語一覧

略語又は用語	略さない表現又は定義
ADR	Adverse drug reaction（薬物有害反応）
AE	Adverse Event（有害事象）
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use（医薬品規制調和国際会議）
MedDRA	The medical dictionary for regulatory activities（ICH で開発された国際医学用語集）
OAG	Open-angle glaucoma（開放隅角緑内障）
OHT	Ocular Hypertension（高眼圧症）
POAG	Primary open-angle glaucoma（原発開放隅角緑内障）
PT	Preferred Term（基本語）
SAE	Serious Adverse Event（重篤有害事象）
SAR	Suspected Adverse Reaction（副作用が疑われる事象） 本剤の臨床試験では、副作用と同義であることから、本文中の記載は副作用とした。
SD	Standard deviation（標準偏差）
STN1012600 点眼液	有効成分としてセペタプロストを含有する点眼液（本資料中、「ONO-9054 点眼液」又は「DE-126 点眼液」と表記される場合もある。）
SOC	System Organ Class（器官別大分類）
TEAE	Treatment-Emergent Adverse Event（投与期間中に生じた有害事象）

2.7.4 臨床的安全性

2.7.4.1 医薬品への曝露

2.7.4.1.1 総括的安全性評価計画及び安全性試験の記述

安全性を評価した臨床試験の一覧を表 2.7.4.1-1 に示した。

STN1012600 点眼液の安全性の評価は、健康成人男性を対象とした国内第 I 相 PK 試験 (101260007LT) 、原発開放隅角緑内障又は高眼圧症を対象とした国際共同後期第 II 相試験 (012601IN) 及び国内第 III 相検証試験 (101260005LT) 、原発開放隅角緑内障（広義）（原発開放隅角緑内障又は正常眼圧緑内障）、偽落屑緑内障、色素性緑内障又は高眼圧症を対象とした国内第 III 相長期投与試験 (101260006LT) の結果に基づき実施した。ただし、健康成人を対象とした第 I 相 PK 試験 (101260007LT) の安全性については 2.7.4.5.9 に記載した。

表 2.7.4.1-1. 安全性を評価した臨床試験の一覧

試験名（治験実施計画書番号）	デザイン（実施国）	対象（人種）	治験使用薬（用法用量）	安全性解析対象集団	安全性評価項目
第 I 相 PK 試験 (101260007LT)	単一施設、非遮蔽、単群試験（日本）	健康成人男性（日本人）	・0.002% STN1012600 点眼液（1 回 1 滴、1 日 1 回、両眼点眼）	8 例	・有害事象及び副作用 ・12 誘導心電図
国際共同後期第 II 相試験 (012601IN)	多施設、無作為化、評価者遮蔽、並行群間比較試験（日本/アメリカ）	POAG OHT（日本人/非日本人）	・0.0005%, 0.001%, 0.002%, 0.003% STN1012600 点眼液（1 回 1 滴、1 日 1 回、両眼点眼） ・プラセボ点眼液（1 回 1 滴、1 日 1 回、両眼点眼） ・0.005%ラタノプロスト点眼液（1 回 1 滴、1 日 1 回、両眼点眼）	241 例（日本人 114 例）	・有害事象 ・矯正視力 ・眼症状 ・細隙灯顕微鏡検査 ・眼底検査 ・中心角膜厚 ・写真による虹彩の色／睫毛／眼瞼 ・血圧・脈拍数 ・臨床検査

Confidential

試験名 （治験実施計画書番号）	デザイン （実施国）	対象 （人種）	治験使用薬 （用法用量）	安全性解析対象集団	安全性評価項目
第 III 相検証試験 (101260005LT)	多施設、無作為化、評価者遮蔽、並行群間比較試験 （日本）	POAG OHT （日本人）	・0.002% STN1012600 点眼液 （1 回 1 滴、1 日 1 回、両眼点眼） ・0.005% ラタノプロスト点眼液 （1 回 1 滴、1 日 1 回、両眼点眼）	325 例	・有害事象 ・眼科的検査（視力検査、細隙灯顕微鏡検査） ・血圧・脈拍数
第 III 相長期投与試験 (101260006LT)	多施設、無作為化、非遮蔽、並行群間比較試験 （日本）	OAG OHT （日本人）	・0.002% STN1012600 点眼液 （1 回 1 滴、1 日 1 回、両眼点眼） ・0.5%チモロール点眼液 （1 回 1 滴、1 日 2 回、両眼点眼）	131 例	・有害事象 ・臨床検査値 ・血圧・脈拍数 ・眼科的検査（視力検査、細隙灯顕微鏡検査、中心角膜厚、虹彩／睫毛／眼瞼の変化）

2.7.4.1.1.1　　安全性の評価方法

(1)　有害事象

1)　有害事象の定義

安全性を評価したすべての試験において、すべての治験使用薬点眼開始から最終規定来院日又は治療期中止時までに治験使用薬を投与された被験者に生じたすべての好ましくない又は意図しない疾病又はその徴候（臨床検査値の異常を含む）とし、治験使用薬との因果関係の有無は問わなかった。ただし、対象疾患の症状の自然な変動は有害事象としなかった。また、治験使用薬との因果関係ありと判断されたものを副作用とした。

なお、国内 3 試験（101260007LT、101260005LT、101260006LT）においては、表 2.7.4.1-2 に示す臨床検査値の異常を有害事象とする際の基準を設定した（012601IN 試験では基準を設定しなかった）。

Confidential

表 2.7.4.1-2. 臨床検査値の異常を有害事象とする際の基準

1) 臨床検査値の異常が重篤な有害事象の定義に該当する場合
2) 臨床検査値の異常により治験使用薬の処置（減量、休薬、中止）が必要になった場合
3) 臨床検査値の異常により内科的治療・外科的治療が必要になった場合
4) 上記には該当しないが臨床検査値の異常が医学的に注目すべきものと医師が判断した場合

2) 有害事象の重症度の基準

国内3試験（101260007LT、101260005LT、101260006LT）においては、以下の基準とした。

軽　度：容易に忍容できる程度

中等度：日常生活に影響を及ぼす程度

高　度：日常生活ができない程度

国際共同試験（012601IN試験）においては、以下の基準とした。

軽　度：日常生活に影響なし、医学的介入／治療の必要はない。

中等度：被験者の日常生活に影響がある可能性がある。医学的介入／治療の必要はない又はわずかにしかない。

高　度：被験者の日常生活にかなりの影響がある。医学的介入／治療の必要がある。

3) 重篤な有害事象の定義

1. 死に至るもの
2. 生命を脅かすもの
3. 治療のため入院又は入院の延長が必要となるもの
4. 失明等永続的又は顕著な障害・機能不全に陥るもの
5. 先天異常を来たすもの
6. その他の重大な医学的事象

4) 有害事象の治験使用薬との因果関係の定義

有害事象が発現した場合、治験責任医師・治験分担医師はその有害事象が治験使用薬によって発現した合理的な可能性があるか判断した。合理的な可能性とは、治験使用薬と有害事象の間の因果関係を示す根拠があることとした。合理的な可能性がありの場合を因果関係ありと扱い、それ以外の場合を因果関係なしと扱った。

Confidential

(2) 有害事象名のコーディング

症例報告書で収集した個々の有害事象は MedDRA Ver.25.0 の器官別大分類（SOC）及び基本語（PT）を用いて分類した。

(3) 併合解析の集計方法

STN1012600 点眼液を 4 週間投与した時の日本人での安全性を検討する目的で、012601IN 試験の日本人及び 101260005LT 試験（計 439 例）について併合解析を実施した。

併合解析の集計方法を表 2.7.4.1-3 に示した。

表 2.7.4.1-3. 併合解析の集計方法

併合解析	集団	使用データ（投与期間）
012601IN 試験の日本人及び 101260005LT 試験	Placebo to 0.003% P2*	012601IN 試験 Placebo to 0.003%群日本人の 0.003% STN1012600 点眼液投与期間（48 日間）
	0.005% Latanoprost	012601IN 試験 ラタノプロスト群日本人（3 ヵ月間）、101260005LT 試験 ラタノプロスト群（3 ヵ月間）
	0.0005% STN1012600	012601IN 試験 0.0005% STN1012600 群日本人（3 ヵ月間）
	0.001% STN1012600	012601IN 試験 0.001% STN1012600 群日本人（3 ヵ月間）
	0.002% STN1012600	012601IN 試験 0.002% STN1012600 群日本人（3 ヵ月間）、101260005LT 試験 0.002% STN1012600 群（3 ヵ月間）
	0.003% STN1012600	012601IN 試験 0.003% STN1012600 群日本人（3 ヵ月間）

* Placebo to 0.003% 群は、Week 6 までプラセボ点眼液を投与し、その後 0.003% STN1012600 点眼液を Month 3 まで投与した。

本集団は、0.003% STN1012600 点眼液投与期間中の有害事象を集計した。

2.7.4.1.2 全般的な曝露状況

安全性を評価したすべての試験において、STN1012600 点眼液の用法・用量は 1 回 1 滴、1 日 1 回、両眼点眼であった。

試験ごとの治験使用薬が投与された期間を表 2.7.4.1-4 (101260007LT) 、表 2.7.4.1-5 (012601IN) 、表 2.7.4.1-6 (101260005LT) 及び表 2.7.4.1-7 (101260006LT) に示した。

各試験における平均投与期間（平均値±標準偏差）は、101260007LT 試験で 7.0±0.00 日、012601IN 試験で 88.5±11.67 日、101260005LT 試験で 85.1±14.19 日、101260006LT 試験で 345.1±68.87 日であった。

表 2.7.4.1-4. 治験使用薬が投与された期間（101260007LT: 安全性解析対象集団）

	0.002% STN1012600 (N=8)
Duration of Exposure to Treatment (days)	
N	8
Mean (SD)	7.0 (0.00)
Median	7.0
Min, Max	7, 7

Cross Reference: 添付資料 5.3.3.1-1 Table 14.1.4

表 2.7.4.1-5. 治験使用薬が投与された期間（012601IN: 安全性解析対象集団）

Duration of Exposure to Treatment (days)	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)	Overall (N=241)
N	22	44	43	43	44	45	241
Mean (SD)	83.4 (23.52)	89.0 (8.01)	88.4 (12.19)	90.9 (2.43)	89.5 (4.72)	87.0 (14.97)	88.5 (11.67)
Median	91.0	91.0	91.0	91.0	91.0	91.0	91.0
Min, Max	8, 93	38, 93	11, 93	84, 98	61, 93	4, 98	4, 98
Week 1 (1- 11 days)	1 (4.5%)	0	1 (2.3%)	0	0	1 (2.2%)	3 (1.2%)
Week 2 (12- 22 days)	1 (4.5%)	0	0	0	0	0	1 (0.4%)
Week 6 (23- 50 days)	0	1 (2.3%)	0	0	0	0	1 (0.4%)
Month 3 (51- 98 days)	20 (90.9%)	43 (97.7%)	42 (97.7%)	43 (100.0%)	44 (100.0%)	44 (97.8%)	236 (97.9%)

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% DE-126 from Week 6 to Month 3.

Cross Reference: 添付資料 5.3.5.1-1 Table 14.1.7

表 2.7.4.1-6. 治験使用薬が投与された期間（101260005LT: 安全性解析対象集団）

	0.002% STN1012600 (N=162)	0.005% Latanoprost (N=163)	Overall (N=325)
Duration of Exposure to Treatment (days)			
N	162	163	325
Mean (SD)	85.6 (14.40)	84.6 (14.01)	85.1 (14.19)
Median	89.0	85.0	87.0
Min, Max	2, 98	4, 98	2, 98
Duration of Exposure to Treatment (category)			
N	162	163	325
1 - 30 days	5 (3.1%)	6 (3.7%)	11 (3.4%)
31 - 60 days	0	2 (1.2%)	2 (0.6%)
>= 61 days	157 (96.9%)	155 (95.1%)	312 (96.0%)

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.1-2 Table 14.1.8

表 2.7.4.1-7. 治験使用薬が投与された期間（101260006LT: 安全性解析対象集団）

	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Duration of Exposure to Treatment (days)					
N	49	42	40	91	131
Mean (SD)	341.8 (75.12)	343.6 (72.20)	350.7 (57.76)	342.6 (73.38)	345.1 (68.87)
Median	364.0	363.0	364.0	364.0	364.0
Min, Max	11, 373	56, 371	42, 372	11, 373	11, 373
Duration of Exposure to Treatment (category)					
N	49	42	40	91	131
1 - 89 days	2 (4.1%)	2 (4.8%)	1 (2.5%)	4 (4.4%)	5 (3.8%)
90 - 179 days	0	1 (2.4%)	0	1 (1.1%)	1 (0.8%)
180 - 269 days	2 (4.1%)	0	1 (2.5%)	2 (2.2%)	3 (2.3%)

Confidential

	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
270 - 359 days	5 (10.2%)	8 (19.0%)	12 (30.0%)	13 (14.3%)	25 (19.1%)
>= 360 days	40 (81.6%)	31 (73.8%)	26 (65.0%)	71 (78.0%)	97 (74.0%)

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.1.8

2.7.4.1.3 治験対象集団の人口統計学的特性及びその他の特性

人口統計学的及び他の基準値の特性を表 2.7.4.1-8 (101260007LT) 、表 2.7.4.1-9 (012601IN) 、表 2.7.4.1-10 (101260005LT) 及び表 2.7.4.1-11 (101260006LT) に示した。

表 2.7.4.1-8. 101260007LT 試験: 人口統計学的及び他の基準値の特性 (安全性解析対象集団)

	0.002% STN1012600 (N=8)
Age on consent date (years)	
N	8
Mean (SD)	27.4 (4.90)
Median	26.0
Min, Max	23, 35
Sex	
N	8
Male	8 (100.0%)
Race	
N	8
American Indian or Alaska Native	0 (0.0%)
Japanese	8 (100.0%)
Other Asian	0 (0.0%)
Black or African American	0 (0.0%)
Native Hawaiian or Other Pacific Islander	0 (0.0%)
White	0 (0.0%)
Other	0 (0.0%)
Height (cm)	
N	8
Mean (SD)	174.19 (7.002)
Median	174.55
Min, Max	165.6, 182.6
Weight (kg)	
N	8
Mean (SD)	67.16 (5.655)
Median	68.35
Min, Max	58.6, 74.6

Cross Reference: 添付資料 5.3.3.1-1 Table 14.1.2

表 2.7.4.1-9. 012601IN 試験: 人口統計学的及び他の基準値の特性（安全性解析対象集団）

	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)	Overall (N=241)
Age at Randomization (years)							
N	22	44	43	43	44	45	241
Mean (SD)	63.2 (11.24)	64.4 (9.28)	65.5 (13.30)	63.7 (9.41)	61.0 (11.84)	63.8 (11.84)	63.6 (11.22)
Median	64.5	65.5	68.0	63.0	64.0	67.0	66.0
Min, Max	39, 79	40, 79	26, 87	47, 82	33, 79	32, 87	26, 87
Age Group (years)							
<65	11 (50.0%)	19 (43.2%)	16 (37.2%)	24 (55.8%)	22 (50.0%)	19 (42.2%)	111 (46.1%)
>=65	11 (50.0%)	25 (56.8%)	27 (62.8%)	19 (44.2%)	22 (50.0%)	26 (57.8%)	130 (53.9%)
Sex							
Male	9 (40.9%)	20 (45.5%)	17 (39.5%)	21 (48.8%)	19 (43.2%)	20 (44.4%)	106 (44.0%)
Female	13 (59.1%)	24 (54.5%)	26 (60.5%)	22 (51.2%)	25 (56.8%)	25 (55.6%)	135 (56.0%)
Country							
Japan	11 (50.0%)	21 (47.7%)	20 (46.5%)	20 (46.5%)	21 (47.7%)	21 (46.7%)	114 (47.3%)
United States	11 (50.0%)	23 (52.3%)	23 (53.5%)	23 (53.5%)	23 (52.3%)	24 (53.3%)	127 (52.7%)
Ethnicity							
Hispanic or Latino	2 (9.1%)	5 (11.4%)	7 (16.3%)	7 (16.3%)	5 (11.4%)	6 (13.3%)	32 (13.3%)
Not Hispanic or Latino	20 (90.9%)	39 (88.6%)	36 (83.7%)	36 (83.7%)	39 (88.6%)	39 (86.7%)	209 (86.7%)
Primary Diagnosis							
Primary Open-angle Glaucoma	9 (40.9%)	26 (59.1%)	22 (51.2%)	24 (55.8%)	21 (47.7%)	23 (51.1%)	125 (51.9%)
Ocular Hypertension	13 (59.1%)	18 (40.9%)	21 (48.8%)	19 (44.2%)	23 (52.3%)	22 (48.9%)	116 (48.1%)
Prior Use of IOP-Lowering Medication(s)							
None	8 (36.4%)	14 (31.8%)	10 (23.3%)	10 (23.3%)	14 (31.8%)	14 (31.1%)	70 (29.0%)
Beta-adrenergic antagonist	1 (4.5%)	11 (25.0%)	15 (34.9%)	11 (25.6%)	6 (13.6%)	14 (31.1%)	58 (24.1%)
Prostamides or prostaglandin analogues	11 (50.0%)	21 (47.7%)	24 (55.8%)	25 (58.1%)	25 (56.8%)	20 (44.4%)	126 (52.3%)
Alpha-adrenergic agonist	1 (4.5%)	0	4 (9.3%)	2 (4.7%)	2 (4.5%)	5 (11.1%)	14 (5.8%)
Carbonic anhydrase inhibitors	2 (9.1%)	8 (18.2%)	8 (18.6%)	10 (23.3%)	4 (9.1%)	5 (11.1%)	37 (15.4%)
ROCK inhibitor	1 (4.5%)	0	1 (2.3%)	0	0	0	2 (0.8%)
Mean Diurnal IOP (mmHg)							
N	22	44	43	43	44	45	241
Mean (SD)	24.5 (2.30)	24.3 (1.96)	24.4 (2.34)	24.2 (2.06)	24.1 (2.20)	24.2 (1.66)	24.3 (2.06)
Median	23.7	23.8	23.7	23.7	23.3	24.0	23.7
Min, Max	22.0, 29.8	22.0, 29.3	22.0, 33.3	22.0, 31.0	22.0, 30.8	22.0, 29.7	22.0, 33.3
IOP at 9:00 (mmHg)							
N	22	44	43	43	44	45	241
Mean (SD)	25.0 (2.72)	25.0 (2.90)	24.9 (2.58)	24.9 (2.50)	24.8 (2.88)	24.7 (2.31)	24.9 (2.63)

	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)	Overall (N=241)
Median	24.0	24.0	24.0	24.0	23.8	24.0	24.0
Min, Max	22.0, 32.0	22.0, 32.0	22.0, 32.0	22.0, 31.0	22.0, 34.0	22.0, 33.5	22.0, 34.0
IOP at 13:00 (mmHg)							
N	22	44	43	43	44	45	241
Mean (SD)	24.0 (1.91)	24.2 (2.21)	24.5 (2.64)	24.2 (2.42)	24.1 (2.59)	24.3 (2.21)	24.2 (2.36)
Median	23.8	24.0	24.0	24.0	23.0	24.0	23.5
Min, Max	22.0, 29.0	22.0, 32.0	22.0, 34.0	22.0, 32.0	22.0, 31.0	22.0, 31.0	22.0, 34.0
IOP at 17:00 (mmHg)							
N	22	44	43	43	44	45	241
Mean (SD)	24.5 (2.93)	23.5 (1.79)	23.8 (2.39)	23.6 (2.03)	23.6 (2.25)	23.6 (1.93)	23.7 (2.17)
Median	23.0	23.0	23.0	23.0	23.0	23.0	23.0
Min, Max	22.0, 33.0	22.0, 28.5	22.0, 34.0	22.0, 31.0	22.0, 32.0	22.0, 30.5	22.0, 34.0
Visual Acuity LogMAR Score							
N	22	44	43	43	44	45	241
Mean (SD)	0.006 (0.0768)	0.013 (0.0874)	0.020 (0.1027)	0.029 (0.1339)	0.019 (0.1144)	-0.002 (0.1022)	0.015 (0.1060)
Median	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Min, Max	-0.17, 0.18	-0.17, 0.23	-0.17, 0.30	-0.17, 0.53	-0.17, 0.40	-0.17, 0.22	-0.17, 0.53
Central Corneal Thickness (um)							
N	22	44	43	43	44	45	241
Mean (SD)	552.4 (39.72)	555.6 (31.45)	551.5 (33.69)	568.1 (28.67)	549.1 (27.61)	555.3 (30.86)	555.6 (31.76)
Median	559.0	551.0	557.0	571.0	552.5	551.0	557.0
Min, Max	494, 613	480, 609	483, 603	509, 630	492, 604	492, 618	480, 630
Glaucomatous Optic Nerve Findings							
None	14 (63.6%)	25 (56.8%)	25 (58.1%)	25 (58.1%)	28 (63.6%)	27 (60.0%)	144 (59.8%)
Mild	7 (31.8%)	15 (34.1%)	16 (37.2%)	15 (34.9%)	11 (25.0%)	14 (31.1%)	78 (32.4%)
Moderate	1 (4.5%)	4 (9.1%)	2 (4.7%)	3 (7.0%)	5 (11.4%)	4 (8.9%)	19 (7.9%)
Degree of Angle Closure (Shaffer Scale)							
Approximately 20 degrees	0	2 (4.5%)	0	0	1 (2.3%)	2 (4.4%)	5 (2.1%)
Approximately 30 degrees	7 (31.8%)	11 (25.0%)	23 (53.5%)	21 (48.8%)	17 (38.6%)	21 (46.7%)	100 (41.5%)
Approximately 40 degrees or more	15 (68.2%)	31 (70.5%)	20 (46.5%)	22 (51.2%)	26 (59.1%)	22 (48.9%)	136 (56.4%)
Glaucoma Hemifield Test							
Humphrey, n (%)	18 (81.8%)	41 (93.2%)	39 (90.7%)	36 (83.7%)	38 (86.4%)	39 (86.7%)	211 (87.6%)
Within Normal Limits	14 (63.6%)	28 (63.6%)	21 (48.8%)	19 (44.2%)	31 (70.5%)	29 (64.4%)	142 (58.9%)
Borderline	2 (9.1%)	2 (4.5%)	2 (4.7%)	4 (9.3%)	2 (4.5%)	5 (11.1%)	17 (7.1%)
Outside Normal Limits	2 (9.1%)	11 (25.0%)	16 (37.2%)	13 (30.2%)	5 (11.4%)	5 (11.1%)	52 (21.6%)
Visual Field Mean Deviation							
Humphrey, n (%)	18 (81.8%)	41 (93.2%)	39 (90.7%)	36 (83.7%)	38 (86.4%)	39 (86.7%)	211 (87.6%)

	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)	Overall (N=241)
Mean (SD)	-1.344 (2.0538)	-1.281 (2.1572)	-1.630 (2.6567)	-1.715 (2.9282)	-0.754 (3.1167)	-0.850 (2.1353)	-1.250 (2.5709)
Median	-1.090	-1.690	-1.160	-0.775	0.050	-0.510	-0.620
Min, Max	-8.26, 0.98	-7.08, 3.09	-10.59, 4.66	-9.77, 1.88	-10.22, 4.16	-7.08, 2.31	-10.59, 4.66
Octopus, n (%)	4 (18.2%)	1 (2.3%)	3 (7.0%)	4 (9.3%)	5 (11.4%)	5 (11.1%)	22 (9.1%)
Mean (SD)	1.100 (1.6892)	-1.400 (NA)	-0.767 (1.6623)	0.025 (1.3889)	0.780 (1.4202)	-0.160 (1.6410)	0.177 (1.5393)
Median	0.800	-1.400	-1.000	0.500	0.800	-0.500	0.350
Min, Max	-0.30, 3.10	-1.40, -1.40	-2.30, 1.00	-2.00, 1.10	-1.30, 2.70	-2.30, 2.20	-2.30, 3.10
KOWA perimeter, n (%)	0	2 (4.5%)	1 (2.3%)	3 (7.0%)	1 (2.3%)	1 (2.2%)	8 (3.3%)
Mean (SD)	-	4.205 (6.6822)	-2.450 (NA)	-1.500 (5.7799)	-1.520 (NA)	3.950 (NA)	0.486 (5.0086)
Median	-	4.205	-2.450	0.240	-1.520	3.950	-0.140
Min, Max	-	-0.52, 8.93	-2.45, -2.45	-7.95, 3.21	-1.52, -1.52	3.95, 3.95	-7.95, 8.93
Visual Field Pattern Standard Deviation							
Humphrey, n (%)	18 (81.8%)	41 (93.2%)	39 (90.7%)	36 (83.7%)	38 (86.4%)	39 (86.7%)	211 (87.6%)
Mean (SD)	2.579 (2.9916)	2.380 (1.6672)	2.943 (1.9750)	3.046 (2.4568)	2.276 (1.8089)	2.529 (1.8554)	2.623 (2.0616)
Median	1.655	1.840	2.310	1.835	1.605	2.040	1.840
Min, Max	1.23, 13.93	0.55, 9.16	1.04, 8.83	1.11, 11.88	0.55, 10.30	1.08, 10.49	0.55, 13.93
Octopus, n (%)	4 (18.2%)	1 (2.3%)	3 (7.0%)	4 (9.3%)	5 (11.4%)	5 (11.1%)	22 (9.1%)
Mean (SD)	2.850 (1.1210)	1.000 (NA)	2.433 (1.4012)	2.025 (0.4573)	2.580 (0.5805)	1.420 (0.3421)	2.173 (0.9077)
Median	3.250	1.000	2.000	2.050	2.300	1.500	2.000
Min, Max	1.20, 3.70	1.00, 1.00	1.30, 4.00	1.50, 2.50	2.00, 3.30	0.90, 1.80	0.90, 4.00
KOWA perimeter, n (%)	0	2 (4.5%)	1 (2.3%)	3 (7.0%)	1 (2.3%)	1 (2.2%)	8 (3.3%)
Mean (SD)	-	5.185 (3.8396)	9.820 (NA)	5.910 (4.5836)	-4.070 (NA)	2.560 (NA)	4.551 (4.9158)
Median	-	5.185	9.820	4.350	-4.070	2.560	3.455
Min, Max	-	2.47, 7.90	9.82, 9.82	2.31, 11.07	-4.07, -4.07	2.56, 2.56	-4.07, 11.07

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% DE-126 from Week 6 to Month 3.

Cross Reference: 添付資料 5.3.5.1-1 Table 14.1.2.1 及び Table 14.1.3.1

表 2.7.4.1-10. 101260005LT 試験: 人口統計学的及び他の基準値の特性（安全性解析対象集団）

	0.002% STN1012600 (N=162)	0.005% Latanoprost (N=163)	Overall (N=325)
Age at Randomization (years)			
N	162	163	325
Mean (SD)	62.6 (12.60)	62.7 (13.43)	62.7 (13.00)
Median	65.0	65.0	65.0
Min, Max	23, 88	27, 90	23, 90

	0.002% STN1012600 (N=162)	0.005% Latanoprost (N=163)	Overall (N=325)
Age Group (years)			
N	162	163	325
< 65	78 (48.1%)	81 (49.7%)	159 (48.9%)
>= 65	84 (51.9%)	82 (50.3%)	166 (51.1%)
Sex			
N	162	163	325
Male	62 (38.3%)	63 (38.7%)	125 (38.5%)
Female	100 (61.7%)	100 (61.3%)	200 (61.5%)
Race			
N	162	163	325
Asian	162 (100.0%)	163 (100.0%)	325 (100.0%)
Primary Diagnosis			
Ocular Hypertension	88 (54.3%)	90 (55.2%)	178 (54.8%)
Primary Open Angle Glaucoma	74 (45.7%)	73 (44.8%)	147 (45.2%)
Mean Diurnal IOP (mmHg)			
N	162	163	325
Mean (SD)	23.32 (1.473)	23.12 (1.224)	23.22 (1.355)
Median	22.83	22.83	22.83
Min, Max	22.0, 30.3	22.0, 31.5	22.0, 31.5
IOP at 9:00 (mmHg)			
N	162	163	325
Mean (SD)	23.56 (1.773)	23.27 (1.519)	23.41 (1.654)
Median	23.00	23.00	23.00
Min, Max	22.0, 34.0	22.0, 32.0	22.0, 34.0
IOP at 13:00 (mmHg)			
N	162	163	325
Mean (SD)	23.29 (1.603)	23.11 (1.360)	23.20 (1.487)
Median	23.00	23.00	23.00
Min, Max	22.0, 32.0	22.0, 30.5	22.0, 32.0
IOP at 17:00 (mmHg)			
N	162	163	325
Mean (SD)	23.12 (1.520)	22.98 (1.340)	23.05 (1.432)
Median	22.50	22.50	22.50
Min, Max	22.0, 29.5	22.0, 32.0	22.0, 32.0
Central Corneal Thickness (um)			
N	162	163	325
Mean (SD)	553.6 (33.13)	560.7 (35.43)	557.2 (34.44)
Median	555.0	563.0	559.0
Min, Max	483, 617	483, 620	483, 620
Visual Acuity (LogMAR)			
N	162	163	325
Mean (SD)	-0.042 (0.1184)	-0.037 (0.0912)	-0.039 (0.1055)
Median	-0.079	-0.079	-0.079
Min, Max	-0.30, 0.52	-0.18, 0.40	-0.30, 0.52
Degree of Angle Closure in Shaffer Scale			
Grade 2	3 (1.9%)	2 (1.2%)	5 (1.5%)
Grade 3-4	159 (98.1%)	161 (98.8%)	320 (98.5%)

Cross Reference: 添付資料 5.3.5.1-2 Table 14.1.2、Table 14.1.3

表 2.7.4.1-11. 101260006LT 試験: 人口統計学的及び他の基準値の特性（安全性解析対象集団）

	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Age (years)					
N	49	42	40	91	131
Mean (SD)	64.7 (11.53)	62.1 (14.57)	64.7 (12.04)	63.5 (13.01)	63.8 (12.69)
Median	68.0	65.0	68.0	67.0	67.0
Min, Max	21, 79	27, 83	28, 84	21, 83	21, 84
Age Group (years)					
N	49	42	40	91	131
< 65	20 (40.8%)	19 (45.2%)	18 (45.0%)	39 (42.9%)	57 (43.5%)
>= 65	29 (59.2%)	23 (54.8%)	22 (55.0%)	52 (57.1%)	74 (56.5%)
Sex					
N	49	42	40	91	131
Male	26 (53.1%)	21 (50.0%)	23 (57.5%)	47 (51.6%)	70 (53.4%)
Female	23 (46.9%)	21 (50.0%)	17 (42.5%)	44 (48.4%)	61 (46.6%)
Race					
N	49	42	40	91	131
Asian	49 (100.0%)	42 (100.0%)	40 (100.0%)	91 (100.0%)	131 (100.0%)
Primary Diagnosis					
Normal Tension Glaucoma	16 (32.7%)	2 (4.8%)	1 (2.5%)	18 (19.8%)	19 (14.5%)
Ocular Hypertension	11 (22.4%)	19 (45.2%)	19 (47.5%)	30 (33.0%)	49 (37.4%)
Pigmentary Glaucoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary Open Angle Glaucoma	22 (44.9%)	21 (50.0%)	20 (50.0%)	43 (47.3%)	63 (48.1%)
Pseudoexfoliation Glaucoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mean Diurnal IOP (mmHg)					
N	49	42	40	91	131
Mean (SD)	18.83 (1.386)	23.21 (1.463)	24.00 (1.829)	20.85 (2.613)	21.82 (2.802)
Median	18.83	23.00	23.50	20.50	22.33
Min, Max	16.0, 21.8	22.0, 30.0	22.2, 30.0	16.0, 30.0	16.0, 30.0
IOP at 9:00 (mmHg)					
N	49	42	40	91	131
Mean (SD)	19.54 (1.944)	23.54 (2.046)	24.24 (2.273)	21.38 (2.817)	22.26 (2.963)
Median	19.50	23.00	24.00	22.00	22.50
Min, Max	16.0, 23.5	20.0, 31.5	21.5, 31.5	16.0, 31.5	16.0, 31.5
IOP at 13:00 (mmHg)					
N	49	42	40	91	131
Mean (SD)	18.65 (1.640)	23.24 (1.639)	24.16 (2.135)	20.77 (2.818)	21.81 (3.054)
Median	19.00	23.00	23.75	21.00	22.00
Min, Max	16.0, 22.0	21.5, 30.5	21.0, 31.0	16.0, 30.5	16.0, 31.0
IOP at 17:00 (mmHg)					
N	49	42	40	91	131
Mean (SD)	18.30 (1.507)	22.87 (1.490)	23.61 (1.778)	20.41 (2.734)	21.39 (2.885)
Median	18.00	23.00	23.00	20.00	22.00

	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Min, Max	16.0, 22.0	20.0, 28.0	20.0, 30.0	16.0, 28.0	16.0, 30.0
Central Corneal Thickness (um)					
N	49	42	40	91	131
Mean (SD)	540.0 (33.23)	549.2 (28.97)	550.6 (31.55)	544.3 (31.50)	546.2 (31.53)
Median	533.0	549.0	555.5	543.0	547.0
Min, Max	466, 619	489, 623	494, 610	466, 623	466, 623
Visual Acuity (LogMAR)					
N	49	42	40	91	131
Mean (SD)	-0.056 (0.0807)	-0.053 (0.0895)	-0.052 (0.0735)	-0.055 (0.0844)	-0.054 (0.0809)
Median	-0.079	-0.079	-0.079	-0.079	-0.079
Min, Max	-0.18, 0.15	-0.30, 0.15	-0.18, 0.10	-0.30, 0.15	-0.30, 0.15
Degree of Angle Closure in Shaffer Scale					
Grade 2	2 (4.1%)	1 (2.4%)	1 (2.5%)	3 (3.3%)	4 (3.1%)
Grade 3-4	47 (95.9%)	41 (97.6%)	39 (97.5%)	88 (96.7%)	127 (96.9%)

Cross Reference: 添付資料 5.3.5.2-1 Table 14.1.2、Table 14.1.3

2.7.4.2 有害事象

2.7.4.2.1 有害事象の解析

(1) 併合解析

併合解析における有害事象及び副作用の発現頻度を表 2.7.4.2-1 に示した。

STN10126 点眼液で認められた有害事象発現頻度は各群で 27.3%～71.4%であり、0.003% STN1012600 点眼液 3 ヵ月投与群は、他の濃度群と比較して発現頻度が高かった。

0.002% STN1012600 群の発現頻度は 50.3%（92/183 例）であり、0.005%ラタノプロスト群 41.8%（77/184 例）と比較し大きな差異はなかった。副作用は 0.002% STN1012600 群で 34.4%（63/183 例）、0.005%ラタノプロスト群で 20.7%（38/184 例）に認められた。

表 2.7.4.2-1. 併合解析: 有害事象の発現頻度

Subjects with any	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
AE(s)	3 (27.3%)	77 (41.8%)	10 (50.0%)	8 (40.0%)	92 (50.3%)	15 (71.4%)	128 (50.2%)
ADR(s)	2 (18.2%)	38 (20.7%)	5 (25.0%)	5 (25.0%)	63 (34.4%)	6 (28.6%)	81 (31.8%)
SAE(s)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Serious ADR(s)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Leading to Study Drug Discontinuation	0 (0.0%)	7 (3.8%)	0 (0.0%)	0 (0.0%)	3 (1.6%)	1 (4.8%)	4 (1.6%)
Resulting in Death	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Cross Reference: 添付資料 5.3.5.1-1 Table 14.3.1.1.2 及び添付資料 5.3.5.1-2 Table 14.3.1.1

(2) 長期投与試験

長期投与試験 (101260006LT) における有害事象及び副作用の発現頻度を表 2.7.4.2-2 に示した。

有害事象は、全体の 86.3%（113/131 例）に認められ、単剤群（グループ 1＋グループ 2）で 82.4%（75/91 例）、0.5%チモロール点眼液併用群（グループ 3）で 95.0%（38/40 例）であった。副作用は全体で 61.1%（80/131 例）、単剤群（グループ 1＋グループ 2）で 59.3%（54/91 例）、併用群（グループ 3）で 65.0%（26/40 例）であった。副作用の程度は、中等度の 1 例〔「角膜炎 (Keratitis)」、グループ 1〕を除き、すべて軽度であった。

表 2.7.4.2-2. 101260006LT: 有害事象の発現頻度（安全性解析対象集団）

Subjects with any	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
AE(s)	43 (87.8%)	32 (76.2%)	38 (95.0%)	75 (82.4%)	113 (86.3%)
ADR(s)	29 (59.2%)	25 (59.5%)	26 (65.0%)	54 (59.3%)	80 (61.1%)
SAE(s)	3 (6.1%)	2 (4.8%)	3 (7.5%)	5 (5.5%)	8 (6.1%)
Serious ADR(s)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Leading to Study Drug Discontinuation	3 (6.1%)	3 (7.1%)	2 (5.0%)	6 (6.6%)	8 (6.1%)
Resulting in Death	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mild AE(s) [1]	39 (79.6%)	28 (66.7%)	33 (82.5%)	67 (73.6%)	100 (76.3%)
Moderate AE(s) [1]	4 (8.2%)	4 (9.5%)	4 (10.0%)	8 (8.8%)	12 (9.2%)
Severe AE(s) [1]	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)

[1] Maximum severity within subject.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.1

2.7.4.2.1.1 比較的よく見られる有害事象

(1) 併合解析

併合解析における事象別の有害事象一覧を表 2.7.4.2-3 に、事象別の副作用一覧を表 2.7.4.2-4 に示した。

比較的よく見られる有害事象（発現頻度 2%以上）は、0.002% STN10126 群では「結膜充血 (Conjunctival hyperaemia)」30.6%（56/183 例）、「点状角膜炎 (Punctate keratitis)」2.7%（5/183 例）、「COVID-19 (COVID-19)」2.7%（5/183 例）、「眼そう痒症 (Eye pruritus)」2.2%（4/183

例）、「上咽頭炎 (Nasopharyngitis) 」2.7%（5/183 例）、「ドライアイ (Dry eye) 」2.2%（4/183 例）、「眼瞼紅斑 (Erythema of eyelid) 」2.2%（4/183 例）であり、0.005% ラタノプロスト群では「結膜充血」13.6%（25/184 例）、「点状角膜炎」6.5%（12/184 例）、「眼刺激 (Eye irritation) 」4.3%（8/184 例）、「COVID-19」2.7%（5/184 例）、「眼そう痒症」2.2%（4/184 例）であった。0.005% ラタノプロスト群と比較して 0.002% STN10126 群の発現頻度が高かった事象は、「結膜充血」、「上咽頭炎」、「ドライアイ」及び「眼瞼紅斑」であったが、「結膜充血」の 3 例を除き、すべて軽度であった。

また、比較的よく見られる副作用（発現頻度 2%以上）は、0.002% STN10126 群では「結膜充血」28.4%（52/183 例）、「ドライアイ」2.2%（4/183 例）、「眼瞼紅斑」2.2%（4/183 例）であり、0.005% ラタノプロスト群では「結膜充血」9.2%（17/184 例）、「眼刺激」4.3%（8/184 例）であった。

なお、STN10126 点眼液ではいずれの濃度群においても、最も高頻度に認められた有害事象は「結膜充血」であった。

表 2.7.4.2-3. 併合解析: 治療期に認められた有害事象一覧

System organ class Preferred term	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
Subjects with any AE(s)	3 (27.3%)	77 (41.8%)	10 (50.0%)	8 (40.0%)	92 (50.3%)	15 (71.4%)	128 (50.2%)
Eye disorders	3 (27.3%)	58 (31.5%)	7 (35.0%)	7 (35.0%)	73 (39.9%)	11 (52.4%)	101 (39.6%)
Conjunctival hyperaemia	1 (9.1%)	25 (13.6%)	3 (15.0%)	2 (10.0%)	56 (30.6%)	4 (19.0%)	66 (25.9%)
Eye pruritus	0 (0.0%)	4 (2.2%)	1 (5.0%)	1 (5.0%)	4 (2.2%)	3 (14.3%)	9 (3.5%)
Punctate keratitis	0 (0.0%)	12 (6.5%)	1 (5.0%)	2 (10.0%)	5 (2.7%)	1 (4.8%)	9 (3.5%)
Dry eye	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	4 (2.2%)	1 (4.8%)	5 (2.0%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (2.2%)	0 (0.0%)	4 (1.6%)
Eye irritation	0 (0.0%)	8 (4.3%)	0 (0.0%)	1 (5.0%)	3 (1.6%)	0 (0.0%)	4 (1.6%)
Foreign body sensation in eyes	0 (0.0%)	2 (1.1%)	1 (5.0%)	0 (0.0%)	2 (1.1%)	1 (4.8%)	4 (1.6%)
Growth of eyelashes	1 (9.1%)	0 (0.0%)	1 (5.0%)	1 (5.0%)	1 (0.5%)	0 (0.0%)	4 (1.6%)
Conjunctival haemorrhage	0 (0.0%)	1 (0.5%)	1 (5.0%)	1 (5.0%)	0 (0.0%)	1 (4.8%)	3 (1.2%)
Eye discharge	0 (0.0%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	3 (1.2%)
Abnormal sensation in eye	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Conjunctival oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Conjunctivitis allergic	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (4.8%)	2 (0.8%)
Keratitis	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (4.8%)	2 (0.8%)
Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Blepharitis	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Cataract	1 (9.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Chalazion	0 (0.0%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

System organ class Preferred term	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
Conjunctival cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Corneal hypertrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Eyelid oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Eyelids pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Posterior capsule opacification	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Scintillating scotoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Vitreous detachment	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Vitreous floaters	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Vitreous opacities	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Asthenopia	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blepharitis allergic	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blepharospasm	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctival telangiectasia	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pain	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid vellus hair changes	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Lacrimation increased	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Infections and infestations	0 (0.0%)	14 (7.6%)	3 (15.0%)	2 (10.0%)	12 (6.6%)	2 (9.5%)	19 (7.5%)
Nasopharyngitis	0 (0.0%)	2 (1.1%)	3 (15.0%)	1 (5.0%)	5 (2.7%)	1 (4.8%)	10 (3.9%)
COVID-19	0 (0.0%)	5 (2.7%)	0 (0.0%)	0 (0.0%)	5 (2.7%)	0 (0.0%)	5 (2.0%)
Bronchitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Cystitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Influenza	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Conjunctivitis bacterial	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Corneal infection	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Coronavirus infection	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Groin abscess	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hordeolum	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Post-acute COVID-19 syndrome	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Rhinitis	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Nervous system disorders	0 (0.0%)	3 (1.6%)	0 (0.0%)	0 (0.0%)	3 (1.6%)	2 (9.5%)	5 (2.0%)
Headache	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	3 (1.6%)	0 (0.0%)	3 (1.2%)
Cervicobrachial syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Parkinson's disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Dizziness	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Investigations	1 (9.1%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	1 (0.5%)	1 (4.8%)	4 (1.6%)
Blood potassium increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Blood triglycerides increased	0 (0.0%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Confidential

System organ class Preferred term	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
Eosinophil count increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Hepatic enzyme increased	1 (9.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Musculoskeletal and connective tissue disorders	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	4 (2.2%)	0 (0.0%)	4 (1.6%)
Back pain	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Pain in extremity	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Spinal stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Arthralgia	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin and subcutaneous tissue disorders	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	3 (1.6%)	1 (4.8%)	4 (1.6%)
Eczema	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Hypertrichosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Urticaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Rash	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
General disorders and administration site conditions	0 (0.0%)	3 (1.6%)	0 (0.0%)	0 (0.0%)	3 (1.6%)	0 (0.0%)	3 (1.2%)
Peripheral swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Pyrexia	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Vaccination site pain	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Malaise	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal disorders	0 (0.0%)	3 (1.6%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Abdominal pain upper	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Nausea	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Pancreatitis	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Injury, poisoning and procedural complications	0 (0.0%)	5 (2.7%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (4.8%)	2 (0.8%)
Radius fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Tooth fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Contusion	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Epicondylitis	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Fall	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Ligament sprain	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Spinal compression fracture	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Ear and labyrinth disorders	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Vertigo	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)

System organ class Preferred term	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
Sudden hearing loss	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Metabolism and nutrition disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Decreased appetite	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Renal and urinary disorders	1 (9.1%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Hypertonic bladder	1 (9.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Pollakiuria	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiratory, thoracic and mediastinal disorders	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Oropharyngeal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Cough	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Vascular disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Hypotension	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Breast cancer	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Product issues	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Device physical property issue	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

表 2.7.4.2-4. 併合解析: 治療期に認められた副作用一覧

System organ class Preferred term	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
Subjects with any ADR(s)	2 (18.2%)	38 (20.7%)	5 (25.0%)	5 (25.0%)	63 (34.4%)	6 (28.6%)	81 (31.8%)
Eye disorders	2 (18.2%)	38 (20.7%)	5 (25.0%)	5 (25.0%)	62 (33.9%)	5 (23.8%)	79 (31.0%)
Conjunctival hyperaemia	1 (9.1%)	17 (9.2%)	3 (15.0%)	2 (10.0%)	52 (28.4%)	3 (14.3%)	61 (23.9%)
Eye pruritus	0 (0.0%)	1 (0.5%)	1 (5.0%)	1 (5.0%)	3 (1.6%)	3 (14.3%)	8 (3.1%)
Dry eye	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	4 (2.2%)	1 (4.8%)	5 (2.0%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (2.2%)	0 (0.0%)	4 (1.6%)

System organ class Preferred term	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
Eye irritation	0 (0.0%)	8 (4.3%)	0 (0.0%)	1 (5.0%)	3 (1.6%)	0 (0.0%)	4 (1.6%)
Growth of eyelashes	1 (9.1%)	0 (0.0%)	1 (5.0%)	1 (5.0%)	1 (0.5%)	0 (0.0%)	4 (1.6%)
Punctate keratitis	0 (0.0%)	7 (3.8%)	1 (5.0%)	1 (5.0%)	2 (1.1%)	0 (0.0%)	4 (1.6%)
Abnormal sensation in eye	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Conjunctival oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Foreign body sensation in eyes	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (4.8%)	2 (0.8%)
Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Conjunctival cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Conjunctivitis allergic	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Blepharitis	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctival telangiectasia	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pain	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid vellus hair changes	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Keratitis	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Lacrimation increased	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Infections and infestations	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Corneal infection	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin and subcutaneous tissue disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Hypertrichosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

(2) 長期投与試験

長期投与試験（101260006LT）における事象別の有害事象一覧を表 2.7.4.2-5 に、事象別の副作用一覧を表 2.7.4.2-6 に、虹彩色、睫毛、眼瞼の変化に関する有害事象の発現頻度を表 2.7.4.2-7 に示した。また、初回発現時期別の有害事象一覧を表 2.7.4.2-8（グループ 1+グループ 2）及び表 2.7.4.2-9（グループ 3）に示した。

比較的よく見られる有害事象（発現頻度 5%以上）は、単剤群（グループ 1+グループ 2）では「結膜充血 (Conjunctival hyperaemia) 」29.7%（27/91 例）、「睫毛の成長 (Growth of eyelashes) 」28.6%（26/91 例）、「睫毛変化 (Eyelash changes) 」16.5%（15/91 例）、「眼瞼のうぶ毛変化(Eyelid vellus hair changes) 」14.3%（13/91 例）、「睫毛剛毛化 (Eyelash thickening) 」12.1%（11/91 例）、「上咽頭炎 (Nasopharyngitis) 」9.9%（9/91 例）、「眼瞼色素沈着 (Blepharal pigmentation) 」8.8%（8/91 例）、「アレルギー性結膜炎 (Conjunctivitis allergic) 」5.5%（5/91 例）、「点状角膜炎 (Punctate keratitis) 」5.5%（5/91 例）であり、併用群（グループ 3）では「睫毛の成長」42.5%（17/40 例）、「結膜充血」32.5%（13/40 例）、「眼瞼のうぶ毛変化」15.0%（6/40 例）、「睫毛変化」7.5%（3/40 例）、「眼瞼色素沈着」7.5%（3/40 例）、「眼刺激 (Eye irritation) 」7.5%（3/40 例）、「胃腸炎 (Gastroenteritis) 」7.5%（3/40 例）、「湿疹 (Eczema) 」7.5%（3/40 例）、「睫毛剛毛化」5.0%（2/40 例）、「アレルギー性結膜炎」5.0%（2/40 例）、「点状角膜炎」5.0%（2/40 例）、「睫毛色素過剰 (Eyelash hyperpigmentation) 」5.0%（2/40 例）、「眼瞼紅斑 (Erythema of eyelid) 」5.0%（2/40 例）、「コロナウイルス感染 (Coronavirus infections) 」5.0%（2/40 例）、「COVID-19 (COVID-19)」5.0%（2/40 例）、「咽頭炎 (Pharyngitis)」5.0%（2/40 例）であった。高頻度に認められた有害事象の程度はすべて軽度であった。

比較的よく見られる副作用（発現頻度 5%以上）は、単剤群（グループ 1+グループ 2）では「睫毛の成長 (Growth of eyelashes) 」28.6%（26/91 例）、「結膜充血 (Conjunctival hyperaemia) 」29.7%（27/91 例）、「睫毛変化 (Eyelash changes) 」16.5%（15/91 例）、「眼瞼のうぶ毛変化(Eyelid vellus hair changes) 」14.3%（13/91 例）、「睫毛剛毛化 (Eyelash thickening) 」12.1%（11/91 例）、「眼瞼色素沈着 (Blepharal pigmentation) 」8.8%（8/91 例）であり、併用群（グループ 3）では「睫毛の成長」42.5%（17/40 例）、「結膜充血」30.0%（12/40 例）、「眼瞼のうぶ毛変化」15.0%（6/40 例）、「睫毛変化」7.5%（3/40 例）、「眼瞼色素沈着」7.5%（3/40 例）、「眼刺激 (Eye irritation) 」7.5%（3/40 例）、「睫毛剛毛化」5.0%（2/40 例）、「睫毛色素過剰 (Eyelash hyperpigmentation) 」5.0%（2/40 例）、「眼瞼紅斑 (Erythema of eyelid) 」5.0%（2/40 例）であった。高頻度に認められた副作用の程度はすべて軽度であった。

上述の (1) 併合解析と比較し、長期投与試験では眼瞼及び睫毛に関する発現頻度が高かった。なお、虹彩色、睫毛、眼瞼の変化に関する有害事象が発現した症例の割合*は、単剤群／併用群でそれぞれ 1.1%（1/91 例）／0.0%（0/40 例）、40.7%（37/91 例）／47.5%（19/40 例）、20.9%（19/91 例）／17.5%（7/40 例）であり、睫毛及び眼瞼の変化に関連した有害事象は高頻度に認められたが、虹彩色の変化に関する有害事象の発現頻度は低かった。

*虹彩：Iris hyperpigmentation、睫毛：Growth of eyelashes、Eyelash thickening、Eyelash changes、Eyelash hyperpigmentation、Trichiasis、Trichomegaly、眼瞼：Blepharal pigmentation、Eyelid vellus hair changes、Hypertrichosis を集計。

また、長期投与試験 (101260006LT) で高頻度に認められた「結膜充血」の初回発現時期は、単剤群で 1～30 日 24.2%（22/91 例）、31～90 日 2.2%（2/90 例）、91～180 日 0.0%（0/87 例）、181～270 日 3.5%（3/86 例）、271～360 日 0.0%（0/84 例）、361 日以降 0.0%（0/71 例）、0.5%チモロール併用群（グループ 3）で 1～30 日 25.0%（10/40 例）、31～90 日 2.5%（1/40 例）、91～180 日 2.5%（1/40 例）、181～270 日 2.6%（1/39 例）、271～360 日 0.0%（0/38 例）、361 日以降 0.0%（0/25 例）であり、初回発現時期は 1～30 日が最も多く、治験期間後半に発現率が増加する傾向は見られなかった。「睫毛の成長」の初回発現時期は、単剤群で 1～30 日 6.6%（6/91 例）、31～90 日 14.4%（13/90 例）、91～180 日 5.7%（5/87 例）、181～270 日 1.2%（1/86 例）、271～360 日 1.2%（1/84 例）、361 日以降 0.0%（0/71 例）、0.5%チモロール併用群（グループ 3）で 1～30 日 2.5%（1/40 例）、31～90 日 20.0%（8/40 例）、91～180 日 5.0%（2/40 例）、181～270 日 7.7%（3/39 例）、271～360 日 5.3%（2/38 例）、361 日以降 4.0%（1/25 例）であり、初回発現時期は 31～90 日が最も多く、治験期間後半に発現率が増加する傾向は見られなかった。

表 2.7.4.2-5. 101260006LT: 治療期に認められた有害事象一覧

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Subjects with any AE(s)	43 (87.8%)	32 (76.2%)	38 (95.0%)	75 (82.4%)	113 (86.3%)
Eye disorders	35 (71.4%)	26 (61.9%)	28 (70.0%)	61 (67.0%)	89 (67.9%)
Growth of eyelashes	11 (22.4%)	15 (35.7%)	17 (42.5%)	26 (28.6%)	43 (32.8%)
Conjunctival hyperaemia	15 (30.6%)	12 (28.6%)	13 (32.5%)	27 (29.7%)	40 (30.5%)
Eyelid vellus hair changes	4 (8.2%)	9 (21.4%)	6 (15.0%)	13 (14.3%)	19 (14.5%)
Eyelash changes	9 (18.4%)	6 (14.3%)	3 (7.5%)	15 (16.5%)	18 (13.7%)
Eyelash thickening	6 (12.2%)	5 (11.9%)	2 (5.0%)	11 (12.1%)	13 (9.9%)
Blepharal pigmentation	4 (8.2%)	4 (9.5%)	3 (7.5%)	8 (8.8%)	11 (8.4%)
Conjunctivitis allergic	3 (6.1%)	2 (4.8%)	2 (5.0%)	5 (5.5%)	7 (5.3%)
Punctate keratitis	4 (8.2%)	1 (2.4%)	2 (5.0%)	5 (5.5%)	7 (5.3%)
Eyelash hyperpigmentation	1 (2.0%)	3 (7.1%)	2 (5.0%)	4 (4.4%)	6 (4.6%)
Dry eye	3 (6.1%)	0 (0.0%)	1 (2.5%)	3 (3.3%)	4 (3.1%)
Conjunctival haemorrhage	1 (2.0%)	1 (2.4%)	1 (2.5%)	2 (2.2%)	3 (2.3%)
Eye irritation	0 (0.0%)	0 (0.0%)	3 (7.5%)	0 (0.0%)	3 (2.3%)
Cataract	1 (2.0%)	1 (2.4%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Conjunctival irritation	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	2 (5.0%)	0 (0.0%)	2 (1.5%)
Keratitis	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Meibomian gland dysfunction	2 (4.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Asthenopia	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Conjunctival deposit	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Corneal disorder	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Corneal erosion	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Diabetic retinopathy	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Eye pruritus	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Eyelid oedema	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Iris hyperpigmentation	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Photopsia	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Pingueculitis	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Trichiasis	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Trichomegaly	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Infections and infestations	15 (30.6%)	9 (21.4%)	13 (32.5%)	24 (26.4%)	37 (28.2%)
Nasopharyngitis	7 (14.3%)	2 (4.8%)	1 (2.5%)	9 (9.9%)	10 (7.6%)
Coronavirus infection	2 (4.1%)	2 (4.8%)	2 (5.0%)	4 (4.4%)	6 (4.6%)
Gastroenteritis	0 (0.0%)	2 (4.8%)	3 (7.5%)	2 (2.2%)	5 (3.8%)
COVID-19	2 (4.1%)	0 (0.0%)	2 (5.0%)	2 (2.2%)	4 (3.1%)
Gingivitis	0 (0.0%)	2 (4.8%)	1 (2.5%)	2 (2.2%)	3 (2.3%)
Periodontitis	2 (4.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Pharyngitis	0 (0.0%)	0 (0.0%)	2 (5.0%)	0 (0.0%)	2 (1.5%)
Bronchitis	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Cellulitis	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Conjunctivitis	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Dermatophytosis of nail	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Furuncle	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Herpes zoster	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Influenza	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Laryngopharyngitis	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Oral candidiasis	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Oral herpes	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Paronychia	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Pneumonia	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Wound infection bacterial	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Gastrointestinal disorders	10 (20.4%)	4 (9.5%)	1 (2.5%)	14 (15.4%)	15 (11.5%)
Abdominal discomfort	2 (4.1%)	2 (4.8%)	0 (0.0%)	4 (4.4%)	4 (3.1%)
Dental caries	3 (6.1%)	1 (2.4%)	0 (0.0%)	4 (4.4%)	4 (3.1%)
Large intestine polyp	1 (2.0%)	1 (2.4%)	1 (2.5%)	2 (2.2%)	3 (2.3%)
Constipation	2 (4.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Diarrhoea	2 (4.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Anal fissure	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Anal pruritus	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Malocclusion	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Nausea	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Toothache	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Skin and subcutaneous tissue disorders	6 (12.2%)	3 (7.1%)	5 (12.5%)	9 (9.9%)	14 (10.7%)
Eczema	2 (4.1%)	1 (2.4%)	3 (7.5%)	3 (3.3%)	6 (4.6%)
Hypertrichosis	3 (6.1%)	1 (2.4%)	0 (0.0%)	4 (4.4%)	4 (3.1%)
Acne	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Cold urticaria	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Dermal cyst	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Miliaria	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Respiratory, thoracic and mediastinal disorders	7 (14.3%)	2 (4.8%)	0 (0.0%)	9 (9.9%)	9 (6.9%)
Oropharyngeal pain	1 (2.0%)	2 (4.8%)	0 (0.0%)	3 (3.3%)	3 (2.3%)
Cough	2 (4.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Rhinitis allergic	2 (4.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Epistaxis	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)

Confidential

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Rhinorrhoea	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Investigations	4 (8.2%)	3 (7.1%)	1 (2.5%)	7 (7.7%)	8 (6.1%)
Glucose urine present	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Intraocular pressure increased	1 (2.0%)	1 (2.4%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Blood potassium increased	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Blood triglycerides increased	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Blood uric acid increased	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Gamma-glutamyltransferase increased	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
White blood cell count increased	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Musculoskeletal and connective tissue disorders	3 (6.1%)	3 (7.1%)	1 (2.5%)	6 (6.6%)	7 (5.3%)
Arthralgia	1 (2.0%)	1 (2.4%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Back pain	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Lumbar spinal stenosis	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Periarthritis	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Spondylolisthesis	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
General disorders and administration site conditions	3 (6.1%)	2 (4.8%)	0 (0.0%)	5 (5.5%)	5 (3.8%)
Pyrexia	1 (2.0%)	2 (4.8%)	0 (0.0%)	3 (3.3%)	3 (2.3%)
Injection site pain	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Malaise	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Thirst	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Immune system disorders	3 (6.1%)	1 (2.4%)	1 (2.5%)	4 (4.4%)	5 (3.8%)
Seasonal allergy	2 (4.1%)	1 (2.4%)	1 (2.5%)	3 (3.3%)	4 (3.1%)
Allergy to arthropod sting	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Injury, poisoning and procedural complications	2 (4.1%)	1 (2.4%)	0 (0.0%)	3 (3.3%)	3 (2.3%)
Contusion	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Epicondylitis	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Hand fracture	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Thermal burn	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (2.0%)	1 (2.4%)	1 (2.5%)	2 (2.2%)	3 (2.3%)
Bladder cancer	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Cholesteatoma	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Colon cancer	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Nervous system disorders	2 (4.1%)	1 (2.4%)	0 (0.0%)	3 (3.3%)	3 (2.3%)
Headache	1 (2.0%)	1 (2.4%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Sciatica	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Cardiac disorders	1 (2.0%)	1 (2.4%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Angina unstable	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Supraventricular tachycardia	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Hepatobiliary disorders	0 (0.0%)	1 (2.4%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Hepatic function abnormal	0 (0.0%)	1 (2.4%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Metabolism and nutrition disorders	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Diabetes mellitus	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Hypokalaemia	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Vascular disorders	1 (2.0%)	1 (2.4%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Aneurysm	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Hypertension	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Ear and labyrinth disorders	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Vertigo	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Psychiatric disorders	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Bipolar disorder	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Renal and urinary disorders	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Urinary retention	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.2.1

Confidential

表 2.7.4.2-6. 101260006LT: 治療期に認められた副作用一覧

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Subjects with any ADR(s)	29 (59.2%)	25 (59.5%)	26 (65.0%)	54 (59.3%)	80 (61.1%)
Eye disorders	28 (57.1%)	25 (59.5%)	26 (65.0%)	53 (58.2%)	79 (60.3%)
Growth of eyelashes	11 (22.4%)	15 (35.7%)	17 (42.5%)	26 (28.6%)	43 (32.8%)
Conjunctival hyperaemia	15 (30.6%)	12 (28.6%)	12 (30.0%)	27 (29.7%)	39 (29.8%)
Eyelid vellus hair changes	4 (8.2%)	9 (21.4%)	6 (15.0%)	13 (14.3%)	19 (14.5%)
Eyelash changes	9 (18.4%)	6 (14.3%)	3 (7.5%)	15 (16.5%)	18 (13.7%)
Eyelash thickening	6 (12.2%)	5 (11.9%)	2 (5.0%)	11 (12.1%)	13 (9.9%)
Blepharal pigmentation	4 (8.2%)	4 (9.5%)	3 (7.5%)	8 (8.8%)	11 (8.4%)
Eyelash hyperpigmentation	1 (2.0%)	3 (7.1%)	2 (5.0%)	4 (4.4%)	6 (4.6%)
Eye irritation	0 (0.0%)	0 (0.0%)	3 (7.5%)	0 (0.0%)	3 (2.3%)
Punctate keratitis	1 (2.0%)	1 (2.4%)	1 (2.5%)	2 (2.2%)	3 (2.3%)
Conjunctival irritation	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	2 (5.0%)	0 (0.0%)	2 (1.5%)
Keratitis	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Corneal disorder	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Eyelid oedema	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Iris hyperpigmentation	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Photopsia	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Trichiasis	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Trichomegaly	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Skin and subcutaneous tissue disorders	3 (6.1%)	1 (2.4%)	0 (0.0%)	4 (4.4%)	4 (3.1%)
Hypertrichosis	3 (6.1%)	1 (2.4%)	0 (0.0%)	4 (4.4%)	4 (3.1%)
Investigations	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
White blood cell count increased	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Nervous system disorders	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Headache	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.2.2

表 2.7.4.2-7. 101260006LT: 虹彩色、睫毛、眼瞼の変化に関する有害事象の発現頻度

Subjects with any adverse event related to	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Eyelash	18 (36.7%)	19 (45.2%)	19 (47.5%)	37 (40.7%)	56 (42.7%)
Eyelid	7 (14.3%)	12 (28.6%)	7 (17.5%)	19 (20.9%)	26 (19.8%)
Iris	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 表 14.3.1.5 から引用

Confidential

表 2.7.4.2-8. 101260006LT: 初回発現時期別の有害事象一覧（グループ 1＋グループ 2）

System organ class Preferred term	1 - 30 days (N=91)	31 - 90 days (N=90)	91 - 180 days (N=87)	181 - 270 days (N=86)	271 - 360 days (N=84)	> 360 days (N=71)
Subjects with any AE(s)	41 (45.1%)	38 (42.2%)	30 (34.5%)	25 (29.1%)	17 (20.2%)	7 (9.9%)
Eye disorders	33 (36.3%)	24 (26.7%)	14 (16.1%)	9 (10.5%)	5 (6.0%)	6 (8.5%)
Conjunctival hyperaemia	22 (24.2%)	2 (2.2%)	0 (0.0%)	3 (3.5%)	0 (0.0%)	0 (0.0%)
Growth of eyelashes	6 (6.6%)	13 (14.4%)	5 (5.7%)	1 (1.2%)	1 (1.2%)	0 (0.0%)
Punctate keratitis	4 (4.4%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelash thickening	3 (3.3%)	5 (5.6%)	1 (1.1%)	1 (1.2%)	0 (0.0%)	1 (1.4%)
Eyelash changes	2 (2.2%)	6 (6.7%)	2 (2.3%)	2 (2.3%)	1 (1.2%)	2 (2.8%)
Eyelash hyperpigmentation	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	1 (1.4%)
Asthenopia	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blepharal pigmentation	1 (1.1%)	2 (2.2%)	1 (1.1%)	3 (3.5%)	1 (1.2%)	0 (0.0%)
Conjunctival irritation	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dry eye	1 (1.1%)	0 (0.0%)	2 (2.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid vellus hair changes	1 (1.1%)	5 (5.6%)	2 (2.3%)	2 (2.3%)	1 (1.2%)	2 (2.8%)
Keratitis	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cataract	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)	0 (0.0%)
Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.3%)	0 (0.0%)	0 (0.0%)
Conjunctivitis allergic	0 (0.0%)	3 (3.3%)	2 (2.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Corneal erosion	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Diabetic retinopathy	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pruritus	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid oedema	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Iris hyperpigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Meibomian gland dysfunction	0 (0.0%)	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Photopsia	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Trichiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
Trichomegaly	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
Gastrointestinal disorders	4 (4.4%)	3 (3.3%)	4 (4.6%)	4 (4.7%)	1 (1.2%)	0 (0.0%)
Abdominal discomfort	1 (1.1%)	2 (2.2%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Constipation	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Dental caries	1 (1.1%)	1 (1.1%)	1 (1.1%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Large intestine polyp	1 (1.1%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Malocclusion	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Anal fissure	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Anal pruritus	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Diarrhoea	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Nausea	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Toothache	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Infections and infestations	4 (4.4%)	6 (6.7%)	9 (10.3%)	3 (3.5%)	7 (8.3%)	0 (0.0%)
Gastroenteritis	1 (1.1%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Confidential

System organ class Preferred term	1 - 30 days (N=91)	31 - 90 days (N=90)	91 - 180 days (N=87)	181 - 270 days (N=86)	271 - 360 days (N=84)	> 360 days (N=71)
Laryngopharyngitis	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Oral herpes	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Periodontitis	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Bronchitis	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
COVID-19	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Conjunctivitis	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Coronavirus infection	0 (0.0%)	1 (1.1%)	1 (1.1%)	1 (1.2%)	1 (1.2%)	0 (0.0%)
Furuncle	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gingivitis	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Herpes zoster	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Influenza	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Nasopharyngitis	0 (0.0%)	2 (2.2%)	3 (3.4%)	1 (1.2%)	3 (3.6%)	0 (0.0%)
Oral candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Musculoskeletal and connective tissue disorders	2 (2.2%)	0 (0.0%)	0 (0.0%)	3 (3.5%)	1 (1.2%)	0 (0.0%)
Arthralgia	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Periarthritis	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Back pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Lumbar spinal stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Spondylolisthesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Nervous system disorders	2 (2.2%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Headache	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sciatica	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiratory, thoracic and mediastinal disorders	2 (2.2%)	2 (2.2%)	1 (1.1%)	3 (3.5%)	1 (1.2%)	0 (0.0%)
Cough	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Epistaxis	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Oropharyngeal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.3%)	1 (1.2%)	0 (0.0%)
Rhinitis allergic	0 (0.0%)	1 (1.1%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Rhinorrhoea	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
General disorders and administration site conditions	1 (1.1%)	2 (2.2%)	1 (1.1%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Pyrexia	1 (1.1%)	0 (0.0%)	1 (1.1%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Injection site pain	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Malaise	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Thirst	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin and subcutaneous tissue disorders	1 (1.1%)	1 (1.1%)	4 (4.6%)	1 (1.2%)	1 (1.2%)	1 (1.4%)
Hypertrichosis	1 (1.1%)	0 (0.0%)	3 (3.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Acne	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Dermal cyst	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eczema	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	1 (1.4%)
Vascular disorders	1 (1.1%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Aneurysm	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypertension	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Angina unstable	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Supraventricular tachycardia	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hepatobiliary disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Hepatic function abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)

Confidential

System organ class Preferred term	1 - 30 days (N=91)	31 - 90 days (N=90)	91 - 180 days (N=87)	181 - 270 days (N=86)	271 - 360 days (N=84)	> 360 days (N=71)
Immune system disorders	0 (0.0%)	1 (1.1%)	2 (2.3%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Allergy to arthropod sting	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Seasonal allergy	0 (0.0%)	1 (1.1%)	2 (2.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Injury, poisoning and procedural complications	0 (0.0%)	1 (1.1%)	1 (1.1%)	1 (1.2%)	1 (1.2%)	0 (0.0%)
Contusion	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Epicondylitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Hand fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Thermal burn	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Investigations	0 (0.0%)	1 (1.1%)	1 (1.1%)	3 (3.5%)	2 (2.4%)	0 (0.0%)
Blood potassium increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
Blood triglycerides increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Blood uric acid increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Gamma-glutamyltransferase Increased	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Glucose urine present	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Intraocular pressure increased	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (1.2%)	0 (0.0%)
White blood cell count Increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Metabolism and nutrition disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Diabetes mellitus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0%)	1 (1.1%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cholesteatoma	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Colon cancer	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Psychiatric disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Bipolar disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Renal and urinary disorders	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Urinary retention	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a preferred term was counted only once for that preferred term, at the earliest incidence day. Any subject who experienced multiple events within a system organ class was counted for each period from that preferred term, at the earliest incidence day.

Subjects are classified by actual treatment received.

Any subject who had any visit in period is included in denominator of each period.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.4.4

Confidential

表 2.7.4.2-9. 101260006LT: 初回発現時期別の有害事象一覧（グループ 3）

System organ class Preferred term	1 - 30 days (N=40)	31 - 90 days (N=40)	91 - 180 days (N=40)	181 - 270 days (N=39)	271 - 360 days (N=38)	> 360 days (N=25)
Subjects with any AE(s)	20 (50.0%)	13 (32.5%)	13 (32.5%)	10 (25.6%)	7 (18.4%)	3 (12.0%)
Eye disorders	16 (40.0%)	10 (25.0%)	6 (15.0%)	6 (15.4%)	4 (10.5%)	2 (8.0%)
Conjunctival hyperaemia	10 (25.0%)	1 (2.5%)	1 (2.5%)	1 (2.6%)	0 (0.0%)	0 (0.0%)
Eye irritation	3 (7.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Erythema of eyelid	2 (5.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Punctate keratitis	2 (5.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctival deposit	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctival irritation	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctivitis allergic	1 (2.5%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dry eye	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Growth of eyelashes	1 (2.5%)	8 (20.0%)	2 (5.0%)	3 (7.7%)	2 (5.3%)	1 (4.0%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	3 (7.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Corneal disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	0 (0.0%)
Eyelash changes	0 (0.0%)	0 (0.0%)	1 (2.5%)	1 (2.6%)	1 (2.6%)	0 (0.0%)
Eyelash hyperpigmentation	0 (0.0%)	0 (0.0%)	2 (5.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelash thickening	0 (0.0%)	0 (0.0%)	2 (5.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid vellus hair changes	0 (0.0%)	2 (5.0%)	1 (2.5%)	1 (2.6%)	1 (2.6%)	1 (4.0%)
Keratitis	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pingueculitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Infections and infestations	3 (7.5%)	2 (5.0%)	4 (10.0%)	4 (10.3%)	3 (7.9%)	0 (0.0%)
Coronavirus infection	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Gastroenteritis	1 (2.5%)	0 (0.0%)	1 (2.5%)	1 (2.6%)	0 (0.0%)	0 (0.0%)
Paronychia	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
COVID-19	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	0 (0.0%)
Cellulitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Dermatophytosis of nail	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gingivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	0 (0.0%)
Nasopharyngitis	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (2.6%)	0 (0.0%)
Pneumonia	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Wound infection bacterial	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal disorders	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Large intestine polyp	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Ear and labyrinth disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Vertigo	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Hepatobiliary disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Hepatic function abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Immune system disorders	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Seasonal allergy	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Investigations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.0%)
Glucose urine present	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.0%)
Metabolism and nutrition disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Hypokalaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Musculoskeletal and connective tissue disorders	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Back pain	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Confidential

System organ class Preferred term	1 - 30 days (N=40)	31 - 90 days (N=40)	91 - 180 days (N=40)	181 - 270 days (N=39)	271 - 360 days (N=38)	> 360 days (N=25)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Bladder cancer	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin and subcutaneous tissue disorders	0 (0.0%)	2 (5.0%)	1 (2.5%)	1 (2.6%)	1 (2.6%)	0 (0.0%)
Cold urticaria	0 (0.0%)	1 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eczema	0 (0.0%)	1 (2.5%)	1 (2.5%)	0 (0.0%)	1 (2.6%)	0 (0.0%)
Miliaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a preferred term was counted only once for that preferred term, at the earliest incidence day. Any subject who experienced multiple events within a system organ class was counted for each period from that preferred term, at the earliest incidence day.

Subjects are classified by actual treatment received.

Any subject who had any visit in period is included in denominator of each period.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.4.3

2.7.4.2.1.2 死亡

安全性を評価した 4 試験（101260007LT、012601IN、101260005LT 及び 101260006LT）における死亡例一覧を表 2.7.4.2-10 に示した。

101260005LT 試験の 0.002% STN1012600 群において「心筋虚血（CRF 記載：虚血性心疾患による溺水吸引）」による死亡が 1 例、0.005%ラタノプロスト群において「心筋梗塞」による死亡が 1 例認められたが、いずれも治験使用薬との因果関係は否定された。

101260007LT 試験、012601IN 試験及び 101260006LT 試験では、死亡例は認められなかった。

表 2.7.4.2-10. 死亡例一覧

Protocol No.	Actual Treatment	Subject	Age(years) /Sex/Race	Eye(s) affected	Adverse event reported (SOC/Preferred Term)	Onset date (Day)/ Stop date (Day)	Serious?/ Severity /Causality	Action taken to study drug	Outcome
101260005LT	0.002% STN1012600	12605-3920109-01	72/F/ Japanese	Non-ocular	DROWNING DUE TO ISCHAEMIC HEART DISEASE (Cardiac disorders/Myocardial ischaemia)	20[redacted](50)/ 20[redacted](50)	Y/Severe/ Not Related (Other (ACCIDENTAL EVENT))	Drug Withdrawn	Fatal
101260005LT	0.005% Latanoprost	12605-3920104-04	69/F/ Japanese	Non-ocular	MYOCARDIAL INFARCTION (Cardiac disorders/Myocardial infarction)	20[redacted](26)/ 20[redacted](26)	Y/Severe/ Not Related (Other (ACCIDENTAL EVENTS))	Drug Withdrawn	Fatal

Cross Reference: 添付資料 5.3.5.1-2 Listing 16.2.4.1 及び Listing 16.2.7.2

Confidential

2.7.4.2.1.3 その他の重篤な有害事象

安全性を評価した 4 試験（101260007LT、012601IN、101260005LT 及び 101260006LT）における、治験使用薬投与後に発生した死亡以外の重篤な有害事象の発現症例一覧を表 2.7.4.2-11 及び表 2.7.4.2-12 に示した。

死亡以外の重篤な有害事象は、012601IN 試験の Placebo - 0.003% STN1012600 群（プラセボ投与期間中に発現）において「筋力低下（CRF 記載：左手脱力）」が 1 例、101260005LT 試験の 0.005% ラタノプロスト群において「脊椎圧迫骨折（CRF 記載：腰椎圧迫骨折）」及び「胆管結石（CRF 記載：胆管結石の悪化）」が各 1 例、101260006LT 試験のグループ 1 に「不安定狭心症」、「真珠腫〔CRF 記載：真珠腫性中耳炎（右）〕」、「大腸ポリープ」が各 1 例、グループ 2 に「結腸癌（CRF 記載：盲腸癌）」、「大腸ポリープ」が各 1 例、グループ 3 に「肺炎（CRF 記載：急性肺炎）」、「蜂巣炎〔CRF 記載：蜂窩織炎（左膝）〕」、「大腸ポリープ」が各 1 例に認められたが、いずれも治験使用薬との因果関係は否定された。

101260007LT 試験では、重篤な有害事象は認められなかった。

表 2.7.4.2-11. 012601IN , 101260005LT: 死亡以外の重篤な有害事象発現症例一覧

Protocol No.	Actual Treatment	Subject	Age(years)/Sex/Race	Eye(s) affected	Adverse event reported (SOC/Preferred Term)	Onset date (Day)/ Stop date (Day)	Serious?/ Severity /Causality	Action taken to study drug	Outcome
012601IN	Placebo - 0.003% DE-126	840295-1131	76/F/White	Non-ocular	LEFT HAND WEAKNESS (Musculoskeletal and connective tissue disorders/Muscular weakness)	20[redacted]-[redacted]-[redacted] (13)/ 20[redacted]-[redacted]-[redacted] (13)	Y/Mild/ Not Related	Dose Not Changed	Recovered/ Resolved
101260005LT	0.005% Latanoprost	12605-3920014-05	75/F/ Japanese	Non-ocular	LUMBAR SPINE COMPRESSION FRACTURE (Injury, poisoning and procedural complications/Spinal compression fracture)	20[redacted]-[redacted]-[redacted] (79)/	Y/Moderate/ Not Related (Other (CAUSED BY FALL))	Drug Withdrawn	Not Recovered/Not Resolved
		12605-3920121-04	48/M/ Japanese	Non-ocular	AGGRAVATION OF BILE DUCT STONE (Hepatobiliary disorders/Bile duct stone)	20[redacted]-[redacted]-[redacted] (-6)/ 20[redacted]-[redacted]-[redacted](61)	Y/Moderate/ Not Related (Other (DUE TO LIFE STYLE))	Not Applicable	Recovered/Resolved

Cross Reference: 添付資料 5.3.5.1-1 Listing 16.2.7.2、添付資料 5.3.5.1-2 Listing 16.2.4.1 及び Listing 16.2.7.4

表 2.7.4.2-12. 101260006LT:重篤な有害事象発現症例一覧

Actual Treatment	Subject	Age(ye ars)/Se x/Race	Eye(s) affecte d	Adverse event reported (SOC/Preferred Term)	Onset date (Day)/ Stop date (Day)	TEAE?/Serious?/Severity/ Lead to study discontinuation?/ Causality to STN1012600/ Timolol (attribute)	Action taken to STN1012600 / Timolol	Outco me
0.002% STN1012600 (Group 1)	12606-392004 1-02	57/M/J apanes e	Non-ocular	ANGINA UNSTABLE (Cardiac disorders/Angina unstable)	20[redacted] (188)	-Y/Y/Moderate/N/ /Not Related/Not Applicable (Other (NO CASUAL RELATIONSHIP TO THE INVESTIGATIONAL DRUG BECAUSE CONCURRENT DISIASES(HYPERTENSION, DYSLIPIDAEMIA, DIABETES MELLITUS) ARE THOUGHT TO BE THE CAUSE.))	Dose Not Changed/ Not Applicable	Recove ring/Re solving
	12606-392007 3-07	36/F/Ja panese	Non-ocular	CHRONIC OTITIS MEDIA WITH CHOLESTEATOMA(RIGHT) (Neoplasms benign, malignant and unspecified (incl cysts and polyps)/Cholesteatoma)	20[redacted] (153) 20[redacted] (365)	-Y/Y/Moderate/N/ /Not Related/Not Applicable -(Other (ACCIDENTAL EVENT))	Dose Not Changed/ Not Applicable	Recove red/Res olved
	12606-392008 5-06	75/M/J apanes e	Non-ocular	LARGE INTESTINE POLYP (Gastrointestinal disorders/Large intestine polyp)	20[redacted] (18)/ 20[redacted] (53)	-Y/Y/Mild/N/ Not Related/Not Applicable -(Other (INCIDENTAL OCCURENCE))	Dose Not Changed/ Not Applicable	Recove red/Res olved
0.002% STN1012600 (Group 2)	12606-392013 7-03	73/F/Ja panese	Non-ocular	CAECAL CANCER (Neoplasms benign, malignant and unspecified (incl cysts and polyps)/Colon cancer)	20[redacted] (75)/	-Y/Y/Moderate/N/ Not Related/Not Applicable (Other (ACCIDENTAL SYMPTOM))	Dose Not Changed/ Not Applicable	Recove ring/Re solving
	12606-392014 3-06	69/F/Ja panese	Non-ocular	LARGE INTESTINE POLYP (Gastrointestinal disorders/Large intestine polyp)	20[redacted] (178) 20[redacted] (179)	-Y/Y/Mild/N/ /Not Related/Not Applicable -(Other (THIS EVENT WAS JUDGED TO BE A COINCIDENCE.))	Dose Not Changed/ Not Applicable	Recove red/Res olved
0.002% STN1012600 + 0.5% Timolol (Group 3)	12606-392001 4-06	84/F/Ja panese	Non-ocular	ACUTE PNEUMONIA (Infections and infestations/Pneumonia)	20[redacted] (38)/ 20[redacted] (121)	-Y/Y/Severe/Y/ Not Related/Not Related (Other -(CONSIDERED TO BE AN ACCIDENTIAL EVENT BASED ON THE MECHANISM OF ACTION OF THE STUDY DRUG.))	Drug Withdrawn/ Drug Withdrawn	Recove red/Res olved
	12606-392008 5-05	72/M/J apanes e	Non-ocular	CELLULITIS(LEFT KNEE) (Infections and infestations/Cellulitis)	20[redacted] (326) 20[redacted] (337)	-Y/Y/Moderate/N/ /Not Related/Not Related (Other -(INCIDENTAL EVENTS DUE TO INFECTION))	Dose Not Changed/ Dose Not Changed	Recove red/Res olved

Confidential

Actual Treatment	Subject	Age(years)/Sex/Race	Eye(s) affected	Adverse event reported (SOC/Preferred Term)	Onset date (Day)/ Stop date (Day)	TEAE?/Serious?/Severity/ Lead to study discontinuation?/ Causality to STN1012600/ Timolol (attribute)	Action taken to STN1012600 / Timolol	Outcome
	12606-392013 4-10	75/M/J	Non-apanes ocular e	LARGE INTESTINE POLYP (Gastrointestinal disorders/Large intestine polyp)	20[redacted]-[redacted] (9)/ 20[redacted]-[redacted] (10)	Y/Y/Moderate/N/ Not Related/Not Related (Other (SINCE THE EYE DROPS ARE UNLIKELY TO HAVE AFFECTED THE OCCURRENCE OF THIS EVENT, IT IS AN INCIDENTAL EVENT AND A CAUSAL RELATIONSHIP WITH THE STUDY DRUG AND TIMOLOL CAN BE RULED OUT.))	Dose Not Changed/ Dose Not Changed	Recovered/Resolved

Cross Reference: 添付資料 5.3.5.2-1 Listing 16.2.4.1 及び Listing 16.2.7.4

2.7.4.2.1.4 その他の重要な有害事象

安全性を評価した 4 試験（101260007LT、012601IN、101260005LT 及び 101260006LT）における、有害事象により治験使用薬の投与中止に至った症例一覧（死亡及びその他の重篤な有害事象を含む）を表 2.7.4.2-13 及び表 2.7.4.2-14 に示した。

死亡を除いた有害事象のため投与中止に至った症例は、012601IN 試験の 0.002% STN1012600 群で 2.3%（1/44 例）、0.003% STN1012600 群で 2.2%（1/45 例）、0.005%ラタノプロスト群で 2.3%（1/44 例）、101260005LT 試験の 0.002% STN1012600 群で 1.2%（2/162 例）、0.005%ラタノプロスト群で 3.7%（6/163 例）、101260006LT 試験全体で 6.1%（8/131 例）報告された。

事象別では「結膜充血」による中止症例が最も多かった。0.005%ラタノプロスト点眼液と比較して 0.002% STN1012600 点眼液で中止例が多くなる傾向はなかった。

101260007LT 試験では、治験使用薬の投与中止に至った症例は認められなかった。

表 2.7.4.2-13. 012601IN , 101260005LT: 有害事象により治験使用薬の投与中止に至った症例一覧

Protocol No.	Actual Treatment	Subject	Age(years) /Sex/Race	Eye(s) affected	Adverse event reported (SOC/Preferred Term)	Onset date (Day)/ Stop date (Day)	Serious?/ Severity /Causality	Action taken to study drug	Outcome
012601IN	0.005% Latanoprost	392306-111970	71/F/ Asian	Non-ocular	SUDDEN HEARING LOSS (Ear and labyrinth disorders/Sudden hearing loss)	20[redacted] (38)/ Ongoing	N/Moderate/ Not Related	Drug Withdrawn; Dropped Subject From Study	Recovering/ Resolving
	0.002% STN101260 0	392326-1201	68/M/ Asian	OD	CONJUNCTIVAL HYPEREMIA (Eye disorders/Conjunctival hyperaemia)	20[redacted] (61)/ Ongoing	N/Moderate/ Not Related	Drug Withdrawn; Dropped Subject From Study	Recovering/ Resolving
				OD	CHEMOSIS (Eye disorders/Conjunctival oedema)	20[redacted] (64)/ 20[redacted] (71)	N/Mild/ Not Related	Not Applicable; Dropped Subject From Study	Recovered/ Resolved
	0.003% STN101260 0	392314-1237	41/F/ Asian	OU	CONJUNCTIVITIS ALLERGIC (Eye disorders/Conjunctivitis allergic)	20[redacted] (3)/ Ongoing	N/Moderate/ Related	Drug Withdrawn; Dropped Subject From Study	Recovering/ Resolving
101260005LT	0.002% STN101260 0	12605-3920082-10	28/M/Japanese	OU	CONJUNCTIVAL HYPEREMIA (Eye disorders/Conjunctival hyperaemia)	20[redacted] (2)/ 20[redacted] (29)	N/Mild/Related	Drug Withdrawn	Recovered/Resolved
				OU	FOREIGN BODY SENSATION IN EYES (Eye disorders/Foreign body sensation in eyes)	20[redacted] (2)/ 20[redacted] (29)	N/Mild/Related	Drug Withdrawn	Recovered/Resolved
				Non-ocular	HEADACHES (Nervous system disorders/Headache)	20[redacted] (2)/ 20[redacted] (15)	N/Mild/ Not Related	Drug Withdrawn	Recovered/Resolved
				Non-ocular	QUEASY (Gastrointestinal disorders/Nausea)	20[redacted] (2)/ 20[redacted] (15)	N/Mild/ Not Related	Drug Withdrawn	Recovered/Resolved
				OU	EYE DISCHARGE (Eye disorders/Eye discharge)	20[redacted] (2)/ 20[redacted] (15)	N/Mild/Related	Drug Withdrawn	Recovered/Resolved
		12605-3920109-01	72/F/Japanese	Non-ocular	DROWNING DUE TO ISCHAEMIC HEART DISEASE (Cardiac disorders/Myocardial ischaemia)	20[redacted] (50)/ 20[redacted] (50)	Y/Severe /Not Related	Drug Withdrawn	Fatal

Confidential

Protocol No.	Actual Treatment	Subject	Age(years) /Sex/Race	Eye(s) affected	Adverse event reported (SOC/Preferred Term)	Onset date (Day)/ Stop date (Day)	Serious?/ Severity /Causality	Action taken to study drug	Outcome
		12605-3920131-01	57/F/Japanese	OU	CONJUNCTIVAL CHEMOSIS (Eye disorders/Conjunctival oedema)	20[redacted] (4)/ 20[redacted] (13)	N/Mild/Related	Not Applicable	Recovered/Resolved
				Non-ocular	PALPITATIONS (Cardiac disorders/Palpitations)	20[redacted] (3)/ 20[redacted] (3)	N/Moderate/Related	Drug Withdrawn	Recovered/Resolved
	0.005% Latanoprost	12605-3920014-05	75/F/Japanese	Non-ocular	LUMBAR SPINE COMPRESSION FRACTURE (Injury, poisoning and procedural complications/Spinal compression fracture)	20[redacted] (79)/	Y/Moderate/Not Related	Drug Withdrawn	Not Recovered/Not Resolved
		12605-3920017-02	70/M/Japanese	OD	CONJUNCTIVAL HYPERAEMIA (Eye disorders/Conjunctival hyperaemia)	20[redacted] (34)/ 20[redacted] (62)	N/Mild/Related	Drug Withdrawn	Recovered/Resolved
				OS	CONJUNCTIVAL HYPERAEMIA (Eye disorders/Conjunctival hyperaemia)	20[redacted] (50)/ 20[redacted] (62)	N/Mild/Related	Drug Withdrawn	Recovered/Resolved
		12605-3920093-09	63/M/Japanese	OS	CORNEAL INFECTION (Infections and infestations/Corneal infection)	20[redacted] (32)/ 20[redacted] (60)	N/Moderate/Related	Drug Withdrawn	Recovered/Resolved
	0.005% Latanoprost	12605-3920104-04	69/F/Japanese	Non-ocular	MYOCARDIAL INFARCTION (Cardiac disorders/Myocardial infarction)	20[redacted] (26)/ 20[redacted] (26)	Y/Severe/Not Related	Drug Withdrawn	Fatal
		12605-3920109-09	82/F/Japanese	OS	CONJUNCTIVITIS BACTERIAL (Infections and infestations/Conjunctivitis bacterial)	20[redacted] (22)/	N/Mild/Not Related	Drug Withdrawn	Not Recovered/Not Resolved
				OD	CONJUNCTIVITIS BACTERIAL (Infections and infestations/Conjunctivitis bacterial)	20[redacted] (24)/	N/Mild/Not Related	Drug Withdrawn	Not Recovered/Not Resolved
		12605-3920130-07	67/F/Japanese	Non-ocular	BREAST CANCER(LEFT) (Neoplasms benign, malignant and unspecified (incl cysts and polyps)/Breast cancer)	20[redacted] (18)/	N/Mild/Not Related	Drug Withdrawn	Not Recovered/Not Resolved
	0.005% Latanoprost	12605-3920133-06	55/M/Japanese	OU	EYE PAIN (Eye disorders/Eye pain)	20[redacted] (3)/ 20[redacted] (8)	N/Mild/Related	Drug Withdrawn	Recovered/Resolved

Cross Reference: 添付資料 5.3.5.1-1 Listing 16.2.4.3 及び Listing 16.2.7.1、添付資料 5.3.5.1-2 Listing 16.2.4.1 及び Listing 16.2.7.3

表 2.7.4.2-14. 101260006LT: 有害事象により治験使用薬の投与中止に至った症例一覧

Actual Treatment	Subject	Age(years)/Sex/ Race	Eye(s) affected	Adverse event reported (SOC/Preferred Term)	Onset date (Day)/ Stop date (Day)	TEAE?/Serious?/Severity/ Lead to study discontinuation?/ Causality to STN1012600/ Timolol (attribute)	Action taken to STN10126 00/ Timolol	Outcome
0.002% STN10126 00 (Group 1)	12606-392007 5-07	79/M/Japanese	Non-ocular	STOMACH UPSET (Gastrointestinal disorders/Abdominal discomfort)	20[redacted]/	Y/N/Moderate/Y/ Not Related/Not Applicable (Other (FOR AN UNKNOWN REASON))	Drug Withdrawn / Not Applicable	Not Recovered/Not Resolved
	12606-392007 8-09	67/M/Japanese	OD	INCREASED INTRAOCULAR PRESSURE (Investigations/Intraocular pressure increased)	20[redacted] (179)/	Y/N/Mild/Y/ Not Related/Not Applicable (Other (ACCIDENTAL EVENT))	Drug Withdrawn / Not Applicable	Not Recovered/Not Resolved
	12606-392014 3-01	51/M/Japanese	OU	KERATOCONJUNCTIVITIS (Eye disorders/Keratitis)	20[redacted] (4)/ 20[redacted] (43)	Y/N/Moderate/Y/ Related/Not Applicable	Drug Withdrawn / Not Applicable	Recovered/Resolved
0.002% STN10126 00 (Group 2)	12606-392005 7-07	64/F/Japanese	Non-ocular	EXACERBATION OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (Cardiac disorders/Supraventricular tachycardia)	20[redacted] (38)/ 20[redacted] (57)	Y/N/Moderate/Y/ Not Related/Not Applicable (Other (PSYCHOGENIC))	Drug Withdrawn / Not Applicable	Recovered/Resolved
	12606-392008 9-01	72/M/Japanese	OU	GROWTH OF EYELASHES (Eye disorders/Growth of eyelashes)	20[redacted] (113)/ 20[redacted] (188)	Y/N/Mild/Y/ Related/Not Applicable	Drug Withdrawn / Not Applicable	Recovered/Resolved
0.002% STN10126 00 (Group 2)	12606-392013 4-08	80/F/Japanese	OU	PHOTOPSIA (Eye disorders/Photopsia)	20[redacted] (31)/ 20[redacted] (160)	Y/N/Mild/Y/ Related/Not Applicable	Drug Withdrawn / Not Applicable	Recovered/Resolved
			OU	EYELID PIGMENTATION (Eye disorders/Blepharal pigmentation)	20[redacted] (33)/ 20[redacted] (160)	Y/N/Mild/Y/ Related/Not Applicable	Drug Withdrawn / Not Applicable	Recovered/Resolved

Confidential

Actual Treatment	Subject	Age(years)/Sex/ Race	Eye(s) affected	Adverse event reported (SOC/Preferred Term)	Onset date (Day)/ Stop date (Day)	TEAE?/Serious?/Severity/ Lead to study discontinuation?/ Causality to STN1012600/ Timolol (attribute)	Action taken to STN10126 00/ Timolol	Outcome
0.002% STN1012600 + 0.5% Timolol (Group 3)	12606-4-06	84/F/Japanese	Non-ocular	ACUTE PNEUMONIA (Infections and infestations/Pneumonia)	20[redacted]-[redacted] (38)/ 20[redacted]-[redacted]-[redacted] (121)	Y/Y/Severe/Y/ Not Related/Not Related (Other (CONSIDERED TO BE AN ACCIDENTIAL EVENT BASED ON THE MECHANISM OF ACTION OF THE STUDY DRUG.))	Drug Withdrawn / Drug Withdrawn	Recovered/Resolved
0.002% STN1012600 + 0.5% Timolol (Group 3)	12606-4-10	75/M/Japanese	Non-ocular	BLADDER CANCER (Neoplasms benign, malignant and unspecified (incl cysts and polyps)/Bladder cancer)	20[redacted]-[redacted] (166)/	Y/N/Moderate/Y/ Not Related/Not Related (Other (BLADDER CANCER WAS FOUND HAPPENDLY, WHILE THE PATIENT WENT THROUGH EXAMS DUE TO HIGH CA19-9.))	Drug Withdrawn / Drug Withdrawn	Not Recovered/Not Resolved

Cross Reference: 添付資料 5.3.5.2-1 Listing 16.2.1 及び Listing 16.2.7.3

2.7.4.2.1.5 器官別又は症候群別有害事象の解析

(1) 併合解析

併合解析における事象別の有害事象及び副作用一覧を表 2.7.4.2-3 及び表 2.7.4.2-4 に、器官別の有害事象及び副作用一覧を表 2.7.4.2-15 及び表 2.7.4.2-16 示した。

STN1012600 点眼液において最も高頻度であった有害事象の器官別大分類はいずれの濃度群でも眼障害であり、0.002% STN1012600 群の眼障害の発現頻度は 39.9%（73/183 例）であった。0.005%ラタノプロスト群の眼障害の発現頻度は 31.5%（58/184 例）であり、大きな差異はなかった。次に、0.002% STN1012600 群において高頻度であった分類は感染症および寄生虫症 6.6%（12/183 例）、筋骨格系および結合組織障害 2.2%（4/183 例）であり、その他の発現頻度は 1.6%以下であった。眼障害以外の分類について、心臓障害の 1 例（PT：動機）及び感染症および寄生虫症の 1 例（PT：結膜炎）を除きいずれの事象も治験使用薬との因果関係はなしと判断された。

また、最も高頻度であった副作用の器官別大分類も眼障害であり、0.002% STN1012600 群 33.9%（62/183 例）、0.005% ラタノプロスト群 20.7%（38/184 例）であった。

以上より、0.002% STN1012600 点眼液の有害事象は主に眼局所に発現すると考えられた。

Confidential

表 2.7.4.2-15. 併合解析: 器官分類別の有害事象一覧

System organ class Preferred term	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
Eye disorders	3 (27.3%)	58 (31.5%)	7 (35.0%)	7 (35.0%)	73 (39.9%)	11 (52.4%)	101 (39.6%)
Infections and infestations	0 (0.0%)	14 (7.6%)	3 (15.0%)	2 (10.0%)	12 (6.6%)	2 (9.5%)	19 (7.5%)
Nervous system disorders	0 (0.0%)	3 (1.6%)	0 (0.0%)	0 (0.0%)	3 (1.6%)	2 (9.5%)	5 (2.0%)
Investigations	1 (9.1%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	1 (0.5%)	1 (4.8%)	4 (1.6%)
Musculoskeletal and connective tissue disorders	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	4 (2.2%)	0 (0.0%)	4 (1.6%)
Skin and subcutaneous tissue disorders	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	3 (1.6%)	1 (4.8%)	4 (1.6%)
General disorders and administration site conditions	0 (0.0%)	3 (1.6%)	0 (0.0%)	0 (0.0%)	3 (1.6%)	0 (0.0%)	3 (1.2%)
Gastrointestinal disorders	0 (0.0%)	3 (1.6%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	0 (0.0%)	2 (0.8%)
Injury, poisoning and procedural complications	0 (0.0%)	5 (2.7%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (4.8%)	2 (0.8%)
Cardiac disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Ear and labyrinth disorders	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Metabolism and nutrition disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Renal and urinary disorders	1 (9.1%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Respiratory, thoracic and mediastinal disorders	0 (0.0%)	2 (1.1%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Vascular disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Product issues	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Confidential

表 2.7.4.2-16. 併合解析: 器官分類別の副作用一覧

System organ class Preferred term	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=184)	0.0005% STN1012600 (N=20)	0.001% STN1012600 (N=20)	0.002% STN1012600 (N=183)	0.003% STN1012600 (N=21)	STN1012600 Total** (N=255)
Eye disorders	2 (18.2%)	38 (20.7%)	5 (25.0%)	5 (25.0%)	62 (33.9%)	5 (23.8%)	79 (31.0%)
Cardiac disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Infections and infestations	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.4%)
Skin and subcutaneous tissue disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.8%)	1 (0.4%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

(2) 長期投与試験

長期投与試験（101260006LT）における事象別の有害事象及び副作用一覧を表 2.7.4.2-5 及び表 2.7.4.2-6 に、器官別の有害事象及び副作用一覧を表 2.7.4.2-17 及び表 2.7.4.2-18 に示した。

最も高頻度であった有害事象の器官別大分類はいずれの群でも眼障害であり、全体の眼障害の有害事象発現頻度は 67.9%（89/131 例）であった。次に、高頻度であった分類は感染症および寄生虫症 28.2%（37/131 例）、胃腸障害 11.5%（15/131 例）、皮膚および皮下組織障害 10.7%（14/131 例）、呼吸器、胸郭および縦隔障害 6.9%（9/131 例）、臨床検査 6.1%（8/131 例）、筋骨格系および結合組織障害 5.3%（7/131 例）であり、その他の発現頻度は 3.8%以下であった。眼障害以外の分類について、皮膚および皮下組織障害の 4 例（PT：多毛症）、臨床検査の 1 例（PT：白血球数増加）及び神経系障害の 1 例（PT：頭痛）を除きいずれの事象も治験使用薬との因果関係はなしと判断された。

また、最も高頻度であった副作用の器官別大分類も眼障害であり、全体の眼障害の副作用発現頻度は 60.3%（79/131 例）であった。

以上より、0.002% STN1012600 点眼液の有害事象は主に眼局所に発現すると考えられた。

表 2.7.4.2-17. 101260006LT: 器官分類別の有害事象一覧

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Eye disorders	35 (71.4%)	26 (61.9%)	28 (70.0%)	61 (67.0%)	89 (67.9%)
Infections and infestations	15 (30.6%)	9 (21.4%)	13 (32.5%)	24 (26.4%)	37 (28.2%)
Gastrointestinal disorders	10 (20.4%)	4 (9.5%)	1 (2.5%)	14 (15.4%)	15 (11.5%)
Skin and subcutaneous tissue disorders	6 (12.2%)	3 (7.1%)	5 (12.5%)	9 (9.9%)	14 (10.7%)
Respiratory, thoracic and mediastinal disorders	7 (14.3%)	2 (4.8%)	0 (0.0%)	9 (9.9%)	9 (6.9%)
Investigations	4 (8.2%)	3 (7.1%)	1 (2.5%)	7 (7.7%)	8 (6.1%)
Musculoskeletal and connective tissue disorders	3 (6.1%)	3 (7.1%)	1 (2.5%)	6 (6.6%)	7 (5.3%)
General disorders and administration site conditions	3 (6.1%)	2 (4.8%)	0 (0.0%)	5 (5.5%)	5 (3.8%)
Immune system disorders	3 (6.1%)	1 (2.4%)	1 (2.5%)	4 (4.4%)	5 (3.8%)
Injury, poisoning and procedural complications	2 (4.1%)	1 (2.4%)	0 (0.0%)	3 (3.3%)	3 (2.3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (2.0%)	1 (2.4%)	1 (2.5%)	2 (2.2%)	3 (2.3%)
Nervous system disorders	2 (4.1%)	1 (2.4%)	0 (0.0%)	3 (3.3%)	3 (2.3%)
Cardiac disorders	1 (2.0%)	1 (2.4%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Hepatobiliary disorders	0 (0.0%)	1 (2.4%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Metabolism and nutrition disorders	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
Vascular disorders	1 (2.0%)	1 (2.4%)	0 (0.0%)	2 (2.2%)	2 (1.5%)
Ear and labyrinth disorders	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
Psychiatric disorders	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Renal and urinary disorders	0 (0.0%)	1 (2.4%)	0 (0.0%)	1 (1.1%)	1 (0.8%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.2.1

表 2.7.4.2-18. 101260006LT: 器官分類別の副作用一覧

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Eye disorders	28 (57.1%)	25 (59.5%)	26 (65.0%)	53 (58.2%)	79 (60.3%)
Skin and subcutaneous tissue disorders	3 (6.1%)	1 (2.4%)	0 (0.0%)	4 (4.4%)	4 (3.1%)
Investigations	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
Nervous system disorders	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.2.2

Confidential

2.7.4.2.1.6　　日本人／非日本人別の有害事象の解析

(1)　国際共同後期第 II 相試験（012601IN）での比較

国際共同後期第 II 相試験（012601IN）における日本人／非日本人別の有害事象及び副作用の発現頻度一覧を表 2.7.4.7-2（日本人）及び表 2.7.4.7-3（非日本人）、表 2.7.4.7-4（日本人）及び表 2.7.4.7-5（非日本人）に示した。

有害事象の発現頻度は、日本人 28.6%（6/21 例）、非日本人 39.1%（9/23 例）であり、やや非日本人で高かった。

有害事象の大部分は眼障害であり、日本人 28.6%（6/21 例）、非日本人 26.1%（6/23 例）であった。よく見られた有害事象（5%以上）は日本人で「結膜充血 (Conjunctival hyperaemia) 」23.8%（5/21 例）、非日本人で「結膜充血」17.4%（4/23 例）及び「滴下投与部位痛 (Instillation site pain) 」13.0%（3/23 例）であり、日本人／非日本人ともに「結膜充血」が最も高頻度に認められた。

副作用の発現頻度は、日本人 19.0%（4/21 例）、非日本人 21.7%（5/23 例）であり、概ね同程度であった。

有害事象と同様、副作用の大部分も眼障害であり、日本人 19.0%（4/21 例）、非日本人 17.4%（4/23 例）であった。よく見られた副作用（5%以上）は日本人で「結膜充血」19.0%（4/21 例）、非日本人で「結膜充血」17.4%（4/23 例）及び「滴下投与部位痛」13.0%（3/23 例）であり、日本人／非日本人ともに「結膜充血」が最も高頻度に認められた。

以上より、国際共同後期第 II 相試験（012601IN）における日本人／非日本人別の有害事象及び副作用について、臨床上問題となる大きな差異はないと考えた。

(2)　併合解析と国際共同後期第 II 相試験（012601IN）非日本人での比較

併合解析における有害事象及び副作用の発現頻度一覧を表 2.7.4.2-3 及び表 2.7.4.2-4 に、国際共同後期第 II 相試験 (012601IN) における非日本人の有害事象及び副作用の発現頻度一覧を表 2.7.4.7-3 及び表 2.7.4.7-5 に示した。

有害事象の発現頻度は、併合解析（日本人）50.3%（92/183 例）、国際共同後期第 II 相試験 (012601IN) 非日本人 39.1%（9/23 例）であり、併合解析（日本人）でやや高かった。

有害事象の大部分は眼障害であり、併合解析（日本人）39.9%（73/183 例）、国際共同後期第 II 相試験 (012601IN) 非日本人 26.1%（6/23 例）であった。よく見られた有害事象（日本人 2%以上、非日本人 5%以上）は併合解析（日本人）で「結膜充血 (Conjunctival hyperaemia) 」30.6%（56/183 例）、「点状角膜炎 (Punctate keratitis) 」2.7%（5/183 例）、「COVID-19 (COVID-19)」2.7%（5/183 例）、「眼そう痒症 (Eye pruritus) 」2.2%（4/183 例）、「上咽頭炎 (Nasopharyngitis) 」2.7%（5/183 例）、「ドライアイ (Dry eye) 」2.2%（4/183 例）、「眼瞼紅斑 (Erythema of eyelid) 」2.2%（4/183 例）であり、国際共同後期第 II 相試験 (012601IN) 非日本人

Confidential

で「結膜充血」17.4%（4/23 例）及び「滴下投与部位痛 (Instillation site pain) 」13.0%（3/23 例）であり、いずれも「結膜充血」が最も高頻度に認められた。

副作用の発現頻度は、併合解析（日本人）34.4%（63/183 例）、国際共同後期第 II 相試験 (012601IN) 非日本人 21.7%（5/23 例）であり、概ね同程度であった。

以上より、併合解析（日本人）と国際共同後期第 II 相試験（012601IN）非日本人の有害事象及び副作用について、臨床上問題となる大きな差異はないと考えた。

2.7.4.2.2 個別有害事象の文章による説明

死亡又はその他の重篤な有害事象及び治験使用薬の投与中止に至った有害事象に関する個別の文章による説明（叙述）は、第 5 部の治験総括報告書中に記載した。

- 第 I 相 PK 試験 (012601IN) ：添付資料 5.3.3.1-1　52 ページ（該当症例なし）
- 国際共同後期第 II 相試験 (012601IN) ：添付資料 5.3.5.1-1　80～81 ページ
- 第 III 相検証試験 (101260005LT) ：添付資料 5.3.5.1-2　107～109 ページ
- 第 III 相長期投与試験 (101260006LT) ：添付資料 5.3.5.2-1　116～122 ページ

2.7.4.3 臨床検査値の評価

国際共同後期第 II 相試験 (012601IN) における、評価時点ごとの異常変動が認められた症例の割合を表 2.7.4.7-6（血液学的検査）、表 2.7.4.7-7（血液生化学検査）及び表 2.7.4.7-8（尿検査）に示した。臨床検査値の変動から安全性に問題は認められなかった。

第 III 相長期投与試験 (101260006LT) における、評価時点ごとの臨床検査値の推移を表 2.7.4.7-9（血液学的検査、血液生化学検査）及び表 2.7.4.7-10（尿検査）に示した。いずれのグループ、検査値においても、大きな変動は認められなかった。

なお、第 III 相検証試験 (101260005LT) においては、安全性の評価項目に設定しなかった。

2.7.4.4 バイタルサイン、身体的所見及び安全性に関連する他の観察項目

2.7.4.4.1 血圧・脈拍数

国際共同後期第 II 相試験 (012601IN) において、特筆すべき安全性の問題は特定されなかった。

第 III 相検証試験 (101260005LT) において、いずれの群も大きな変動なく推移した。

第 III 相長期投与試験 (101260006LT) において、いずれのグループにおいても、測定時点ごとのベースラインからの変化値に大きな変動は認めなかった。

2.7.4.4.2 視力検査

国際共同後期第 II 相試験 (012601IN) において、特筆すべき安全性の問題は特定されなかった。

第 III 相検証試験 (101260005LT) において、いずれの群においても大きな変動は認めなかった。

第 III 相長期投与試験 (101260006LT) において、いずれのグループにおいても、測定時点ごとのベースラインからの変化値は有効性評価眼及び対側眼ともに大きな変動は認めなかった。また、治験期間中に LogMAR 変換後の矯正視力が 0.2 以上悪化した症例は、グループ 1 で 2 例、グループ 2 で 2 例、グループ 3 で 2 例であったが、関連する有害事象はなかった。

2.7.4.4.3 眼症状

国際共同後期第 II 相試験 (012601IN) においては、眼症状の重症度スコア（6 症状に対する質問票）について評価したが、特筆すべき安全性の問題は特定されなかった。眼症状の重症度スコアから最も多く報告された症状は、そう痒感、流涙、灼熱感/刺激感であり、発現率は被験者の 10%未満であった。

なお、第 III 相検証試験 (101260005LT) 及び第 III 相長期投与試験 (101260006LT)においては、安全性の評価項目に設定しなかった。

2.7.4.4.4 細隙灯顕微鏡検査

国際共同後期第 II 相試験 (012601IN) において、細隙灯顕微鏡検査の重症度スコアのわずかな悪化（1 段階）が観察された（結膜充血：被験者の 14%以下、角膜染色：被験者の 5%以下）が、特筆すべき安全性の問題は特定されなかった。

第 III 相検証試験 (101260005LT) において、角膜フルオレセイン染色及び結膜充血を除き、いずれのグループにおいても、有効性評価眼及び対側眼ともに各所見のスコアに大きな変動は認めなかった。0.002%STN1012600 群の結膜充血スコア（スコア 0、1、2、3 で評価）は、ベースライン時にスコア 1 を 3.7%（12/324 眼）に認め、Week 2 及び Week 4 で 14.8%（48/324 眼）及び 14.2%（45/318 眼）と、ベースライン時に比べスコア 1 は発現割合が 増加していたものの、Month 3/中止時で 8.0%（26/324 眼）と減少した。また、スコア 2 は Week 2 及び Week 4 で 1.2%（4/324 眼）及び 1.3%（4/318 眼）と、ベースライン時に比べ発現割合が微増していたものの、Month 3/中止時では 0.6%（2/324 眼）と減少した。スコア 3 は Month 3/中止時で 0.6%（2/324 眼）に認めた。角膜フルオレセイン染色スコア（スコア 0、1、2、3 で評価）は、ベースライン時にスコア 1 を 3.7%（12/324 眼）、スコア 2 を 0.6%（2/324 眼）に認め、スコア 1 は Week 2、Week 4 及び Month 3/中止時で 4.9%（16/324 眼）、6.0%（19/318 眼）及び 4.9%（16/324 眼）、ス

コア 2 は Week 2、Week 4 及び Month 3/中止時で 0.6%（2/324 眼）、0.3%（1/318 眼）及び 0.3%（1/324 眼）とスコア 1 がベースライン時と比べて発現割合は微増していた。スコア 3 はいずれの時期においても認めなかった。

第 III 相長期投与試験 (101260006LT) において、角膜フルオレセイン染色及び結膜充血を除き、いずれのグループにおいても、有効性評価眼及び対側眼ともに各所見のスコアに大きな変動は認めなかった。治験期間中にスコアが 2 段階以上悪化した症例は、角膜フルオレセイン染色 2 例（グループ 1：1 例、グループ 2：1 例）、結膜充血 1 例（グループ 1：1 例）のみであった。

2.7.4.4.5　　中心角膜厚

国際共同後期第 II 相試験 (012601IN) において、特筆すべき安全性の問題は特定されなかった。

第 III 相長期投与試験 (101260006LT) において、いずれのグループにおいても、ベースラインからの変化値は有効性評価眼及び対側眼ともに大きな変動は認めなかった。

なお、第 III 相検証試験 (101260005LT) においては、安全性の評価項目に設定しなかった。

2.7.4.4.6　　虹彩、睫毛、眼瞼の変化

国際共同後期第 II 相試験 (012601IN) において、睫毛の長さ及び太さの増加が少数の被験者（1～4 例/群、2～10%）で認められたが、特筆すべき安全性の問題は特定されなかった。

第 III 相長期投与試験 (101260006LT) において、各評価項目について、投与後 2 週 (Week 2) から投与後 52 週 (Week 52) に増加の変化が認められた症例の割合は、虹彩色素沈着の有効性評価眼で 0.0～0.8%、対側眼で 0.0～0.8%、睫毛の長さの有効性評価眼で 3.8～37.5%、対側眼で 3.8～38.3%、睫毛の太さの有効性評価眼で 3.8～31.7%、対側眼で 3.8～30.8%、睫毛の色調の有効性評価眼で 2.3～19.2%、対側眼で 2.3～17.5%、睫毛の本数の有効性評価眼で 0.8～27.5%、対側眼で 0.8～25.8%、眼瞼の色素沈着の有効性評価眼で 0.0～6.5%、対側眼で 0.0～6.5%、眼瞼の多毛の有効性評価眼で 0.8～16.7%、対側眼で 0.8～16.7%であった。治験使用薬投与後に睫毛及び眼瞼に関する評価項目が増加した症例は多かったが、虹彩色素沈着の増加が認められた症例は 1 例のみであった。上眼瞼溝深化は認められなかった。

なお、第 III 相検証試験 (101260005LT) においては、安全性の評価項目に設定しなかった。

2.7.4.5 特別な患者集団及び状況下における安全性

2.7.4.5.1 内因性要因

2.7.4.5.1.1 性別

併合解析における男女別の有害事象一覧を表 2.7.4.7-11（男性）及び表 2.7.4.7-12（女性）、副作用一覧を表 2.7.4.7-13（男性）及び表 2.7.4.7-14（女性）、長期投与試験（101260006LT）における男女別の有害事象一覧を表 2.7.4.7-15（男性）及び表 2.7.4.7-16（女性）、副作用一覧を表 2.7.4.7-17（男性）及び表 2.7.4.7-18（女性）に示した。

併合解析における 0.002% STN1012600 群の男女別の有害事象の発現頻度は、男性で 43.2%（32/74 例）、女性で 55.0%（60/109 例）、副作用の発現頻度は男性で 32.4%（24/74 例）、女性で 35.8%（39/109 例）であった。男女いずれかで 5%以上認められた有害事象は、「結膜充血」男性 31.1%（23/74 例）及び女性 30.3%（33/109 例）であった。

長期投与試験（101260006LT）全体における男女別の有害事象の発現頻度は、男性で 87.1%（61/70 例）、女性で 85.2%（52/61 例）、副作用の発現頻度は男性で 62.9%（44/70 例）、女性で 59.0%（36/61 例）であった。男女いずれかで 5%以上認められた有害事象は、「結膜充血」男性 32.9%（23/70 例）及び女性 27.9%（17/61 例）、「睫毛の成長」男性 31.4%（22/70 例）及び女性 34.4%（21/61 例）、「睫毛変化」男性 17.1%（12/70 例）及び女性 9.8%（6/61 例）、「睫毛剛毛化」男性 11.4%（8/70 例）及び女性 8.2%（5/61 例）、「眼瞼のうぶ毛変化」男性 11.4%（8/70 例）及び女性 18.0%（11/61 例）、「眼瞼色素沈着」男性 7.1%（5/70 例）及び女性 9.8%（6/61 例）、「点状角膜炎」男性 2.9%（2/70 例）及び女性 8.2%（5/61 例）、「アレルギー性結膜炎」男性 4.3%（3/70 例）及び女性 6.6%（4/61 例）、「上咽頭炎」男性 7.1%（5/70 例）及び女性 8.2%（5/61 例）、「齲歯」男性 0.0%（0/70 例）及び女性 6.6%（4/61 例）、「湿疹」男性 2.9%（2/70 例）及び女性 6.6%（4/61 例）であった。

以上より、男女による大きな差異は認められなかった。

2.7.4.5.1.2 年齢別

併合解析における年齢別の有害事象一覧を表 2.7.4.7-11（65 歳未満）及び表 2.7.4.7-12（65 歳以上）、副作用一覧を表 2.7.4.7-13（65 歳未満）及び表 2.7.4.7-14（65 歳以上）、長期投与試験（101260006LT）における年齢別の有害事象一覧を表 2.7.4.2-3（65 歳未満）及び表 2.7.4.7-16（65 歳以上）、副作用一覧を表 2.7.4.7-17（65 歳未満）及び表 2.7.4.7-18（65 歳以上）に示した。

併合解析における 0.002% STN1012600 群の年齢別の有害事象の発現頻度は、65 歳未満で 55.6%（50/90 例）、65 歳以上で 45.2%（42/93 例）、副作用の発現頻度は 65 歳未満で 42.2%（38/90 例）、65 歳以上で 26.9%（25/93 例）であった。いずれかの年齢で 5%以上認められた有害事象は、「結膜充血」65 歳未満 41.1%（37/90 例）及び 65 歳以上 20.4%（19/93 例）であった。

長期投与試験（101260006LT）全体における年齢別の有害事象の発現頻度は、65 歳未満で 84.2%（48/57 例）、65 歳以上で 87.8%（65/74 例）、副作用の発現頻度は 65 歳未満で 70.2%（40/57 例）、65 歳以上で 54.1%（40/74 例）であった。いずれかの年齢で 5%以上認められた有害事象は、「結膜充血」65 歳未満 33.3%（19/57 例）及び 65 歳以上 28.4%（21/74 例）、「睫毛の成長」65 歳未満 33.3%（19/57 例）及び 65 歳以上 32.4%（24/74 例）、「睫毛変化」65 歳未満 17.5%（10/57 例）及び 65 歳以上 10.8%（8/74 例）、「睫毛剛毛化」65 歳未満 12.3%（7/57 例）及び 65 歳以上 8.1%（6/74 例）、「アレルギー性結膜炎」65 歳未満 8.8%（5/57 例）及び 65 歳以上 2.7%（2/74 例）、「眼瞼のうぶ毛変化」65 歳未満 8.8%（5/57 例）及び 65 歳以上 18.9%（14/74 例）、「眼瞼色素沈着」65 歳未満 7.0%（4/57 例）及び 65 歳以上性 9.5%（7/74 例）、「点状角膜炎」65 歳未満 7.0%（4/57 例）及び 65 歳以上 4.1%（3/74 例）、「眼刺激」65 歳未満 5.3%（3/57 例）及び 65 歳以上 0.0%（0/74 例）、「睫毛色素過剰」65 歳未満 3.5%（2/57 例）及び 65 歳以上 5.4%（4/74 例）、「上咽頭炎」65 歳未満 8.8%（5/57 例）及び 65 歳以上 6.8%（5/74 例）、「湿疹」65 歳未満 1.8%（1/57 例）及び 65 歳以上 6.8%（5/74 例）、「齲歯」65 歳未満 5.3%（3/57 例）及び 65 歳以上 1.4%（1/74 例）、「季節性アレルギー」65 歳未満 7.0%（4/57 例）及び 65 歳以上 0.0%（0/74 例）、「口腔咽頭痛」65 歳未満 5.3%（3/57 例）及び 65 歳以上 0.0%（0/74 例）であった。

以上より、高齢者による 0.002% STN1012600 点眼液の安全性に大きな問題はないと考えられた。

2.7.4.5.2 外因性要因

外因性要因に関する検討は行わなかった。

2.7.4.5.3 薬物相互作用

2.7.4.5.3.1 0.5% チモロール点眼液との併用

長期投与試験 (101260006LT) における有害事象及び副作用の発現頻度を表 2.7.4.2-2 に示した。有害事象は、全体の 86.3%（113/131 例）に認められ、単剤群のグループ 1 で 87.8%（43/49 例）、グループ 2 で 76.2%（32/42 例）、グループ 1+グループ 2 で 82.4%（75/91 例）、併用群のグループ 3 で 95.0%（38/40 例）であった。副作用は、全体で 61.1%（80/131 例）、単剤群のグループ 1 で 59.2%（29/49 例）、グループ 2 で 59.5%（25/42 例）、グループ 1+グループ 2 で 59.3%（54/91 例）、併用群のグループ 3 で 65.0%（26/40 例）であった。0.002%STN1012600 点眼液単剤を使用したグループ 1 及びグループ 2 と、0.002%STN1012600 点眼液と 0.5%チモロール点眼液を併用したグループ 3 の有害事象及び副作用の発現率に大きな差異は認めず、副作用の程度は中等度の 1 例〔「角膜炎 (Keratitis)」、グループ 1〕を除き、すべて軽度であった。

以上より、0.002%STN1012600 点眼液と 0.5%チモロール点眼液の併用に特段の懸念はないと考えられた。

Confidential

2.7.4.5.4 妊娠及び授乳時の使用

STN1012600 点眼液の臨床開発においては、妊婦、授乳婦、妊娠の可能性のある女性は選択・除外基準により除外したため、妊娠及び授乳時の安全性に関する情報は得られていない。

2.7.4.5.5 過量投与

安全性を評価した 4 試験（012601IN、101260005LT、101260006LT 及び 101260007LT）において、用法を 1 回 1 滴、1 日 1 回点眼と規定し、それぞれの試験で設定した点眼期間での安全性は確認した。0.002%STN1012600 点眼液を規定より多く点眼した症例が第 III 相検証試験 (101260005LT) で 1 例（治験期間中 1 日のみ片眼に 1 回 2 滴点眼）、長期投与試験 (101260006LT) で 1 例（治験期間中 1 日のみ 1 日 2 回点眼）に認められたが、関連する有害事象の発現はなかった。

2.7.4.5.6 薬物乱用

本項に該当する事象は報告されていない。

2.7.4.5.7 離脱症状及び反跳現象

本項に該当する事象は報告されていない。

2.7.4.5.8 自動車運転及び機械操作に対する影響又は精神機能の障害

本項に該当する事象は報告されていない。

2.7.4.5.9 健康成人男性を対象とした試験における安全性の解析

健康成人男性を対象として実施した、第 I 相 PK 試験 (101260007LT) における有害事象の発現頻度を表 2.7.4.5-1 に、治療期に認められた有害事象一覧を表 2.7.4.5-2 示した。

重篤な有害事象及び他の重要な有害事象（治験の中止に至った有害事象）は認められなかった。

有害事象は 100%（8/8 例）に認められ、結膜充血が 100%（8/8 例）、点状角膜炎が 12.5%（1/8 例）であった。認められた有害事象は、すべて治験使用薬との因果関係あり（副作用）と判断された。有害事象の程度はいずれも軽度で、無処置にて回復した。全身性（眼以外）の有害事象は認められなかった。

その他の安全性評価項目である 12 誘導心電図においても、治験期間中に正常範囲内から異常に変動した症例は認められず、関連する有害事象は認められなかった。

これらの結果から、高頻度で結膜充血が認められたものの程度は軽度で回復性の事象であり、全身の安全性に問題点も認められず、安全性に問題はないと考えられた。

表 2.7.4.5-1. 101260007LT: 有害事象の発現頻度（安全性解析対象集団）

Subjects with any	0.002% STN1012600 (N=8)
AE(s)	8 (100.0%)
ADR(s)	8 (100.0%)
SAE(s)	0 (0.0%)
Serious ADR(s)	0 (0.0%)
Leading to Study Drug Discontinuation	0 (0.0%)
Resulting in Death	0 (0.0%)
Mild AE(s) [1]	8 (100.0%)
Moderate AE(s) [1]	0 (0.0%)
Severe AE(s) [1]	0 (0.0%)

[1] Maximum severity within subject.

Cross Reference: 添付資料 5.3.3.1-1 Table 14.3.1.1

表 2.7.4.5-2. 101260007LT: 有害事象一覧（重症度別、安全性解析対象集団）

System organ class Preferred term Severity	0.002% STN1012600 (N=8)
Subjects with any AE(s)	8 (100.0%)
Eye disorders	8 (100.0%)
Conjunctival hyperaemia	8 (100.0%)
Mild	8 (100.0%)
Punctate keratitis	1 (12.5%)
Mild	1 (12.5%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term, at the maximum severity.

Cross Reference: 添付資料 5.3.3.1-1 Table 14.3.1.3.1

2.7.4.6 市販後データ

該当しない。

Confidential

2.7.4.7 付録

表 2.7.4.7-1. 本文中に含めないが引用する表の一覧

表 2.7.4.7-2. 012601IN: 治療期に認められた有害事象一覧（日本人）
表 2.7.4.7-3. 012601IN: 治療期に認められた有害事象一覧（非日本人）
表 2.7.4.7-4. 012601IN: 治療期に認められた副作用一覧（日本人）
表 2.7.4.7-5. 012601IN: 治療期に認められた副作用一覧（非日本人）
表 2.7.4.7-6. 012601IN: 臨床検査の異常変動が認められた症例の割合（血液学的検査）
表 2.7.4.7-7. 012601IN: 臨床検査の異常変動が認められた症例の割合（血液生化学検査）
表 2.7.4.7-8. 012601IN: 臨床検査の異常変動が認められた症例の割合（尿検査）
表 2.7.4.7-9. 101260006LT: 臨床検査値の推移（血液学的検査、血液生化学検査）
表 2.7.4.7-10. 101260006LT: 臨床検査値の推移（尿検査）
表 2.7.4.7-11. 併合解析: 男女別の有害事象一覧（男性）
表 2.7.4.7-12. 併合解析: 男女別の有害事象一覧（女性）
表 2.7.4.7-13. 併合解析: 男女別の副作用一覧（男性）
表 2.7.4.7-14. 併合解析: 男女別の副作用一覧（女性）
表 2.7.4.7-15. 101260006LT: 男女別の有害事象一覧（男性）
表 2.7.4.7-16. 101260006LT: 男女別の有害事象一覧（女性）
表 2.7.4.7-17. 101260006LT: 男女別の副作用一覧（男性）
表 2.7.4.7-18. 101260006LT: 男女別の副作用一覧（女性）
表 2.7.4.7-19. 併合解析: 年齢別の有害事象一覧（65 歳未満）
表 2.7.4.7-20. 併合解析: 年齢別の有害事象一覧（65 歳以上）
表 2.7.4.7-21. 併合解析: 年齢別の副作用一覧（65 歳未満）
表 2.7.4.7-22. 併合解析: 年齢別の副作用一覧（65 歳以上）
表 2.7.4.7-23. 101260006LT: 年齢別の有害事象一覧（65 歳未満）
表 2.7.4.7-24. 101260006LT: 年齢別の有害事象一覧（65 歳以上）
表 2.7.4.7-25. 101260006LT: 年齢別の副作用一覧（65 歳未満）
表 2.7.4.7-26. 101260006LT: 年齢別の副作用一覧（65 歳以上）

Confidential

表 2.7.4.7-2. 012601IN: 治療期に認められた有害事象一覧（日本人）

System organ class Preferred term	Placebo to 0.003% P1* (N=11)	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=21)	0.0005% DE-126 (N=20)	0.001% DE-126 (N=20)	0.002% DE-126 (N=21)	0.003% DE-126 (N=21)	0.003% Total** (N=32)	DE-126 Total*** (N=93)
Subjects with Any AE	1 (9.1%)	3 (27.3%)	9 (42.9%)	10 (50.0%)	8 (40.0%)	6 (28.6%)	15 (71.4%)	18 (56.3%)	42 (45.2%)
Eye disorders	0	3 (27.3%)	7 (33.3%)	7 (35.0%)	7 (35.0%)	6 (28.6%)	11 (52.4%)	14 (43.8%)	34 (36.6%)
Conjunctival Hyperaemia	0	1 (9.1%)	4 (19.0%)	3 (15.0%)	2 (10.0%)	5 (23.8%)	4 (19.0%)	5 (15.6%)	15 (16.1%)
Eye pruritus	0	0	3 (14.3%)	1 (5.0%)	1 (5.0%)	0	3 (14.3%)	3 (9.4%)	5 (5.4%)
Punctate keratitis	0	0	1 (4.8%)	1 (5.0%)	2 (10.0%)	0	1 (4.8%)	1 (3.1%)	4 (4.3%)
Conjunctival Haemorrhage	0	0	0	1 (5.0%)	1 (5.0%)	0	1 (4.8%)	1 (3.1%)	3 (3.2%)
Growth of eyelashes	0	1 (9.1%)	0	1 (5.0%)	1 (5.0%)	0	0	1 (3.1%)	3 (3.2%)
Dry eye	0	0	0	0	0	1 (4.8%)	1 (4.8%)	1 (3.1%)	2 (2.2%)
Foreign body sensation in eyes	0	0	1 (4.8%)	1 (5.0%)	0	0	1 (4.8%)	1 (3.1%)	2 (2.2%)
Blepharal pigmentation	0	0	0	0	0	1 (4.8%)	0	0	1 (1.1%)
Blepharitis	0	0	0	0	0	1 (4.8%)	0	0	1 (1.1%)
Cataract	0	1 (9.1%)	0	0	0	0	0	1 (3.1%)	1 (1.1%)
Chalazion	0	0	0	1 (5.0%)	0	0	0	0	1 (1.1%)
Conjunctivitis allergic	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Corneal hypertrophy	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Eye discharge	0	0	0	1 (5.0%)	0	0	0	0	1 (1.1%)
Eye irritation	0	0	1 (4.8%)	0	1 (5.0%)	0	0	0	1 (1.1%)
Eyelid oedema	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Keratitis	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Scintillating scotoma	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Vision blurred	0	0	0	0	1 (5.0%)	0	0	0	1 (1.1%)
Lacrimation increased	0	0	1 (4.8%)	0	0	0	0	0	0
Infections and infestations	0	0	2 (9.5%)	3 (15.0%)	2 (10.0%)	1 (4.8%)	2 (9.5%)	2 (6.3%)	8 (8.6%)
Viral upper respiratory tract infection	0	0	1 (4.8%)	3 (15.0%)	1 (5.0%)	1 (4.8%)	1 (4.8%)	1 (3.1%)	6 (6.5%)
Cystitis	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Influenza	0	0	0	0	1 (5.0%)	0	0	0	1 (1.1%)
Rhinitis	0	0	1 (4.8%)	0	0	0	0	0	0
Investigations	0	1 (9.1%)	0	1 (5.0%)	0	1 (4.8%)	1 (4.8%)	2 (6.3%)	4 (4.3%)
Blood potassium Increased	0	0	0	0	0	1 (4.8%)	0	0	1 (1.1%)
Blood triglycerides Increased	0	0	0	1 (5.0%)	0	0	0	0	1 (1.1%)
Eosinophil count Increased	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Hepatic enzyme Increased	0	1 (9.1%)	0	0	0	0	0	1 (3.1%)	1 (1.1%)
Nervous system disorders	0	0	0	0	0	0	2 (9.5%)	2 (6.3%)	2 (2.2%)
Cervicobrachial Syndrome	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Parkinson's disease	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Injury, poisoning and procedural complications	0	0	1 (4.8%)	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Radius fracture	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Fall	0	0	1 (4.8%)	0	0	0	0	0	0

Confidential

System organ class Preferred term	Placebo to 0.003% P1* (N=11)	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=21)	0.0005% DE-126 (N=20)	0.001% DE-126 (N=20)	0.002% DE-126 (N=21)	0.003% DE-126 (N=21)	0.003% Total** (N=32)	DE-126 Total*** (N=93)
Metabolism and nutrition disorders	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Decreased appetite	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Renal and urinary disorders	0	1 (9.1%)	0	0	0	0	0	1 (3.1%)	1 (1.1%)
Hypertonic bladder	0	1 (9.1%)	0	0	0	0	0	1 (3.1%)	1 (1.1%)
Skin and subcutaneous tissue disorders	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Hypertrichosis	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Vascular disorders	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Hypotension	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Ear and labyrinth disorders	0	0	1 (4.8%)	0	0	0	0	0	0
Sudden hearing loss	0	0	1 (4.8%)	0	0	0	0	0	0
Gastrointestinal disorders	1 (9.1%)	0	0	0	0	0	0	0	0
Constipation	1 (9.1%)	0	0	0	0	0	0	0	0
Musculoskeletal and connective tissue disorders	0	0	1 (4.8%)	0	0	0	0	0	0
Musculoskeletal pain	0	0	1 (4.8%)	0	0	0	0	0	0

Any subject who experienced multiple AEs within a system organ class or preferred term is counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% DE-126 from Week 6 to Month 3. "Placebo to 0.003% P1" column shows AEs reported through Week 6, and "Placebo to 0.003% P2" shows AEs reported after the switch.

** 0.003% Total summarizes columns "0.003%" and "Placebo to 0.003% P2".

*** DE-126 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Cross Reference: 添付資料 5.3.5.1-1 Table 14.3.1.2.2

Confidential

表 2.7.4.7-3. 012601IN: 治療期に認められた有害事象一覧（非日本人）

System organ class Preferred term	Placebo to 0.003% P1* (N=11)	Placebo to 0.003% P2* (N=9)	0.005% Latanoprost (N=23)	0.0005% DE-126 (N=23)	0.001% DE-126 (N=23)	0.002% DE-126 (N=23)	0.003% DE-126 (N=24)	0.003% Total** (N=33)	DE-126 Total*** (N=102)
Subjects with Any AE	4 (36.4%)	7 (77.8%)	13 (56.5%)	11 (47.8%)	11 (47.8%)	9 (39.1%)	8 (33.3%)	15 (45.5%)	46 (45.1%)
Eye disorders	2 (18.2%)	2 (22.2%)	10 (43.5%)	8 (34.8%)	7 (30.4%)	6 (26.1%)	7 (29.2%)	9 (27.3%)	30 (29.4%)
Conjunctival hyperaemia	0	1 (11.1%)	8 (34.8%)	2 (8.7%)	3 (13.0%)	4 (17.4%)	3 (12.5%)	4 (12.1%)	13 (12.7%)
Eye pruritus	0	0	2 (8.7%)	1 (4.3%)	0	0	2 (8.3%)	2 (6.1%)	3 (2.9%)
Foreign body sensation in eyes	0	0	0	1 (4.3%)	0	1 (4.3%)	1 (4.2%)	1 (3.0%)	3 (2.9%)
Growth of eyelashes	0	0	2 (8.7%)	2 (8.7%)	1 (4.3%)	0	0	0	3 (2.9%)
Lacrimation increased	0	1 (11.1%)	2 (8.7%)	1 (4.3%)	1 (4.3%)	0	0	1 (3.0%)	3 (2.9%)
Photophobia	0	0	0	0	1 (4.3%)	0	2 (8.3%)	2 (6.1%)	3 (2.9%)
Blepharitis	0	0	0	2 (8.7%)	0	0	0	0	2 (2.0%)
Conjunctival haemorrhage	0	0	0	1 (4.3%)	0	1 (4.3%)	0	0	2 (2.0%)
Eye irritation	1 (9.1%)	0	1 (4.3%)	0	2 (8.7%)	0	0	0	2 (2.0%)
Vision blurred	0	0	0	0	1 (4.3%)	0	1 (4.2%)	1 (3.0%)	2 (2.0%)
Cataract	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Dry eye	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Erythema of eyelid	1 (9.1%)	0	0	1 (4.3%)	0	0	0	0	1 (1.0%)
Eye pain	0	0	1 (4.3%)	0	1 (4.3%)	0	0	0	1 (1.0%)
Eyelash thickening	0	0	1 (4.3%)	0	1 (4.3%)	0	0	0	1 (1.0%)
Iris hyperpigmentation	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Iritis	0	0	0	0	0	1 (4.3%)	0	0	1 (1.0%)
Metamorphopsia	0	0	0	1 (4.3%)	0	0	0	0	1 (1.0%)
Ocular hyperaemia	0	0	0	1 (4.3%)	0	0	0	0	1 (1.0%)
Punctate keratitis	0	0	0	0	0	1 (4.3%)	0	0	1 (1.0%)
Visual acuity reduced	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Vitreous detachment	0	0	1 (4.3%)	0	1 (4.3%)	0	0	0	1 (1.0%)
Asthenopia	0	0	1 (4.3%)	0	0	0	0	0	0
Infections and infestations	1 (9.1%)	4 (44.4%)	5 (21.7%)	1 (4.3%)	4 (17.4%)	1 (4.3%)	2 (8.3%)	6 (18.2%)	12 (11.8%)
Upper respiratory tract infection	0	1 (11.1%)	2 (8.7%)	1 (4.3%)	2 (8.7%)	0	1 (4.2%)	2 (6.1%)	5 (4.9%)
Sinusitis	0	3 (33.3%)	1 (4.3%)	0	0	0	0	3 (9.1%)	3 (2.9%)
Viral upper respiratory tract infection	1 (9.1%)	0	0	0	1 (4.3%)	0	1 (4.2%)	1 (3.0%)	2 (2.0%)
Alveolar osteitis	0	1 (11.1%)	0	0	0	0	0	1 (3.0%)	1 (1.0%)
Bronchitis	0	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)
Pharyngitis streptococcal	0	0	0	0	0	1 (4.3%)	0	0	1 (1.0%)
Urinary tract infection	0	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)
Cellulitis	0	0	1 (4.3%)	0	0	0	0	0	0
Conjunctivitis	0	0	1 (4.3%)	0	0	0	0	0	0
General disorders and administration site conditions	1 (9.1%)	1 (11.1%)	0	0	1 (4.3%)	3 (13.0%)	1 (4.2%)	2 (6.1%)	6 (5.9%)
Instillation site pain	0	0	0	0	1 (4.3%)	3 (13.0%)	1 (4.2%)	1 (3.0%)	5 (4.9%)
Instillation site pruritus	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Pyrexia	0	1 (11.1%)	0	0	0	0	0	1 (3.0%)	1 (1.0%)
Cyst	1 (9.1%)	0	0	0	0	0	0	0	0
Investigations	2 (18.2%)	0	0	3 (13.0%)	1 (4.3%)	0	1 (4.2%)	1 (3.0%)	5 (4.9%)

Confidential

System organ class Preferred term	Placebo to 0.003% P1* (N=11)	Placebo to 0.003% P2* (N=9)	0.005% Latanoprost (N=23)	0.0005% DE-126 (N=23)	0.001% DE-126 (N=23)	0.002% DE-126 (N=23)	0.003% DE-126 (N=24)	0.003% Total** (N=33)	DE-126 Total*** (N=102)
Vital dye staining cornea present	1 (9.1%)	0	0	2 (8.7%)	0	0	1 (4.2%)	1 (3.0%)	3 (2.9%)
Blood pressure diastolic decreased	0	0	0	1 (4.3%)	0	0	0	0	1 (1.0%)
Blood pressure diastolic increased	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Blood pressure systolic increased	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Glucose urine present	0	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)
Protein urine present	0	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)
Computerised tomogram abnormal	1 (9.1%)	0	0	0	0	0	0	0	0
Electrocardiogram T wave inversion	1 (9.1%)	0	0	0	0	0	0	0	0
Nervous system disorders	1 (9.1%)	0	1 (4.3%)	1 (4.3%)	1 (4.3%)	1 (4.3%)	0	0	3 (2.9%)
Headache	0	0	0	1 (4.3%)	0	1 (4.3%)	0	0	2 (2.0%)
Dysgeusia	0	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)
Carotid arteriosclerosis	1 (9.1%)	0	0	0	0	0	0	0	0
Dizziness	0	0	1 (4.3%)	0	0	0	0	0	0
Injury, poisoning and procedural complications	0	0	1 (4.3%)	2 (8.7%)	0	0	0	0	2 (2.0%)
Laceration	0	0	0	1 (4.3%)	0	0	0	0	1 (1.0%)
Lip injury	0	0	0	1 (4.3%)	0	0	0	0	1 (1.0%)
Procedural pain	0	0	1 (4.3%)	0	0	0	0	0	0
Musculoskeletal and connective tissue disorders	2 (18.2%)	0	0	1 (4.3%)	1 (4.3%)	0	0	0	2 (2.0%)
Arthralgia	0	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)
Osteoporosis	0	0	0	1 (4.3%)	0	0	0	0	1 (1.0%)
Back pain	1 (9.1%)	0	0	0	0	0	0	0	0
Muscular weakness	1 (9.1%)	0	0	0	0	0	0	0	0
Renal and urinary disorders	0	0	0	0	0	1 (4.3%)	1 (4.2%)	1 (3.0%)	2 (2.0%)
Nephrolithiasis	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Urinary retention	0	0	0	0	0	1 (4.3%)	0	0	1 (1.0%)
Skin and subcutaneous tissue disorders	0	1 (11.1%)	0	0	0	1 (4.3%)	0	1 (3.0%)	2 (2.0%)
Skin lesion	0	1 (11.1%)	0	0	0	0	0	1 (3.0%)	1 (1.0%)
Urticaria	0	0	0	0	0	1 (4.3%)	0	0	1 (1.0%)
Vascular disorders	0	1 (11.1%)	0	0	0	0	0	1 (3.0%)	1 (1.0%)
Phlebitis	0	1 (11.1%)	0	0	0	0	0	1 (3.0%)	1 (1.0%)
Cardiac disorders	1 (9.1%)	0	0	0	0	0	0	0	0
Cardiomegaly	1 (9.1%)	0	0	0	0	0	0	0	0
Gastrointestinal disorders	1 (9.1%)	0	1 (4.3%)	0	0	0	0	0	0
Haematochezia	1 (9.1%)	0	0	0	0	0	0	0	0
Gastrointestinal disorders	1 (9.1%)	0	1 (4.3%)	0	0	0	0	0	0
Nausea	0	0	1 (4.3%)	0	0	0	0	0	0

Any subject who experienced multiple AEs within a system organ class or preferred term is counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Confidential

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% DE-126 from Week 6 to Month 3. "Placebo to 0.003% P1" column shows AEs reported through Week 6, and "Placebo to 0.003% P2" shows AEs reported after the switch.

** 0.003% Total summarizes columns "0.003%" and "Placebo to 0.003% P2".

*** DE-126 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Cross Reference: 添付資料 5.3.5.1-1 Table 14.3.1.2.3

Confidential

表 2.7.4.7-4. 012601IN: 治療期に認められた副作用一覧（日本人）

System organ class Preferred term	Placebo to 0.003% P1* (N=11)	Placebo to 0.003% P2* (N=11)	0.005% Latanoprost (N=21)	0.0005% DE-126 (N=20)	0.001% DE-126 (N=20)	0.002% DE-126 (N=21)	0.003% DE-126 (N=21)	0.003% Total** (N=32)	DE-126 Total*** (N=93)
Subjects with Any SAR	0	2 (18.2%)	5 (23.8%)	5 (25.0%)	5 (25.0%)	4 (19.0%)	6 (28.6%)	8 (25.0%)	22 (23.7%)
Eye disorders	0	2 (18.2%)	5 (23.8%)	5 (25.0%)	5 (25.0%)	4 (19.0%)	5 (23.8%)	7 (21.9%)	21 (22.6%)
Conjunctival hyperaemia	0	1 (9.1%)	3 (14.3%)	3 (15.0%)	2 (10.0%)	4 (19.0%)	3 (14.3%)	4 (12.5%)	13 (14.0%)
Eye pruritus	0	0	1 (4.8%)	1 (5.0%)	1 (5.0%)	0	3 (14.3%)	3 (9.4%)	5 (5.4%)
Growth of eyelashes	0	1 (9.1%)	0	1 (5.0%)	1 (5.0%)	0	0	1 (3.1%)	3 (3.2%)
Dry eye	0	0	0	0	0	1 (4.8%)	1 (4.8%)	1 (3.1%)	2 (2.2%)
Punctate keratitis	0	0	1 (4.8%)	1 (5.0%)	1 (5.0%)	0	0	0	2 (2.2%)
Blepharal pigmentation	0	0	0	0	0	1 (4.8%)	0	0	1 (1.1%)
Conjunctivitis allergic	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Eye irritation	0	0	1 (4.8%)	0	1 (5.0%)	0	0	0	1 (1.1%)
Foreign body sensation in eyes	0	0	1 (4.8%)	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Vision blurred	0	0	0	0	1 (5.0%)	0	0	0	1 (1.1%)
Lacrimation increased	0	0	1 (4.8%)	0	0	0	0	0	0
Skin and subcutaneous tissue disorders	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)
Hypertrichosis	0	0	0	0	0	0	1 (4.8%)	1 (3.1%)	1 (1.1%)

Any subject who experienced multiple AEs within a system organ class or preferred term is counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% DE-126 from Week 6 to Month 3. "Placebo to 0.003% P1" column shows AEs reported through Week 6, and "Placebo to 0.003% P2" shows AEs reported after the switch.

** 0.003% Total summarizes columns "0.003%" and "Placebo to 0.003% P2".

*** DE-126 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Cross Reference: 添付資料 5.3.5.1-1 Table 14.3.1.5.2

Confidential

表 2.7.4.7-5. 012601IN: 治療期に認められた副作用一覧（非日本人）

System organ class Preferred term	Placebo to 0.003% P1* (N=11)	Placebo to 0.003% P2* (N=9)	0.005% Latanoprost (N=23)	0.0005% DE-126 (N=23)	0.001% DE-126 (N=23)	0.002% DE-126 (N=23)	0.003% DE-126 (N=24)	0.003% Total** (N=33)	DE-126 Total*** (N=102)
Subjects with Any SAR	1 (9.1%)	2 (22.2%)	8 (34.8%)	4 (17.4%)	6 (26.1%)	5 (21.7%)	5 (20.8%)	7 (21.2%)	22 (21.6%)
Eye disorders	1 (9.1%)	2 (22.2%)	8 (34.8%)	4 (17.4%)	5 (21.7%)	4 (17.4%)	5 (20.8%)	7 (21.2%)	20 (19.6%)
Conjunctival hyperaemia	0	1 (11.1%)	6 (26.1%)	2 (8.7%)	2 (8.7%)	4 (17.4%)	2 (8.3%)	3 (9.1%)	11 (10.8%)
Growth of eyelashes	0	0	2 (8.7%)	2 (8.7%)	1 (4.3%)	0	0	0	3 (2.9%)
Conjunctival haemorrhage	0	0	0	0	0	1 (4.3%)	0	0	1 (1.0%)
Eye irritation	1 (9.1%)	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)
Eye pain	0	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)
Eye pruritus	0	0	1 (4.3%)	1 (4.3%)	0	0	0	0	1 (1.0%)
Eyelash thickening	0	0	1 (4.3%)	0	1 (4.3%)	0	0	0	1 (1.0%)
Iris hyperpigmentation	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Iritis	0	0	0	0	0	1 (4.3%)	0	0	1 (1.0%)
Lacrimation increased	0	1 (11.1%)	2 (8.7%)	0	0	0	0	1 (3.0%)	1 (1.0%)
Ocular hyperaemia	0	0	0	1 (4.3%)	0	0	0	0	1 (1.0%)
Photophobia	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Vision blurred	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
General disorders and administration site conditions	0	0	0	0	1 (4.3%)	3 (13.0%)	1 (4.2%)	1 (3.0%)	5 (4.9%)
Instillation site pain	0	0	0	0	1 (4.3%)	3 (13.0%)	1 (4.2%)	1 (3.0%)	5 (4.9%)
Instillation site pruritus	0	0	0	0	0	0	1 (4.2%)	1 (3.0%)	1 (1.0%)
Nervous system disorders	0	0	0	0	1 (4.3%)	1 (4.3%)	0	0	2 (2.0%)
Dysgeusia	0	0	0	0	1 (4.3%)	0	0	0	1 (1.0%)

Any subject who experienced multiple AEs within a system organ class or preferred term is counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% DE-126 from Week 6 to Month 3. "Placebo to 0.003% P1" column shows AEs reported through Week 6, and "Placebo to 0.003% P2" shows AEs reported after the switch.

** 0.003% Total summarizes columns "0.003%" and "Placebo to 0.003% P2".

*** DE-126 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Cross Reference: 添付資料 5.3.5.1-1 Table 14.3.1.5.3

Confidential

表 2.7.4.7-6. 012601IN: 臨床検査の異常変動が認められた症例の割合（血液学的検査）

Parameter	Analysis Visit	Result	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)
Erythrocytes (10^12/L)	Screening	n	22	44	42	43	44	45
		Low	0	1 (2.3%)	1 (2.4%)	2 (4.7%)	2 (4.5%)	6 (13.3%)
		High	1 (4.5%)	0	0	0	1 (2.3%)	2 (4.4%)
	Month 3	n	20	42	42	43	44	42
		Low	1 (5.0%)	1 (2.4%)	0	4 (9.3%)	1 (2.3%)	3 (7.1%)
		High	0	0	0	0	1 (2.3%)	2 (4.8%)
Leukocytes (10^9/L)	Screening	n	22	44	42	43	44	45
		Low	1 (4.5%)	0	2 (4.8%)	0	3 (6.8%)	0
		High	0	0	2 (4.8%)	0	0	2 (4.4%)
	Month 3	n	20	42	42	43	44	42
		Low	1 (5.0%)	0	4 (9.5%)	2 (4.7%)	0	1 (2.4%)
		High	0	0	2 (4.8%)	0	0	2 (4.8%)
Hemoglobin (g/L)	Screening	n	22	44	42	43	44	45
		Low	0	1 (2.3%)	3 (7.1%)	1 (2.3%)	3 (6.8%)	3 (6.7%)
		High	0	0	0	0	0	1 (2.2%)
	Month 3	n	20	42	42	43	44	42
		Low	1 (5.0%)	2 (4.8%)	4 (9.5%)	3 (7.0%)	2 (4.5%)	6 (14.3%)
		High	0	0	0	0	0	1 (2.4%)
Hematocrit (v/v)	Screening	n	22	44	42	43	44	45
		Low	0	1 (2.3%)	1 (2.4%)	1 (2.3%)	1 (2.3%)	2 (4.4%)
		High	0	0	0	2 (4.7%)	0	4 (8.9%)
	Month 3	n	20	42	42	43	44	42
		Low	1 (5.0%)	0	0	3 (7.0%)	0	2 (4.8%)
		High	0	0	0	2 (4.7%)	0	1 (2.4%)
Platelets (10^9/L)	Screening	n	21	44	42	43	44	45
		Low	0	0	1 (2.4%)	1 (2.3%)	1 (2.3%)	1 (2.2%)
		High	0	0	0	0	0	1 (2.2%)
	Month 3	n	19	42	42	43	44	41
		Low	0	0	0	2 (4.7%)	1 (2.3%)	0
		High	0	0	0	0	0	1 (2.4%)
Neutrophils (10^9/L)	Screening	n	22	44	42	43	44	45
		Low	1 (4.5%)	0	2 (4.8%)	1 (2.3%)	4 (9.1%)	0
		High	0	1 (2.3%)	1 (2.4%)	0	0	2 (4.4%)
	Month 3	n	20	42	42	43	44	42
		Low	1 (5.0%)	0	5 (11.9%)	3 (7.0%)	1 (2.3%)	0
		High	0	1 (2.4%)	1 (2.4%)	0	0	1 (2.4%)
Neutrophils/Leukocytes (%)	Screening	n	22	44	42	43	44	45
		Low	1 (4.5%)	1 (2.3%)	1 (2.4%)	1 (2.3%)	2 (4.5%)	1 (2.2%)
		High	1 (4.5%)	2 (4.5%)	1 (2.4%)	1 (2.3%)	1 (2.3%)	1 (2.2%)

Confidential

Parameter	Analysis Visit	Result	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)
	Month 3	n	20	42	42	43	44	42
		Low	1 (5.0%)	0	3 (7.1%)	4 (9.3%)	0	2 (4.8%)
		High	0	1 (2.4%)	0	0	0	1 (2.4%)
Eosinophils (10^9/L)	Screening	n	22	44	42	43	44	45
		Low	0	0	0	0	0	0
		High	1 (4.5%)	1 (2.3%)	1 (2.4%)	1 (2.3%)	0	0
	Month 3	n	20	42	42	43	44	42
		Low	0	0	0	0	0	0
		High	0	3 (7.1%)	0	2 (4.7%)	1 (2.3%)	1 (2.4%)
Eosinophils/Leukocytes (%)	Screening	n	22	44	42	43	44	45
		Low	0	0	0	0	0	0
		High	1 (4.5%)	4 (9.1%)	3 (7.1%)	4 (9.3%)	2 (4.5%)	2 (4.4%)
	Month 3	n	20	42	42	43	44	42
		Low	0	0	0	0	0	0
		High	1 (5.0%)	4 (9.5%)	1 (2.4%)	6 (14.0%)	2 (4.5%)	2 (4.8%)
Basophils (10^9/L)	Month 3	n	20	42	42	43	44	42
		Low	0	0	0	0	0	0
		High	0	0	1 (2.4%)	1 (2.3%)	0	0
Monocytes (10^9/L)	Screening	n	22	44	42	43	44	45
		Low	2 (9.1%)	2 (4.5%)	2 (4.8%)	4 (9.3%)	2 (4.5%)	1 (2.2%)
		High	0	0	0	2 (4.7%)	0	0
	Month 3	n	20	42	42	43	44	42
		Low	0	3 (7.1%)	0	2 (4.7%)	0	1 (2.4%)
		High	1 (5.0%)	0	0	0	0	2 (4.8%)
Monocytes/Leukocytes (%)	Screening	n	22	44	42	43	44	45
		Low	2 (9.1%)	3 (6.8%)	4 (9.5%)	6 (14.0%)	1 (2.3%)	0
		High	0	0	1 (2.4%)	1 (2.3%)	0	0
	Month 3	n	20	42	42	43	44	42
		Low	0	2 (4.8%)	3 (7.1%)	2 (4.7%)	0	2 (4.8%)
		High	0	1 (2.4%)	1 (2.4%)	0	0	1 (2.4%)
Lymphocytes (10^9/L)	Screening	n	22	44	42	43	44	45
		Low	3 (13.6%)	0	1 (2.4%)	0	0	0
		High	1 (4.5%)	1 (2.3%)	1 (2.4%)	0	4 (9.1%)	4 (8.9%)
	Month 3	n	20	42	42	43	44	42
		Low	3 (15.0%)	1 (2.4%)	0	1 (2.3%)	0	2 (4.8%)
		High	1 (5.0%)	1 (2.4%)	3 (7.1%)	1 (2.3%)	3 (6.8%)	4 (9.5%)
Lymphocytes/Leukocytes (%)	Screening	n	22	44	42	43	44	45
		Low	1 (4.5%)	1 (2.3%)	0	1 (2.3%)	0	1 (2.2%)
		High	1 (4.5%)	1 (2.3%)	2 (4.8%)	1 (2.3%)	3 (6.8%)	1 (2.2%)
	Month 3	n	20	42	42	43	44	42

Parameter	Analysis Visit	Result	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)
		Low	1 (5.0%)	1 (2.4%)	0	0	0	0
		High	1 (5.0%)	1 (2.4%)	4 (9.5%)	2 (4.7%)	1 (2.3%)	1 (2.4%)

* Placebo arm received placebo by Week 6, then DE-126 0.003% from Week 6 to Month 3.

Cross Reference: 添付資料 5.3.5.1-1 Table 14.3.4.1

Confidential

表 2.7.4.7-7. 012601IN: 臨床検査の異常変動が認められた症例の割合（血液生化学検査）

Parameter	Analysis Visit	Result	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)
Aspartate Aminotransferase (U/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	0	0	0
		High	3 (13.6%)	4 (9.1%)	2 (4.7%)	1 (2.3%)	6 (13.6%)	5 (11.1%)
	Month 3	n	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	2 (10.0%)	2 (4.7%)	3 (7.1%)	3 (7.0%)	4 (9.1%)	5 (11.9%)
Alanine Aminotransferase (U/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	0	0	0
		High	5 (22.7%)	6 (13.6%)	4 (9.3%)	3 (7.0%)	6 (13.6%)	4 (8.9%)
	Month 3	n	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	2 (10.0%)	6 (14.0%)	4 (9.5%)	4 (9.3%)	7 (15.9%)	6 (14.3%)
Gamma Glutamyl Transferase (U/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	0	0	0
		High	2 (9.1%)	5 (11.4%)	9 (20.9%)	8 (18.6%)	6 (13.6%)	5 (11.1%)
	Month 3	n	20	43	42	43	44	42
		Low	0	1 (2.3%)	0	0	0	0
		High	1 (5.0%)	4 (9.3%)	8 (19.0%)	8 (18.6%)	7 (15.9%)	5 (11.9%)
Alkaline Phosphatase (IU/L)	Screening	n	22	44	43	43	44	45
		Low	1 (4.5%)	1 (2.3%)	1 (2.3%)	1 (2.3%)	2 (4.5%)	1 (2.2%)
		High	2 (9.1%)	3 (6.8%)	2 (4.7%)	3 (7.0%)	0	4 (8.9%)
	Month 3	n	20	43	42	43	44	42
		Low	1 (5.0%)	1 (2.3%)	1 (2.4%)	1 (2.3%)	1 (2.3%)	2 (4.8%)
		High	1 (5.0%)	2 (4.7%)	3 (7.1%)	2 (4.7%)	2 (4.5%)	3 (7.1%)
Lactate Dehydrogenase (U/L)	Screening	n	22	43	42	43	42	45
		Low	0	0	0	0	0	0
		High	1 (4.5%)	0	0	1 (2.3%)	1 (2.4%)	1 (2.2%)
	Month 3	n	20	43	41	43	43	42
		Low	0	0	0	0	0	0
		High	1 (5.0%)	0	0	0	1 (2.3%)	2 (4.8%)
Bilirubin (umol/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	0	0	0
		High	1 (4.5%)	0	0	2 (4.7%)	0	1 (2.2%)
	Month 3	n	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	0	0	1 (2.4%)	1 (2.3%)	0	1 (2.4%)

Confidential

Parameter	Analysis Visit	Result	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)
Protein (g/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	0	0	0
		High	0	2 (4.5%)	0	0	2 (4.5%)	0
	Month 3	n	20	43	42	43	44	42
		Low	0	0	1 (2.4%)	0	0	0
		High	0	2 (4.7%)	0	0	1 (2.3%)	0
Albumin (g/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	1 (2.3%)	0	0
		High	0	0	0	0	0	0
Cholesterol (mmol/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	0	0	0
		High	10 (45.5%)	21 (47.7%)	16 (37.2%)	19 (44.2%)	20 (45.5%)	17 (37.8%)
	Month 3	n	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	7 (35.0%)	19 (44.2%)	12 (28.6%)	17 (39.5%)	20 (45.5%)	14 (33.3%)
HDL Cholesterol (mmol/L)	Screening	n	22	44	43	43	44	45
		Low	4 (18.2%)	6 (13.6%)	3 (7.0%)	3 (7.0%)	9 (20.5%)	6 (13.3%)
		High	0	0	0	0	0	0
HDL Cholesterol (mmol/L)	Month 3	n	20	43	42	43	44	42
		Low	4 (20.0%)	5 (11.6%)	2 (4.8%)	4 (9.3%)	8 (18.2%)	5 (11.9%)
		High	0	0	0	0	0	0
LDL Cholesterol (mmol/L)	Screening	n	22	42	42	43	41	41
		Low	0	0	0	0	0	0
		High	5 (22.7%)	5 (11.9%)	6 (14.3%)	13 (30.2%)	9 (22.0%)	6 (14.6%)
	Month 3	n	19	41	41	43	41	42
		Low	0	0	0	0	0	0
		High	4 (21.1%)	8 (19.5%)	5 (12.2%)	8 (18.6%)	9 (22.0%)	7 (16.7%)
Triglycerides (mmol/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	0	0	0
		High	7 (31.8%)	22 (50.0%)	19 (44.2%)	18 (41.9%)	17 (38.6%)	22 (48.9%)
	Month 3	n	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	7 (35.0%)	23 (53.5%)	12 (28.6%)	18 (41.9%)	17 (38.6%)	17 (40.5%)
Urea Nitrogen (mmol/L)	Screening	n	22	44	43	43	44	45
		Low	0	1 (2.3%)	0	0	0	0
		High	2 (9.1%)	5 (11.4%)	4 (9.3%)	5 (11.6%)	4 (9.1%)	9 (20.0%)
Urea Nitrogen (mmol/L)	Month 3	n	20	43	42	43	44	42
		Low	1 (5.0%)	0	0	0	0	0
		High	1 (5.0%)	2 (4.7%)	5 (11.9%)	3 (7.0%)	3 (6.8%)	11 (26.2%)

Confidential

Parameter	Analysis Visit	Result	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)
Creatinine (umol/L)	Screening	n	22	44	43	43	44	45
		Low	1 (4.5%)	1 (2.3%)	0	2 (4.7%)	0	0
		High	3 (13.6%)	4 (9.1%)	5 (11.6%)	7 (16.3%)	7 (15.9%)	8 (17.8%)
	Month 3	n	20	43	42	43	44	42
		Low	1 (5.0%)	0	0	2 (4.7%)	0	2 (4.8%)
		High	2 (10.0%)	6 (14.0%)	6 (14.3%)	7 (16.3%)	11 (25.0%)	7 (16.7%)
Urate (umol/L)	Screening	n	21	44	43	43	44	45
		Low	0	1 (2.3%)	0	0	0	1 (2.2%)
		High	10 (47.6%)	12 (27.3%)	12 (27.9%)	11 (25.6%)	18 (40.9%)	5 (11.1%)
	Month 3	n	20	43	42	43	44	42
		Low	0	2 (4.7%)	0	1 (2.3%)	0	0
		High	5 (25.0%)	9 (20.9%)	9 (21.4%)	9 (20.9%)	13 (29.5%)	11 (26.2%)
Sodium (mmol/L)	Screening	n	22	44	43	43	44	45
		Low	2 (9.1%)	1 (2.3%)	0	0	0	0
		High	0	0	0	0	0	0
Sodium (mmol/L)	Month 3	n	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	0	0	0	0	1 (2.3%)	0
Potassium (mmol/L)	Screening	n	22	44	43	43	44	45
		Low	0	0	0	0	0	0
		High	1 (4.5%)	1 (2.3%)	2 (4.7%)	3 (7.0%)	2 (4.5%)	5 (11.1%)
	Month 3	n	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	0	3 (7.0%)	3 (7.1%)	3 (7.0%)	4 (9.1%)	3 (7.1%)
Chloride (mmol/L)	Screening	n	22	44	43	43	44	45
		Low	3 (13.6%)	0	2 (4.7%)	1 (2.3%)	4 (9.1%)	2 (4.4%)
		High	0	0	0	0	0	0
	Month 3	n	20	43	42	43	44	42
		Low	3 (15.0%)	2 (4.7%)	2 (4.8%)	2 (4.7%)	4 (9.1%)	3 (7.1%)
		High	0	0	0	0	0	0

* Placebo arm received placebo by Week 6, then DE-126 0.003% from Week 6 to Month 3.

Cross Reference: 添付資料 5.3.5.1-1 Table 14.3.4.2

Confidential

表 2.7.4.7-8. 012601IN: 臨床検査の異常変動が認められた症例の割合（尿検査）

Parameter	Analysis Visit	Result	Placebo to 0.003%* (N=22)	0.005% Latanoprost (N=44)	0.0005% DE-126 (N=43)	0.001% DE-126 (N=43)	0.002% DE-126 (N=44)	0.003% DE-126 (N=45)
Glucose	Screening	N	21	44	42	43	44	45
		Low	0	0	0	0	0	0
		High	3 (14.3%)	3 (6.8%)	4 (9.5%)	9 (20.9%)	5 (11.4%)	6 (13.3%)
	Month 3	N	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	2 (10.0%)	4 (9.3%)	4 (9.5%)	11 (25.6%)	5 (11.4%)	5 (11.9%)
Protein	Screening	N	21	44	42	43	44	45
		Low	0	0	0	0	0	0
		High	5 (23.8%)	9 (20.5%)	12 (28.6%)	8 (18.6%)	10 (22.7%)	11 (24.4%)
	Month 3	N	20	43	42	43	44	42
		Low	0	0	0	0	0	0
		High	2 (10.0%)	10 (23.3%)	8 (19.0%)	10 (23.3%)	8 (18.2%)	6 (14.3%)
Urobilinogen	Screening	N	21	44	42	43	44	45
		Low	0	0	0	0	0	0
		High	0	0	0	0	0	1 (2.2%)

* Placebo arm received placebo by Week 6, then DE-126 0.003% from Week 6 to Month 3.

Cross Reference: 添付資料 5.3.5.1-1 Table 14.3.4.3

Confidential

表 2.7.4.7-9. 101260006LT: 臨床検査値の推移（血液学的検査、血液生化学検査）

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Hematology: Erythrocytes (10^4/uL)							
Screening	Observed Value	N	49	42	40	91	131
		Mean (SD)	464.3 (48.51)	468.6 (47.91)	470.0 (45.61)	466.3 (48.01)	467.4 (47.15)
		Median	469.0	467.5	464.5	469.0	466.0
		Min, Max	352, 555	321, 558	380, 572	321, 558	321, 572
Week 26	Observed Value	n	47	40	39	87	126
		Mean (SD)	470.4 (49.77)	469.5 (46.94)	470.0 (47.98)	470.0 (48.21)	470.0 (47.95)
		Median	474.0	464.5	468.0	466.0	466.0
		Min, Max	344, 583	329, 578	370, 557	329, 583	329, 583
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	7.7 (32.83)	-1.7 (23.74)	-1.6 (20.40)	3.4 (29.23)	1.8 (26.83)
		Median	0.0	-2.0	-1.0	0.0	0.0
		Min, Max	-42, 183	-51, 50	-48, 41	-51, 183	-51, 183
Hematology: Erythrocytes (10^4/uL)							
Week 52	Observed Value	n	43	39	38	82	120
		Mean (SD)	466.8 (43.59)	469.6 (45.91)	473.4 (44.46)	468.1 (44.45)	469.8 (44.34)
		Median	468.0	468.0	473.0	468.0	469.5
		Min, Max	381, 558	349, 589	372, 573	349, 589	349, 589
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.1 (27.84)	0.3 (19.88)	1.7 (18.21)	0.1 (24.24)	0.6 (22.44)
		Median	0.0	-2.0	0.5	-1.5	-0.5
		Min, Max	-46, 136	-47, 42	-37, 50	-47, 136	-47, 136
Week 52 / Early withdrawal	Observed Value	n	49	41	39	90	129
		Mean (SD)	464.4 (47.05)	470.8 (47.15)	472.8 (44.06)	467.3 (46.94)	469.0 (45.98)
		Median	468.0	468.0	473.0	468.0	469.0
		Min, Max	341, 558	349, 589	372, 573	341, 589	341, 589
Hematology: Erythrocytes (10^4/uL)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.1 (26.65)	1.0 (19.58)	1.2 (18.33)	0.5 (23.57)	0.7 (22.05)
		Median	0.0	-1.0	0.0	-0.5	0.0
		Min, Max	-46, 136	-47, 42	-37, 50	-47, 136	-47, 136
Hematology: Leukocytes (/uL)							
Screening	Observed Value	n	49	42	40	91	131
		Mean (SD)	5756.7 (1420.60)	6061.7 (2855.61)	5770.5 (1369.59)	5897.5 (2194.20)	5858.7 (1974.66)
		Median	5630.0	5620.0	5595.0	5630.0	5610.0
		Min, Max	3360, 9210	2950, 20920	2640, 9770	2950, 20920	2640, 20920
Week 26	Observed Value	n	47	40	39	87	126
		Mean (SD)	5641.5 (1571.49)	6110.8 (3296.28)	5753.8 (1306.13)	5857.2 (2510.70)	5825.2 (2204.05)
		Median	5230.0	5205.0	5710.0	5230.0	5330.0

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
		Min, Max	3640, 8780	3220, 23800	3190, 8930	3220, 23800	3190, 23800
Hematology: Leukocytes (/uL)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-148.1 (995.33)	13.8 (1054.79)	-26.7 (1047.57)	-73.7 (1020.31)	-59.1 (1024.85)
		Median	-290.0	-140.0	-160.0	-200.0	-175.0
		Min, Max	-2410, 2520	-2270, 2880	-1700, 3510	-2410, 2880	-2410, 3510
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	6204.4 (2039.32)	5991.0 (3087.96)	5767.9 (1322.65)	6102.9 (2577.09)	5996.8 (2255.89)
		Median	5930.0	5400.0	5660.0	5680.0	5660.0
		Min, Max	3910, 12980	3690, 23360	2920, 9190	3690, 23360	2920, 23360
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	377.9 (1387.18)	20.8 (1241.17)	21.8 (926.11)	208.0 (1323.89)	149.1 (1211.30)
		Median	180.0	-90.0	-150.0	50.0	25.0
		Min, Max	-2760, 6510	-2590, 3040	-1850, 1800	-2760, 6510	-2760, 6510
Hematology: Leukocytes (/uL)							
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	6049.0 (1981.25)	6102.7 (3080.64)	5761.0 (1305.83)	6073.4 (2526.48)	5979.0 (2228.28)
		Median	5470.0	5570.0	5570.0	5520.0	5570.0
		Min, Max	3480, 12980	3690, 23360	2920, 9190	3480, 23360	2920, 23360
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	292.2 (1377.52)	44.1 (1251.21)	-19.5 (949.60)	179.2 (1320.02)	119.1 (1219.69)
		Median	180.0	-90.0	-150.0	50.0	20.0
		Min, Max	-2760, 6510	-2590, 3040	-1850, 1800	-2760, 6510	-2760, 6510
Hematology: Hemoglobin (g/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	14.27 (1.701)	14.06 (1.624)	14.40 (1.454)	14.17 (1.660)	14.24 (1.598)
		Median	14.30	14.20	14.60	14.20	14.30
		Min, Max	8.3, 17.2	10.2, 16.9	11.8, 17.5	8.3, 17.2	8.3, 17.5
Hematology: Hemoglobin (g/dL)							
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	14.45 (1.552)	13.89 (1.958)	14.47 (1.503)	14.19 (1.763)	14.28 (1.686)
		Median	14.50	14.15	14.80	14.20	14.30
		Min, Max	11.6, 17.8	9.2, 18.2	11.8, 17.8	9.2, 18.2	9.2, 18.2
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.22 (1.200)	-0.25 (0.900)	0.02 (0.628)	0.01 (1.093)	0.01 (0.970)
		Median	0.10	-0.15	0.10	0.00	0.00
		Min, Max	-1.4, 7.1	-3.7, 1.3	-1.6, 1.6	-3.7, 7.1	-3.7, 7.1

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Week 52	Observed Value	n	43	39	38	82	120
		Mean (SD)	14.52 (1.507)	13.94 (1.945)	14.55 (1.432)	14.24 (1.743)	14.34 (1.651)
		Median	14.60	13.90	14.60	14.35	14.50
		Min, Max	12.0, 17.6	8.7, 17.5	11.3, 18.0	8.7, 17.6	8.7, 18.0
Hematology: Hemoglobin (g/dL)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	0.21 (1.291)	-0.14 (0.929)	0.11 (0.567)	0.04 (1.140)	0.06 (0.992)
		Median	0.00	0.00	0.10	0.00	0.00
		Min, Max	-1.1, 7.6	-3.0, 1.7	-1.4, 1.5	-3.0, 7.6	-3.0, 7.6
Week 52 / Early withdrawal	Observed Value	n	49	41	39	90	129
		Mean (SD)	14.40 (1.517)	13.98 (1.935)	14.55 (1.414)	14.21 (1.724)	14.31 (1.638)
		Median	14.60	13.90	14.60	14.25	14.40
		Min, Max	11.9, 17.6	8.7, 17.5	11.3, 18.0	8.7, 17.6	8.7, 18.0
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.13 (1.228)	-0.12 (0.909)	0.09 (0.570)	0.02 (1.096)	0.04 (0.966)
		Median	-0.10	0.00	0.10	-0.05	0.00
		Min, Max	-1.1, 7.6	-3.0, 1.7	-1.4, 1.5	-3.0, 7.6	-3.0, 7.6
Hematology: Hematocrit (%)							
Screening	Observed Value	n	49	42	40	91	131
		Mean (SD)	42.82 (4.350)	42.30 (4.086)	43.23 (3.723)	42.58 (4.215)	42.78 (4.068)
		Median	42.80	42.50	43.20	42.60	42.80
		Min, Max	29.0, 51.1	32.3, 49.9	36.5, 51.3	29.0, 51.1	29.0, 51.3
Week 26	Observed Value	n	47	40	39	87	126
		Mean (SD)	44.17 (4.058)	42.65 (4.727)	43.94 (3.997)	43.47 (4.418)	43.61 (4.282)
		Median	44.20	42.75	44.30	43.60	43.65
		Min, Max	37.0, 54.7	31.8, 54.2	36.5, 52.0	31.8, 54.7	31.8, 54.7
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	1.47 (3.182)	0.13 (2.475)	0.57 (1.915)	0.86 (2.941)	0.77 (2.661)
		Median	1.00	0.40	0.80	0.80	0.80
		Min, Max	-3.4, 18.8	-8.0, 6.0	-4.6, 4.1	-8.0, 18.8	-8.0, 18.8
Hematology: Hematocrit (%)							
Week 52	Observed Value	n	43	39	38	82	120
		Mean (SD)	43.37 (3.790)	42.35 (4.584)	43.71 (3.644)	42.89 (4.191)	43.15 (4.029)
		Median	43.30	42.50	44.10	43.00	43.05
		Min, Max	36.7, 51.9	31.2, 52.0	36.3, 51.3	31.2, 52.0	31.2, 52.0
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	0.45 (3.327)	-0.02 (2.140)	0.39 (1.591)	0.23 (2.819)	0.28 (2.491)
		Median	0.10	0.30	0.40	0.10	0.25
		Min, Max	-3.8, 18.7	-5.7, 4.2	-3.6, 3.8	-5.7, 18.7	-5.7, 18.7

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Week 52 / Early withdrawal	Observed Value	n	49	41	39	90	129
		Mean (SD)	43.25 (3.740)	42.52 (4.637)	43.71 (3.596)	42.92 (4.165)	43.16 (4.004)
		Median	43.30	42.50	43.90	43.00	43.10
		Min, Max	36.7, 51.9	31.2, 52.0	36.3, 51.3	31.2, 52.0	31.2, 52.0
Hematology: Hematocrit (%)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.43 (3.132)	0.09 (2.142)	0.33 (1.609)	0.27 (2.717)	0.29 (2.429)
		Median	0.10	0.40	0.40	0.15	0.30
		Min, Max	-3.8, 18.7	-5.7, 4.2	-3.6, 3.8	-5.7, 18.7	-5.7, 18.7
Hematology: Platelets (10^4/uL)							
Screening	Observed Value	n	49	42	40	91	131
		Mean (SD)	24.77 (8.098)	24.93 (7.251)	23.95 (6.697)	24.84 (7.676)	24.57 (7.377)
		Median	23.20	24.30	24.20	23.70	23.90
		Min, Max	15.8, 62.1	12.4, 53.6	13.3, 45.1	12.4, 62.1	12.4, 62.1
Week 26	Observed Value	n	47	40	39	87	126
		Mean (SD)	24.37 (6.255)	26.17 (9.104)	23.23 (7.048)	25.20 (7.703)	24.59 (7.534)
		Median	22.80	24.60	22.00	24.30	23.65
		Min, Max	14.9, 37.9	13.1, 60.4	13.6, 47.8	13.1, 60.4	13.1, 60.4
Hematology: Platelets (10^4/uL)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-0.53 (5.091)	0.82 (5.486)	-0.71 (2.766)	0.09 (5.288)	-0.16 (4.659)
		Median	-0.20	-0.20	-0.50	-0.20	-0.40
		Min, Max	-25.6, 9.0	-4.1, 30.2	-5.9, 5.3	-25.6, 30.2	-25.6, 30.2
Week 52	Observed Value	n	43	39	38	82	120
		Mean (SD)	24.30 (5.880)	25.88 (10.519)	22.39 (6.700)	25.05 (8.394)	24.21 (7.967)
		Median	24.80	25.40	22.80	24.80	23.80
		Min, Max	15.4, 37.2	10.4, 75.7	12.6, 43.2	10.4, 75.7	10.4, 75.7
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-1.25 (4.918)	0.61 (4.753)	-1.16 (3.333)	-0.37 (4.900)	-0.62 (4.465)
		Median	-0.70	0.10	-0.75	-0.30	-0.60
		Min, Max	-29.9, 5.7	-10.1, 22.1	-9.2, 5.8	-29.9, 22.1	-29.9, 22.1
Hematology: Platelets (10^4/uL)							
Week 52 / Early withdrawal	Observed Value	n	49	41	39	90	129
		Mean (SD)	23.78 (5.845)	25.76 (10.299)	22.77 (7.035)	24.68 (8.190)	24.10 (7.881)
		Median	22.30	25.40	23.30	24.40	23.60
		Min, Max	13.6, 37.2	10.4, 75.7	12.6, 43.2	10.4, 75.7	10.4, 75.7
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.99 (4.871)	0.52 (4.649)	-1.17 (3.290)	-0.30 (4.805)	-0.56 (4.407)
		Median	-0.70	0.10	-0.90	-0.45	-0.60

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
		Min, Max	-29.9, 8.8	-10.1, 22.1	-9.2, 5.8	-29.9, 22.1	-29.9, 22.1
Hematology: Neutrophils/Leukocytes (%)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	57.82 (8.658)	59.92 (10.011)	59.53 (7.326)	58.79 (9.313)	59.02 (8.733)
		Median	58.00	59.05	59.60	58.60	58.90
		Min, Max	33.3, 74.0	36.6, 91.0	45.0, 74.4	33.3, 91.0	33.3, 91.0
Hematology: Neutrophils/Leukocytes (%)							
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	57.62 (9.340)	61.17 (9.062)	58.99 (7.479)	59.25 (9.331)	59.17 (8.770)
		Median	60.10	61.45	59.30	60.70	60.50
		Min, Max	36.5, 78.0	35.8, 84.0	44.2, 73.5	35.8, 84.0	35.8, 84.0
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.04 (7.001)	1.15 (6.545)	-0.49 (6.475)	0.55 (6.779)	0.23 (6.678)
		Median	-0.60	-0.25	-1.40	-0.40	-0.65
		Min, Max	-14.0, 17.3	-11.7, 23.1	-12.0, 15.0	-14.0, 23.1	-14.0, 23.1
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	57.86 (9.667)	60.49 (9.405)	57.88 (7.387)	59.11 (9.576)	58.72 (8.929)
		Median	57.90	60.80	57.95	60.20	59.30
		Min, Max	35.3, 80.0	34.7, 87.0	44.5, 74.1	34.7, 87.0	34.7, 87.0
Hematology: Neutrophils/Leukocytes (%)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	0.57 (8.156)	0.63 (8.046)	-1.32 (5.879)	0.60 (8.053)	-0.01 (7.463)
		Median	0.70	-0.30	-1.05	0.05	-0.25
		Min, Max	-13.4, 31.0	-15.4, 25.1	-17.9, 10.3	-15.4, 31.0	-17.9, 31.0
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	57.60 (9.978)	60.82 (9.290)	57.91 (7.293)	59.07 (9.751)	58.72 (9.066)
		Median	57.80	60.90	58.20	60.20	59.30
		Min, Max	35.3, 80.0	34.7, 87.0	44.5, 74.1	34.7, 87.0	34.7, 87.0
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.23 (8.318)	0.73 (7.887)	-1.57 (6.013)	0.21 (8.093)	-0.33 (7.547)
		Median	0.10	-0.30	-1.20	-0.10	-0.30
		Min, Max	-16.0, 31.0	-15.4, 25.1	-17.9, 10.3	-16.0, 31.0	-17.9, 31.0
Hematology: Eosinophils/Leukocytes (%)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	2.54 (1.909)	3.03 (1.641)	3.47 (2.812)	2.77 (1.797)	2.98 (2.171)
		Median	2.00	2.70	2.55	2.30	2.40
		Min, Max	0.0, 8.3	0.6, 7.7	0.6, 14.4	0.0, 8.3	0.0, 14.4
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	2.85 (2.455)	3.17 (1.569)	4.09 (3.318)	3.00 (2.089)	3.33 (2.570)
		Median	2.20	3.05	3.00	2.50	2.60
		Min, Max	0.0, 11.1	0.6, 6.3	0.9, 15.0	0.0, 11.1	0.0, 15.0

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.30 (1.716)	0.13 (1.381)	0.61 (2.330)	0.22 (1.564)	0.34 (1.835)
		Median	0.30	0.20	0.20	0.30	0.25
		Min, Max	-3.6, 5.7	-3.8, 4.0	-3.3, 8.8	-3.8, 5.7	-3.8, 8.8
Hematology: Eosinophils/Leukocytes (%)							
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	2.52 (1.603)	3.00 (1.842)	4.21 (4.593)	2.75 (1.727)	3.21 (3.009)
		Median	2.00	2.60	2.80	2.40	2.50
		Min, Max	0.0, 8.4	0.0, 10.3	0.7, 26.5	0.0, 10.3	0.0, 26.5
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.11 (1.617)	-0.02 (1.613)	0.65 (2.625)	-0.07 (1.606)	0.16 (2.002)
		Median	0.20	0.00	0.25	0.10	0.20
		Min, Max	-5.9, 2.2	-4.7, 5.5	-4.3, 12.1	-5.9, 5.5	-5.9, 12.1
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	2.43 (1.576)	3.01 (1.814)	4.28 (4.556)	2.69 (1.704)	3.17 (2.952)
		Median	2.00	2.60	2.80	2.30	2.50
		Min, Max	0.0, 8.4	0.0, 10.3	0.7, 26.5	0.0, 10.3	0.0, 26.5
Hematology: Eosinophils/Leukocytes (%)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.11 (1.557)	-0.04 (1.594)	0.80 (2.754)	-0.08 (1.566)	0.19 (2.030)
		Median	0.10	0.00	0.30	0.05	0.20
		Min, Max	-5.9, 2.2	-4.7, 5.5	-4.3, 12.1	-5.9, 5.5	-5.9, 12.1
Hematology: Basophils/Leukocytes (%)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	0.56 (0.388)	0.65 (0.311)	0.61 (0.371)	0.60 (0.355)	0.60 (0.359)
		Median	0.40	0.65	0.60	0.50	0.60
		Min, Max	0.0, 1.9	0.0, 1.3	0.0, 2.0	0.0, 1.9	0.0, 2.0
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	0.62 (0.393)	0.67 (0.445)	0.68 (0.380)	0.64 (0.416)	0.66 (0.404)
		Median	0.50	0.60	0.60	0.60	0.60
		Min, Max	0.0, 1.9	0.0, 2.0	0.2, 2.3	0.0, 2.0	0.0, 2.3
Hematology: Basophils/Leukocytes (%)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.05 (0.311)	0.02 (0.422)	0.08 (0.320)	0.04 (0.364)	0.05 (0.350)
		Median	0.00	-0.05	0.00	0.00	0.00
		Min, Max	-0.6, 0.9	-0.8, 1.6	-0.6, 0.7	-0.8, 1.6	-0.8, 1.6
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	0.61 (0.419)	0.68 (0.490)	0.63 (0.340)	0.64 (0.453)	0.64 (0.419)
		Median	0.60	0.60	0.60	0.60	0.60
		Min, Max	0.0, 2.3	0.0, 2.0	0.2, 2.0	0.0, 2.3	0.0, 2.3

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	0.02 (0.250)	0.02 (0.412)	0.03 (0.291)	0.02 (0.335)	0.02 (0.320)
		Median	0.00	0.00	0.00	0.00	0.00
		Min, Max	-0.6, 0.4	-0.8, 1.0	-0.8, 0.8	-0.8, 1.0	-0.8, 1.0
Hematology: Basophils/Leukocytes (%)							
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	0.59 (0.403)	0.67 (0.482)	0.64 (0.352)	0.63 (0.440)	0.63 (0.414)
		Median	0.50	0.60	0.60	0.60	0.60
		Min, Max	0.0, 2.3	0.0, 2.0	0.2, 2.0	0.0, 2.3	0.0, 2.3
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.03 (0.276)	0.01 (0.405)	0.04 (0.302)	0.02 (0.339)	0.03 (0.327)
		Median	0.00	0.00	0.00	0.00	0.00
		Min, Max	-0.6, 0.7	-0.8, 1.0	-0.8, 0.8	-0.8, 1.0	-0.8, 1.0
Hematology: Monocytes/Leukocytes (%)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	6.54 (1.810)	6.08 (2.289)	6.33 (1.340)	6.33 (2.047)	6.33 (1.855)
		Median	6.30	5.80	6.15	6.00	6.00
		Min, Max	4.0, 15.0	1.0, 15.0	3.7, 8.7	1.0, 15.0	1.0, 15.0
Hematology: Monocytes/Leukocytes (%)							
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	6.23 (1.443)	6.01 (1.545)	6.42 (1.213)	6.13 (1.486)	6.22 (1.409)
		Median	6.10	6.00	6.40	6.10	6.20
		Min, Max	3.0, 9.8	2.0, 9.3	3.8, 9.1	2.0, 9.8	2.0, 9.8
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-0.27 (1.560)	-0.01 (1.547)	0.04 (1.081)	-0.15 (1.550)	-0.09 (1.420)
		Median	-0.10	0.05	-0.10	-0.10	-0.10
		Min, Max	-7.5, 3.1	-7.1, 2.2	-2.3, 2.8	-7.5, 3.1	-7.5, 3.1
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	6.33 (1.215)	6.18 (1.735)	6.58 (1.328)	6.26 (1.478)	6.36 (1.435)
		Median	6.00	6.00	6.70	6.00	6.20
		Min, Max	4.2, 9.1	3.0, 11.1	3.6, 9.0	3.0, 11.1	3.0, 11.1
Hematology: Monocytes/Leukocytes (%)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.03 (1.075)	0.14 (1.455)	0.15 (1.198)	0.05 (1.265)	0.08 (1.240)
		Median	-0.10	0.10	0.15	0.05	0.10
		Min, Max	-3.0, 2.2	-5.1, 3.0	-2.2, 3.1	-5.1, 3.0	-5.1, 3.1
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	6.37 (1.337)	6.24 (1.768)	6.59 (1.311)	6.31 (1.540)	6.40 (1.475)
		Median	6.00	6.00	6.70	6.00	6.20
		Min, Max	3.9, 9.8	3.0, 11.1	3.6, 9.0	3.0, 11.1	3.0, 11.1

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.17 (1.493)	0.16 (1.420)	0.20 (1.231)	-0.02 (1.461)	0.05 (1.395)
		Median	-0.10	0.20	0.20	0.10	0.10
		Min, Max	-7.5, 2.2	-5.1, 3.0	-2.2, 3.1	-7.5, 3.0	-7.5, 3.1
Hematology: Lymphocytes/Leukocytes (%)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	32.54 (7.738)	30.32 (9.186)	30.06 (7.700)	31.51 (8.463)	31.07 (8.235)
		Median	32.00	29.45	31.10	31.90	31.40
		Min, Max	17.0, 55.7	5.0, 52.3	12.2, 44.9	5.0, 55.7	5.0, 55.7
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	32.67 (9.060)	28.98 (8.538)	29.82 (7.065)	30.98 (8.966)	30.62 (8.412)
		Median	30.10	27.45	29.10	28.80	28.85
		Min, Max	13.0, 53.8	9.0, 52.9	14.0, 43.4	9.0, 53.8	9.0, 53.8
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-0.12 (6.129)	-1.29 (5.572)	-0.24 (5.381)	-0.66 (5.875)	-0.53 (5.708)
		Median	-0.60	0.65	0.20	0.00	0.15
		Min, Max	-14.8, 11.1	-19.5, 9.0	-13.2, 10.0	-19.5, 11.1	-19.5, 11.1
Hematology: Lymphocytes/Leukocytes (%)							
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	32.68 (9.452)	29.62 (8.529)	30.71 (7.302)	31.23 (9.100)	31.06 (8.544)
		Median	31.20	30.20	30.40	30.90	30.75
		Min, Max	11.0, 57.1	6.0, 48.2	17.5, 44.3	6.0, 57.1	6.0, 57.1
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.46 (7.026)	-0.79 (6.557)	0.49 (4.958)	-0.62 (6.767)	-0.27 (6.252)
		Median	-0.10	0.00	1.10	-0.05	0.50
		Min, Max	-22.3, 12.9	-20.7, 11.4	-11.8, 8.3	-22.3, 12.9	-22.3, 12.9
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	33.01 (9.749)	29.24 (8.506)	30.58 (7.251)	31.29 (9.346)	31.08 (8.744)
		Median	31.20	29.70	30.10	30.55	30.20
		Min, Max	11.0, 57.1	6.0, 48.2	17.5, 44.3	6.0, 57.1	6.0, 57.1
Hematology: Lymphocytes/Leukocytes (%)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.47 (7.424)	-0.88 (6.422)	0.52 (4.896)	-0.15 (6.980)	0.06 (6.410)
		Median	0.00	-0.40	1.10	0.00	0.80
		Min, Max	-22.3, 15.3	-20.7, 11.4	-11.8, 8.3	-22.3, 15.3	-22.3, 15.3
Chemistry: Aspartate Aminotransferase (U/L)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	24.6 (11.58)	23.1 (6.28)	27.7 (9.95)	23.9 (9.49)	25.1 (9.75)
		Median	21.0	21.5	25.5	21.0	23.0
		Min, Max	12, 84	12, 39	14, 57	12, 84	12, 84

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	23.0 (7.91)	23.2 (9.06)	26.4 (11.97)	23.1 (8.41)	24.1 (9.73)
		Median	22.0	20.5	24.0	22.0	22.0
		Min, Max	13, 62	15, 66	14, 78	13, 66	13, 78
Chemistry: Aspartate Aminotransferase (U/L)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-1.3 (7.53)	0.4 (9.28)	-1.2 (10.00)	-0.5 (8.37)	-0.7 (8.87)
		Median	-1.0	-1.0	-2.0	-1.0	-1.0
		Min, Max	-31, 16	-10, 48	-28, 27	-31, 48	-31, 48
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	23.9 (9.10)	23.7 (9.18)	27.8 (12.73)	23.8 (9.08)	25.1 (10.49)
		Median	21.0	21.0	24.5	21.0	22.0
		Min, Max	13, 69	15, 65	16, 83	13, 69	13, 83
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.8 (7.12)	0.6 (8.51)	0.1 (10.39)	-0.1 (7.79)	-0.1 (8.66)
		Median	-1.0	0.0	0.0	-0.5	-0.5
		Min, Max	-33, 12	-18, 34	-33, 30	-33, 34	-33, 34
Chemistry: Aspartate Aminotransferase (U/L)							
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	23.9 (8.96)	23.5 (9.00)	27.6 (12.62)	23.7 (8.93)	24.9 (10.29)
		Median	22.0	21.0	24.0	21.0	22.0
		Min, Max	11, 69	15, 65	16, 83	11, 69	11, 83
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.7 (7.07)	0.7 (8.38)	0.1 (10.26)	-0.0 (7.68)	-0.0 (8.50)
		Median	-1.0	0.0	-1.0	-1.0	-1.0
		Min, Max	-33, 12	-18, 34	-33, 30	-33, 34	-33, 34
Chemistry: Alanine Aminotransferase (U/L)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	27.3 (22.33)	24.2 (12.78)	28.9 (18.65)	25.9 (18.51)	26.8 (18.53)
		Median	20.0	19.0	21.5	20.0	20.0
		Min, Max	11, 153	7, 58	10, 96	7, 153	7, 153
Chemistry: Alanine Aminotransferase (U/L)							
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	24.1 (14.84)	26.5 (22.12)	27.0 (17.85)	25.2 (18.47)	25.8 (18.23)
		Median	21.0	20.5	22.0	21.0	21.0
		Min, Max	13, 109	8, 116	5, 99	8, 116	5, 116
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-2.3 (10.45)	2.2 (19.07)	-2.1 (14.07)	-0.2 (15.12)	-0.8 (14.77)
		Median	-1.0	-1.0	-2.0	-1.0	-1.0
		Min, Max	-44, 16	-23, 98	-49, 30	-44, 98	-49, 98

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	26.1 (17.66)	25.4 (19.02)	28.4 (19.59)	25.8 (18.21)	26.6 (18.61)
		Median	23.0	19.0	23.0	21.0	21.5
		Min, Max	10, 124	7, 96	6, 123	7, 124	6, 124
Chemistry: Alanine Aminotransferase (U/L)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.9 (11.06)	1.0 (14.72)	-1.0 (17.98)	-0.0 (12.89)	-0.3 (14.62)
		Median	0.0	-1.0	2.0	0.0	0.0
		Min, Max	-49, 20	-32, 45	-66, 54	-49, 45	-66, 54
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	26.2 (17.17)	25.2 (18.69)	28.2 (19.38)	25.8 (17.78)	26.5 (18.24)
		Median	23.0	19.0	23.0	21.0	22.0
		Min, Max	10, 124	7, 96	6, 123	7, 124	6, 124
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-1.0 (10.47)	1.2 (14.50)	-0.9 (17.75)	0.0 (12.44)	-0.3 (14.19)
		Median	0.0	-1.0	2.0	0.0	0.0
		Min, Max	-49, 20	-32, 45	-66, 54	-49, 45	-66, 54
Chemistry: Gamma Glutamyl Transferase (U/L)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	36.7 (27.11)	36.4 (22.94)	37.2 (25.02)	36.5 (25.13)	36.7 (25.00)
		Median	31.0	29.0	30.5	29.0	29.0
		Min, Max	11, 160	12, 104	8, 131	11, 160	8, 160
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	32.5 (19.16)	35.9 (27.09)	38.2 (34.63)	34.1 (23.06)	35.4 (27.10)
		Median	26.0	26.5	30.0	26.0	27.0
		Min, Max	11, 102	12, 132	9, 212	11, 132	9, 212
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-3.3 (11.59)	0.4 (11.94)	1.0 (20.98)	-1.6 (11.82)	-0.8 (15.21)
		Median	-2.0	-1.0	-2.0	-1.0	-1.0
		Min, Max	-58, 11	-25, 28	-47, 81	-58, 28	-58, 81
Chemistry: Gamma Glutamyl Transferase (U/L)							
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	34.0 (27.04)	37.5 (32.03)	38.2 (31.49)	35.6 (29.39)	36.4 (29.96)
		Median	27.0	28.0	30.0	27.0	27.5
		Min, Max	11, 169	10, 175	8, 176	10, 175	8, 176
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-1.2 (9.24)	1.7 (22.13)	1.2 (15.87)	0.2 (16.62)	0.5 (16.32)
		Median	0.0	0.0	-1.0	0.0	0.0
		Min, Max	-44, 19	-39, 83	-39, 45	-44, 83	-44, 83

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	36.7 (29.57)	36.6 (31.53)	38.2 (31.08)	36.6 (30.31)	37.1 (30.43)
		Median	27.0	27.0	30.0	27.0	28.0
		Min, Max	11, 169	10, 175	8, 176	10, 175	8, 176
Chemistry: Gamma Glutamyl Transferase (U/L)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.0 (13.34)	1.6 (21.58)	1.0 (15.69)	0.7 (17.49)	0.8 (16.91)
		Median	0.0	0.0	-1.0	0.0	0.0
		Min, Max	-44, 60	-39, 83	-39, 45	-44, 83	-44, 83
Chemistry: Alkaline Phosphatase (U/L)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	77.4 (21.46)	76.0 (25.49)	71.3 (18.33)	76.8 (23.28)	75.1 (21.97)
		Median	76.0	70.0	69.0	74.0	73.0
		Min, Max	38, 131	31, 144	45, 118	31, 144	31, 144
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	76.0 (20.22)	72.3 (22.81)	72.1 (19.48)	74.3 (21.41)	73.6 (20.78)
		Median	74.0	69.0	71.0	73.0	72.0
		Min, Max	39, 138	31, 142	46, 116	31, 142	31, 142
Chemistry: Alkaline Phosphatase (U/L)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-1.3 (12.99)	-3.2 (9.47)	0.9 (11.56)	-2.1 (11.48)	-1.2 (11.55)
		Median	-1.0	-3.0	-1.0	-3.0	-2.0
		Min, Max	-33, 40	-25, 24	-38, 28	-33, 40	-38, 40
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	74.2 (16.42)	76.6 (25.92)	73.0 (19.78)	75.3 (21.36)	74.6 (20.82)
		Median	73.0	70.0	71.0	71.5	71.0
		Min, Max	41, 107	38, 143	41, 131	38, 143	38, 143
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-2.5 (11.09)	1.0 (11.56)	2.0 (10.32)	-0.8 (11.39)	0.1 (11.10)
		Median	-2.0	-1.0	1.0	-1.0	-1.0
		Min, Max	-28, 18	-38, 26	-20, 31	-38, 26	-38, 31
Chemistry: Alkaline Phosphatase (U/L)							
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	76.7 (19.20)	77.6 (26.66)	73.0 (19.53)	77.1 (22.77)	75.9 (21.85)
		Median	77.0	70.0	71.0	73.0	71.0
		Min, Max	41, 138	38, 143	41, 131	38, 143	38, 143
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.8 (12.95)	1.6 (12.13)	1.8 (10.23)	0.3 (12.57)	0.8 (11.89)
		Median	-1.0	-1.0	1.0	-1.0	-1.0

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
		Min, Max	-28, 40	-38, 29	-20, 31	-38, 40	-38, 40
Chemistry: Lactate Dehydrogenase (U/L)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	175.5 (29.01)	173.6 (38.23)	174.5 (28.01)	174.6 (33.40)	174.6 (31.74)
		Median	173.0	174.0	174.0	173.0	173.0
		Min, Max	116, 247	69, 318	113, 254	69, 318	69, 318
Chemistry: Lactate Dehydrogenase (U/L)							
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	176.6 (28.37)	172.5 (42.10)	170.5 (29.61)	174.7 (35.20)	173.4 (33.51)
		Median	169.0	161.5	172.0	169.0	169.0
		Min, Max	118, 250	91, 348	123, 264	91, 348	91, 348
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.1 (15.92)	-0.4 (18.82)	-3.2 (19.28)	-0.1 (17.21)	-1.0 (17.86)
		Median	2.0	-1.0	-3.0	1.0	0.5
		Min, Max	-44, 33	-35, 35	-42, 44	-44, 35	-44, 44
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	172.7 (32.64)	176.8 (52.11)	172.6 (29.31)	174.7 (42.79)	174.0 (38.91)
		Median	166.0	163.0	173.5	164.5	166.0
		Min, Max	116, 259	94, 425	119, 245	94, 425	94, 425
Chemistry: Lactate Dehydrogenase (U/L)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-4.2 (17.42)	4.3 (25.11)	-0.3 (27.51)	-0.1 (21.71)	-0.2 (23.58)
		Median	-2.0	7.0	0.5	-0.5	0.0
		Min, Max	-44, 29	-30, 107	-52, 55	-44, 107	-52, 107
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	172.4 (32.32)	178.2 (51.18)	173.5 (29.54)	175.1 (41.82)	174.6 (38.41)
		Median	168.0	165.0	174.0	165.0	168.0
		Min, Max	116, 259	94, 425	119, 245	94, 425	94, 425
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-3.1 (16.89)	4.7 (24.60)	-0.2 (27.16)	0.5 (21.00)	0.3 (22.93)
		Median	-1.0	7.0	1.0	1.0	1.0
		Min, Max	-44, 29	-30, 107	-52, 55	-44, 107	-52, 107
Chemistry: Bilirubin (mg/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	0.61 (0.251)	0.61 (0.208)	0.74 (0.328)	0.61 (0.231)	0.65 (0.270)
		Median	0.50	0.60	0.70	0.60	0.60
		Min, Max	0.2, 1.3	0.3, 1.2	0.3, 1.8	0.2, 1.3	0.2, 1.8
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	0.60 (0.167)	0.58 (0.211)	0.73 (0.253)	0.59 (0.188)	0.63 (0.219)
		Median	0.60	0.50	0.70	0.60	0.60
		Min, Max	0.3, 1.1	0.2, 1.2	0.4, 1.3	0.2, 1.2	0.2, 1.3

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-0.01 (0.211)	-0.02 (0.202)	-0.01 (0.239)	-0.01 (0.206)	-0.01 (0.216)
		Median	0.00	0.00	0.00	0.00	0.00
		Min, Max	-0.6, 0.4	-0.5, 0.6	-0.5, 0.6	-0.6, 0.6	-0.6, 0.6
Chemistry: Bilirubin (mg/dL)							
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	0.65 (0.222)	0.59 (0.180)	0.73 (0.428)	0.62 (0.204)	0.66 (0.296)
		Median	0.60	0.60	0.70	0.60	0.60
		Min, Max	0.3, 1.4	0.2, 1.1	0.3, 2.7	0.2, 1.4	0.2, 2.7
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	0.04 (0.172)	-0.02 (0.147)	-0.01 (0.263)	0.01 (0.162)	0.00 (0.198)
		Median	0.00	0.00	0.00	0.00	0.00
		Min, Max	-0.4, 0.4	-0.4, 0.2	-0.6, 1.1	-0.4, 0.4	-0.6, 1.1
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	0.64 (0.216)	0.59 (0.177)	0.73 (0.422)	0.62 (0.199)	0.65 (0.289)
		Median	0.60	0.60	0.70	0.60	0.60
		Min, Max	0.3, 1.4	0.2, 1.1	0.3, 2.7	0.2, 1.4	0.2, 2.7
Chemistry: Bilirubin (mg/dL)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.03 (0.177)	-0.01 (0.144)	-0.01 (0.260)	0.01 (0.163)	0.00 (0.197)
		Median	0.00	0.00	0.00	0.00	0.00
		Min, Max	-0.4, 0.4	-0.4, 0.2	-0.6, 1.1	-0.4, 0.4	-0.6, 1.1
Chemistry: Protein (g/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	6.97 (0.377)	6.94 (0.365)	7.00 (0.359)	6.95 (0.369)	6.97 (0.365)
		Median	6.90	6.90	7.00	6.90	6.90
		Min, Max	6.1, 7.9	6.1, 7.6	6.4, 7.8	6.1, 7.9	6.1, 7.9
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	6.86 (0.355)	6.81 (0.361)	6.92 (0.343)	6.84 (0.357)	6.86 (0.353)
		Median	6.80	6.80	6.90	6.80	6.85
		Min, Max	6.1, 7.8	6.1, 7.7	6.1, 7.7	6.1, 7.8	6.1, 7.8
Chemistry: Protein (g/dL)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-0.11 (0.325)	-0.14 (0.342)	-0.09 (0.348)	-0.12 (0.332)	-0.11 (0.336)
		Median	-0.10	-0.10	-0.10	-0.10	-0.10
		Min, Max	-1.0, 0.7	-0.7, 0.5	-0.8, 0.7	-1.0, 0.7	-1.0, 0.7
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	6.80 (0.408)	6.88 (0.387)	6.96 (0.379)	6.84 (0.398)	6.88 (0.394)
		Median	6.70	6.80	6.90	6.80	6.80
		Min, Max	6.1, 7.8	6.3, 7.8	6.3, 8.0	6.1, 7.8	6.1, 8.0

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.16 (0.287)	-0.05 (0.314)	-0.03 (0.272)	-0.11 (0.303)	-0.08 (0.294)
		Median	-0.10	-0.10	0.00	-0.10	-0.10
		Min, Max	-1.0, 0.5	-0.5, 0.7	-0.8, 0.4	-1.0, 0.7	-1.0, 0.7
Chemistry: Protein (g/dL)							
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	6.81 (0.401)	6.91 (0.404)	6.96 (0.375)	6.85 (0.403)	6.89 (0.396)
		Median	6.70	6.80	6.90	6.80	6.80
		Min, Max	6.1, 7.8	6.3, 7.8	6.3, 8.0	6.1, 7.8	6.1, 8.0
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.16 (0.275)	-0.04 (0.309)	-0.05 (0.279)	-0.11 (0.295)	-0.09 (0.291)
		Median	-0.10	-0.10	0.00	-0.10	-0.10
		Min, Max	-1.0, 0.5	-0.5, 0.7	-0.8, 0.4	-1.0, 0.7	-1.0, 0.7
Chemistry: Albumin (g/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	4.38 (0.284)	4.37 (0.298)	4.44 (0.294)	4.37 (0.289)	4.39 (0.291)
		Median	4.40	4.40	4.40	4.40	4.40
		Min, Max	3.8, 4.9	3.7, 4.9	3.7, 5.1	3.7, 4.9	3.7, 5.1
Chemistry: Albumin (g/dL)							
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	4.35 (0.260)	4.37 (0.356)	4.43 (0.266)	4.36 (0.306)	4.38 (0.295)
		Median	4.40	4.40	4.40	4.40	4.40
		Min, Max	3.9, 5.0	3.1, 5.0	3.9, 4.9	3.1, 5.0	3.1, 5.0
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-0.02 (0.226)	-0.02 (0.229)	-0.03 (0.215)	-0.02 (0.226)	-0.02 (0.222)
		Median	0.00	0.00	0.00	0.00	0.00
		Min, Max	-0.5, 0.6	-0.6, 0.4	-0.4, 0.4	-0.6, 0.6	-0.6, 0.6
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	4.37 (0.296)	4.45 (0.310)	4.50 (0.326)	4.41 (0.304)	4.44 (0.313)
		Median	4.40	4.50	4.50	4.45	4.50
		Min, Max	3.8, 5.0	3.5, 5.0	3.8, 5.2	3.5, 5.0	3.5, 5.2
Chemistry: Albumin (g/dL)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.02 (0.206)	0.08 (0.195)	0.05 (0.239)	0.03 (0.206)	0.03 (0.216)
		Median	0.00	0.10	0.10	0.00	0.00
		Min, Max	-0.4, 0.6	-0.5, 0.5	-0.5, 0.6	-0.5, 0.6	-0.5, 0.6
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	4.35 (0.302)	4.46 (0.311)	4.50 (0.323)	4.40 (0.310)	4.43 (0.316)
		Median	4.40	4.50	4.50	4.40	4.50
		Min, Max	3.7, 5.0	3.5, 5.0	3.8, 5.2	3.5, 5.0	3.5, 5.2

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.03 (0.199)	0.08 (0.193)	0.04 (0.239)	0.02 (0.202)	0.03 (0.213)
		Median	-0.10	0.10	0.10	0.00	0.00
		Min, Max	-0.4, 0.6	-0.5, 0.5	-0.5, 0.6	-0.5, 0.6	-0.5, 0.6
Chemistry: Cholesterol (mg/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	202.6 (32.60)	195.8 (34.99)	202.9 (38.99)	199.5 (33.70)	200.5 (35.29)
		Median	200.0	188.5	203.5	196.0	199.0
		Min, Max	130, 339	117, 303	123, 308	117, 339	117, 339
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	203.1 (33.05)	196.8 (32.17)	206.9 (43.37)	200.2 (32.61)	202.3 (36.24)
		Median	202.0	193.0	203.0	200.0	200.0
		Min, Max	156, 316	134, 264	121, 327	134, 316	121, 327
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-2.1 (19.80)	0.4 (20.59)	2.8 (29.08)	-0.9 (20.08)	0.2 (23.19)
		Median	-3.0	3.0	1.0	-1.0	0.0
		Min, Max	-48, 46	-39, 56	-67, 96	-48, 56	-67, 96
Chemistry: Cholesterol (mg/dL)							
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	198.1 (34.32)	196.3 (34.36)	201.8 (35.78)	197.2 (34.14)	198.7 (34.58)
		Median	194.0	192.0	197.0	192.5	194.5
		Min, Max	135, 341	112, 279	129, 267	112, 341	112, 341
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-7.6 (19.65)	-2.1 (22.55)	-1.7 (21.66)	-5.0 (21.13)	-4.0 (21.26)
		Median	-9.0	-2.0	-2.5	-5.5	-4.0
		Min, Max	-65, 39	-49, 71	-68, 54	-65, 71	-68, 71
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	194.7 (34.98)	194.5 (34.89)	202.0 (35.32)	194.6 (34.74)	196.8 (34.94)
		Median	191.0	192.0	198.0	191.5	193.0
		Min, Max	119, 341	112, 279	129, 267	112, 341	112, 341
Chemistry: Cholesterol (mg/dL)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-7.9 (18.59)	-1.8 (22.21)	-2.2 (21.55)	-5.1 (20.43)	-4.2 (20.74)
		Median	-9.0	-2.0	-4.0	-6.5	-5.0
		Min, Max	-65, 39	-49, 71	-68, 54	-65, 71	-68, 71
Chemistry: HDL Cholesterol (mg/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	57.1 (11.70)	60.5 (17.53)	58.7 (13.96)	58.7 (14.70)	58.7 (14.42)
		Median	56.0	57.0	55.0	57.0	56.0
		Min, Max	39, 90	35, 103	34, 87	35, 103	34, 103

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Week 26	Observed Value	n	47	40	39	87	126
		Mean (SD)	59.0 (12.73)	60.3 (17.17)	56.9 (12.01)	59.6 (14.86)	58.7 (14.05)
		Median	60.0	59.5	56.0	60.0	59.0
		Min, Max	34, 102	30, 101	33, 89	30, 102	30, 102
Chemistry: HDL Cholesterol (mg/dL)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	1.6 (5.65)	0.2 (7.49)	-1.9 (9.04)	1.0 (6.56)	0.1 (7.50)
		Median	1.0	0.0	-1.0	1.0	0.0
		Min, Max	-12, 13	-19, 16	-23, 18	-19, 16	-23, 18
Week 52	Observed Value	n	43	39	38	82	120
		Mean (SD)	55.8 (10.92)	60.2 (16.70)	55.7 (12.43)	57.9 (14.05)	57.2 (13.54)
		Median	55.0	57.0	52.0	56.0	55.0
		Min, Max	36, 85	34, 105	36, 82	34, 105	34, 105
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.6 (5.46)	-0.4 (7.60)	-2.4 (9.03)	-0.5 (6.52)	-1.1 (7.42)
		Median	0.0	0.0	-2.5	0.0	-1.0
		Min, Max	-12, 11	-15, 21	-18, 30	-15, 21	-18, 30
Chemistry: HDL Cholesterol (mg/dL)							
Week 52 / Early withdrawal	Observed Value	n	49	41	39	90	129
		Mean (SD)	56.3 (10.95)	60.5 (16.47)	55.9 (12.33)	58.2 (13.82)	57.5 (13.38)
		Median	55.0	57.0	52.0	56.0	55.0
		Min, Max	36, 85	34, 105	36, 82	34, 105	34, 105
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.8 (5.32)	0.0 (7.84)	-2.9 (9.51)	-0.4 (6.56)	-1.2 (7.62)
		Median	-1.0	0.0	-3.0	0.0	-1.0
		Min, Max	-12, 11	-15, 21	-23, 30	-15, 21	-23, 30
Chemistry: LDL Cholesterol (mg/dL)							
Screening	Observed Value	n	49	42	40	91	131
		Mean (SD)	116.6 (30.84)	109.2 (28.09)	118.4 (34.72)	113.2 (29.67)	114.8 (31.26)
		Median	113.0	105.5	109.5	110.0	110.0
		Min, Max	54, 235	60, 194	58, 204	54, 235	54, 235
Chemistry: LDL Cholesterol (mg/dL)							
Week 26	Observed Value	n	47	40	39	87	126
		Mean (SD)	117.6 (31.43)	108.4 (25.95)	123.0 (35.35)	113.4 (29.24)	116.4 (31.44)
		Median	113.0	106.5	122.0	110.0	113.0
		Min, Max	48, 218	65, 162	58, 232	48, 218	48, 232
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-0.7 (20.60)	-1.8 (18.17)	3.4 (20.48)	-1.2 (19.42)	0.2 (19.78)
		Median	-3.0	-1.5	1.0	-2.0	-1.0
		Min, Max	-50, 86	-47, 63	-44, 69	-50, 86	-50, 86

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	114.9 (31.48)	110.8 (29.23)	118.6 (32.60)	112.9 (30.31)	114.7 (31.03)
		Median	108.0	112.0	119.0	109.0	112.5
		Min, Max	54, 241	60, 181	61, 189	54, 241	54, 241
Chemistry: LDL Cholesterol (mg/dL)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-4.2 (16.48)	-0.8 (21.51)	-1.1 (16.68)	-2.6 (19.00)	-2.1 (18.24)
		Median	-4.0	-2.0	-2.0	-3.0	-3.0
		Min, Max	-45, 29	-43, 84	-36, 41	-45, 84	-45, 84
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	111.9 (31.64)	109.0 (29.63)	118.7 (32.17)	110.6 (30.60)	113.0 (31.18)
		Median	105.0	109.0	119.0	107.0	109.0
		Min, Max	47, 241	60, 181	61, 189	47, 241	47, 241
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-4.7 (15.59)	-0.8 (21.01)	-0.9 (16.49)	-2.9 (18.25)	-2.3 (17.70)
		Median	-5.0	-2.0	-1.0	-3.5	-3.0
		Min, Max	-45, 29	-43, 84	-36, 41	-45, 84	-45, 84
Chemistry: Triglycerides (mg/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	190.7 (106.72)	160.0 (121.70)	165.0 (122.57)	176.5 (114.27)	173.0 (116.51)
		Median	167.0	124.5	137.5	145.0	145.0
		Min, Max	54, 480	35, 665	33, 653	35, 665	33, 665
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	165.0 (67.50)	180.8 (273.26)	166.4 (106.27)	172.2 (190.69)	170.4 (168.69)
		Median	163.0	109.5	129.0	139.0	137.0
		Min, Max	30, 331	27, 1764	42, 546	27, 1764	27, 1764
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	-28.2 (79.32)	17.7 (244.55)	2.2 (110.91)	-7.1 (176.11)	-4.2 (158.42)
		Median	-15.0	-0.5	-3.0	-8.0	-6.0
		Min, Max	-238, 168	-461, 1391	-446, 264	-461, 1391	-461, 1391
Chemistry: Triglycerides (mg/dL)							
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	169.8 (73.98)	146.8 (83.99)	168.9 (88.03)	158.9 (79.25)	162.0 (81.89)
		Median	151.0	127.0	165.5	147.0	148.5
		Min, Max	54, 360	39, 376	56, 444	39, 376	39, 444
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-28.6 (84.31)	-17.5 (109.55)	2.8 (126.01)	-23.3 (96.68)	-15.0 (106.99)
		Median	-7.0	3.0	25.5	-4.0	4.5
		Min, Max	-291, 85	-486, 124	-378, 279	-486, 124	-486, 279

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Week 52 / Early withdrawal	Observed Value	n	49	41	39	90	129
		Mean (SD)	162.9 (72.36)	142.9 (83.71)	166.3 (88.38)	153.8 (77.93)	157.5 (81.09)
		Median	149.0	123.0	163.0	143.5	144.0
		Min, Max	54, 360	39, 376	56, 444	39, 376	39, 444
Chemistry: Triglycerides (mg/dL)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-27.8 (79.42)	-17.4 (107.07)	2.1 (124.41)	-23.0 (92.63)	-15.4 (103.42)
		Median	-12.0	3.0	25.0	-7.0	3.0
		Min, Max	-291, 85	-486, 124	-378, 279	-486, 124	-486, 279
Chemistry: Urea Nitrogen (mg/dL)							
Screening	Observed Value	n	49	42	40	91	131
		Mean (SD)	15.39 (4.584)	14.63 (4.125)	14.88 (3.670)	15.04 (4.371)	14.99 (4.156)
		Median	15.30	14.10	14.60	14.40	14.40
		Min, Max	6.8, 29.9	8.0, 26.0	7.7, 25.3	6.8, 29.9	6.8, 29.9
Week 26	Observed Value	n	47	40	39	87	126
		Mean (SD)	15.59 (3.642)	15.19 (3.769)	15.67 (3.954)	15.41 (3.685)	15.49 (3.756)
		Median	14.60	14.70	15.00	14.60	14.60
		Min, Max	9.2, 25.4	8.5, 24.7	9.5, 24.7	8.5, 25.4	8.5, 25.4
Chemistry: Urea Nitrogen (mg/dL)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.30 (3.633)	0.55 (3.144)	0.72 (3.180)	0.42 (3.400)	0.51 (3.324)
		Median	0.20	-0.20	0.60	0.00	0.15
		Min, Max	-7.9, 7.7	-5.6, 6.5	-4.0, 11.2	-7.9, 7.7	-7.9, 11.2
Week 52	Observed Value	n	43	39	38	82	120
		Mean (SD)	15.06 (3.428)	14.73 (3.892)	15.58 (4.111)	14.90 (3.637)	15.12 (3.789)
		Median	15.00	14.00	15.50	14.45	14.70
		Min, Max	9.5, 23.7	9.2, 25.4	8.0, 27.2	9.2, 25.4	8.0, 27.2
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.07 (3.014)	0.10 (3.743)	0.61 (3.401)	0.01 (3.360)	0.20 (3.370)
		Median	-0.20	-0.20	0.10	-0.20	-0.15
		Min, Max	-8.8, 5.6	-6.0, 9.2	-6.2, 9.0	-8.8, 9.2	-8.8, 9.2
Chemistry: Urea Nitrogen (mg/dL)							
Week 52 / Early withdrawal	Observed Value	n	49	41	39	90	129
		Mean (SD)	15.45 (3.652)	14.74 (3.821)	15.64 (4.071)	15.13 (3.725)	15.28 (3.824)
		Median	15.40	14.00	15.50	14.70	15.00
		Min, Max	9.5, 24.7	9.2, 25.4	8.0, 27.2	9.2, 25.4	8.0, 27.2
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.06 (3.073)	0.08 (3.683)	0.69 (3.395)	0.07 (3.345)	0.26 (3.359)
		Median	0.00	-0.20	0.10	-0.10	0.00

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
		Min, Max	-8.8, 5.6	-6.0, 9.2	-6.2, 9.0	-8.8, 9.2	-8.8, 9.2
Chemistry: Creatinine (mg/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	0.736 (0.1573)	0.702 (0.1819)	0.806 (0.2261)	0.720 (0.1690)	0.746 (0.1915)
		Median	0.760	0.650	0.775	0.670	0.750
		Min, Max	0.44, 1.20	0.45, 1.27	0.48, 1.65	0.44, 1.27	0.44, 1.65
Chemistry: Creatinine (mg/dL)							
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	0.737 (0.1646)	0.715 (0.1855)	0.791 (0.2377)	0.727 (0.1738)	0.747 (0.1971)
		Median	0.760	0.655	0.750	0.700	0.725
		Min, Max	0.41, 1.17	0.50, 1.31	0.48, 1.70	0.41, 1.31	0.41, 1.70
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.007 (0.0620)	0.008 (0.0708)	-0.017 (0.0695)	0.007 (0.0658)	-0.000 (0.0677)
		Median	0.000	0.000	-0.030	0.000	-0.010
		Min, Max	-0.14, 0.16	-0.15, 0.21	-0.15, 0.13	-0.15, 0.21	-0.15, 0.21
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	0.753 (0.1619)	0.732 (0.1931)	0.797 (0.2236)	0.743 (0.1766)	0.760 (0.1934)
		Median	0.780	0.710	0.775	0.725	0.730
		Min, Max	0.41, 1.25	0.48, 1.28	0.47, 1.59	0.41, 1.28	0.41, 1.59
Chemistry: Creatinine (mg/dL)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	0.015 (0.0506)	0.028 (0.0878)	-0.013 (0.0927)	0.021 (0.0706)	0.010 (0.0795)
		Median	0.020	0.020	-0.015	0.020	0.005
		Min, Max	-0.10, 0.10	-0.18, 0.31	-0.25, 0.26	-0.18, 0.31	-0.25, 0.31
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	0.752 (0.1826)	0.730 (0.1926)	0.799 (0.2211)	0.742 (0.1865)	0.759 (0.1984)
		Median	0.750	0.710	0.790	0.720	0.730
		Min, Max	0.41, 1.35	0.48, 1.28	0.47, 1.59	0.41, 1.35	0.41, 1.59
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.016 (0.0625)	0.027 (0.0858)	-0.010 (0.0936)	0.021 (0.0738)	0.012 (0.0812)
		Median	0.010	0.020	-0.010	0.015	0.010
		Min, Max	-0.10, 0.27	-0.18, 0.31	-0.25, 0.26	-0.18, 0.31	-0.25, 0.31
Chemistry: Urate (mg/dL)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	5.36 (1.248)	5.32 (1.366)	6.08 (1.525)	5.34 (1.297)	5.57 (1.407)
		Median	5.20	5.40	6.00	5.30	5.50
		Min, Max	2.9, 8.2	1.0, 7.9	3.2, 11.0	1.0, 8.2	1.0, 11.0
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	5.52 (1.285)	5.62 (1.428)	5.98 (1.293)	5.57 (1.345)	5.70 (1.338)
		Median	5.30	5.55	5.90	5.40	5.60
		Min, Max	3.2, 9.6	0.9, 8.3	3.3, 8.3	0.9, 9.6	0.9, 9.6

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.11 (0.788)	0.27 (0.618)	-0.11 (0.841)	0.18 (0.715)	0.09 (0.765)
		Median	0.10	0.30	0.00	0.20	0.10
		Min, Max	-1.6, 2.4	-1.4, 1.3	-3.7, 1.2	-1.6, 2.4	-3.7, 2.4
Chemistry: Urate (mg/dL)							
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	5.41 (1.285)	5.64 (1.569)	5.99 (1.436)	5.52 (1.423)	5.67 (1.438)
		Median	5.20	5.80	5.90	5.45	5.55
		Min, Max	3.0, 8.1	1.0, 9.0	3.1, 9.3	1.0, 9.0	1.0, 9.3
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.01 (0.752)	0.27 (0.687)	-0.13 (0.980)	0.12 (0.732)	0.04 (0.823)
		Median	0.10	0.40	-0.05	0.30	0.20
		Min, Max	-2.6, 1.2	-1.7, 1.5	-4.4, 2.0	-2.6, 1.5	-4.4, 2.0
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	5.34 (1.258)	5.59 (1.563)	5.98 (1.417)	5.45 (1.402)	5.61 (1.423)
		Median	5.20	5.80	5.90	5.35	5.50
		Min, Max	3.0, 8.1	1.0, 9.0	3.1, 9.3	1.0, 9.0	1.0, 9.3
Chemistry: Urate (mg/dL)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.02 (0.773)	0.28 (0.670)	-0.10 (0.984)	0.12 (0.738)	0.05 (0.823)
		Median	0.10	0.40	0.00	0.25	0.20
		Min, Max	-2.6, 1.2	-1.7, 1.5	-4.4, 2.0	-2.6, 1.5	-4.4, 2.0
Chemistry: Sodium (mEq/L)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	142.3 (1.70)	142.3 (1.75)	142.5 (1.69)	142.3 (1.71)	142.3 (1.70)
		Median	142.0	142.0	142.5	142.0	142.0
		Min, Max	137, 145	139, 146	139, 148	137, 146	137, 148
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	142.4 (1.68)	141.8 (1.68)	142.1 (1.52)	142.2 (1.70)	142.1 (1.64)
		Median	142.0	142.0	142.0	142.0	142.0
		Min, Max	139, 146	139, 145	139, 145	139, 146	139, 146
Chemistry: Sodium (mEq/L)							
Week 26	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.2 (1.75)	-0.4 (1.57)	-0.5 (1.90)	-0.1 (1.69)	-0.2 (1.76)
		Median	0.0	-0.5	-1.0	0.0	0.0
		Min, Max	-3, 5	-4, 3	-5, 5	-4, 5	-5, 5
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	142.6 (1.59)	142.4 (2.11)	143.0 (1.62)	142.5 (1.85)	142.7 (1.78)
		Median	143.0	142.0	143.0	143.0	143.0
		Min, Max	139, 145	138, 146	140, 146	138, 146	138, 146

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	0.3 (1.39)	0.2 (1.86)	0.4 (1.59)	0.2 (1.62)	0.3 (1.61)
		Median	0.0	1.0	0.5	0.5	0.5
		Min, Max	-3, 4	-4, 4	-3, 3	-4, 4	-4, 4
Chemistry: Sodium (mEq/L)							
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	142.6 (1.67)	142.5 (2.07)	142.9 (1.63)	142.5 (1.86)	142.7 (1.79)
		Median	143.0	143.0	143.0	143.0	143.0
		Min, Max	139, 146	138, 146	140, 146	138, 146	138, 146
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	0.3 (1.47)	0.2 (1.82)	0.4 (1.57)	0.2 (1.63)	0.3 (1.61)
		Median	0.0	1.0	0.0	1.0	1.0
		Min, Max	-4, 4	-4, 4	-3, 3	-4, 4	-4, 4
Chemistry: Potassium (mEq/L)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	4.30 (0.382)	4.30 (0.370)	4.37 (0.443)	4.30 (0.374)	4.32 (0.396)
		Median	4.30	4.25	4.30	4.30	4.30
		Min, Max	3.0, 5.2	3.7, 5.5	3.6, 5.5	3.0, 5.5	3.0, 5.5
Chemistry: Potassium (mEq/L)							
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	4.33 (0.447)	4.33 (0.400)	4.31 (0.375)	4.33 (0.424)	4.32 (0.408)
		Median	4.40	4.30	4.30	4.30	4.30
		Min, Max	3.2, 6.0	3.6, 5.6	3.7, 5.6	3.2, 6.0	3.2, 6.0
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.04 (0.397)	0.03 (0.359)	-0.05 (0.384)	0.03 (0.377)	0.01 (0.380)
		Median	0.10	0.00	-0.10	0.10	0.00
		Min, Max	-0.8, 1.0	-0.8, 0.8	-0.7, 1.3	-0.8, 1.0	-0.8, 1.3
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	4.19 (0.319)	4.38 (0.527)	4.38 (0.340)	4.28 (0.439)	4.31 (0.411)
		Median	4.20	4.30	4.40	4.30	4.30
		Min, Max	3.3, 5.2	3.6, 6.2	3.5, 5.1	3.3, 6.2	3.3, 6.2
Chemistry: Potassium (mEq/L)							
Week 52	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.09 (0.330)	0.08 (0.331)	0.02 (0.420)	-0.01 (0.340)	0.00 (0.365)
		Median	-0.10	0.10	0.05	-0.10	-0.05
		Min, Max	-0.9, 0.4	-0.5, 0.9	-1.0, 0.7	-0.9, 0.9	-1.0, 0.9
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	4.21 (0.323)	4.39 (0.519)	4.38 (0.335)	4.29 (0.430)	4.32 (0.405)
		Median	4.30	4.30	4.40	4.30	4.30

Confidential

Parameter Analysis Visit	Measurement	Statistics	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
		Min, Max	3.3, 5.2	3.6, 6.2	3.5, 5.1	3.3, 6.2	3.3, 6.2
	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.09 (0.357)	0.09 (0.327)	0.02 (0.414)	-0.01 (0.354)	0.00 (0.372)
		Median	-0.10	0.10	0.10	-0.05	0.00
		Min, Max	-0.9, 0.6	-0.5, 0.9	-1.0, 0.7	-0.9, 0.9	-1.0, 0.9
Chemistry: Chloride (mEq/L)							
Screening	Observed Valuen		49	42	40	91	131
		Mean (SD)	105.5 (2.06)	105.5 (1.80)	105.2 (2.18)	105.5 (1.93)	105.4 (2.01)
		Median	105.0	105.0	105.0	105.0	105.0
		Min, Max	102, 110	102, 110	101, 113	102, 110	101, 113
Week 26	Observed Valuen		47	40	39	87	126
		Mean (SD)	105.4 (2.16)	105.7 (2.30)	105.4 (2.04)	105.5 (2.22)	105.5 (2.16)
		Median	105.0	106.0	105.0	106.0	105.0
		Min, Max	101, 110	98, 110	101, 112	98, 110	98, 112
	Change from Baseline	n	47	40	39	87	126
		Mean (SD)	0.0 (1.85)	0.2 (2.27)	0.2 (1.91)	0.1 (2.04)	0.1 (2.00)
		Median	0.0	0.0	0.0	0.0	0.0
		Min, Max	-4, 4	-7, 5	-4, 4	-7, 5	-7, 5
Chemistry: Chloride (mEq/L)							
Week 52	Observed Valuen		43	39	38	82	120
		Mean (SD)	104.9 (1.80)	104.9 (2.31)	105.3 (2.36)	104.9 (2.05)	105.0 (2.15)
		Median	105.0	105.0	105.0	105.0	105.0
		Min, Max	99, 110	100, 110	100, 113	99, 110	99, 113
	Change from Baseline	n	43	39	38	82	120
		Mean (SD)	-0.4 (1.48)	-0.6 (1.94)	0.1 (1.87)	-0.5 (1.71)	-0.3 (1.78)
		Median	0.0	0.0	0.0	0.0	0.0
		Min, Max	-3, 3	-6, 3	-4, 5	-6, 3	-6, 5
Week 52 / Early withdrawal	Observed Valuen		49	41	39	90	129
		Mean (SD)	105.1 (1.99)	104.9 (2.26)	105.3 (2.33)	105.0 (2.11)	105.1 (2.17)
		Median	105.0	105.0	105.0	105.0	105.0
		Min, Max	99, 110	100, 110	100, 113	99, 110	99, 113
Chemistry: Chloride (mEq/L)							
Week 52 / Early withdrawal	Change from Baseline	n	49	41	39	90	129
		Mean (SD)	-0.3 (1.43)	-0.7 (1.91)	0.1 (1.87)	-0.5 (1.66)	-0.3 (1.74)
		Median	0.0	0.0	0.0	0.0	0.0
		Min, Max	-3, 3	-6, 3	-4, 5	-6, 3	-6, 5

Subjects are classified by actual treatment received.

Screening visit is the baseline.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.7.1

表 2.7.4.7-10. 101260006LT: 臨床検査値の推移（尿検査）

Parameter	Analysis Visit	Score	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
Urinalysis: Glucose	Screening	n	49	42	40	91	131
		(-)	35 (71.4%)	35 (83.3%)	33 (82.5%)	70 (76.9%)	103 (78.6%)
		(+-)	1 (2.0%)	0 (0.0%)	1 (2.5%)	1 (1.1%)	2 (1.5%)
		(+)	0 (0.0%)	1 (2.4%)	3 (7.5%)	1 (1.1%)	4 (3.1%)
		(2+)	2 (4.1%)	1 (2.4%)	1 (2.5%)	3 (3.3%)	4 (3.1%)
		(3+)	0 (0.0%)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (0.8%)
		(4+)	11 (22.4%)	5 (11.9%)	1 (2.5%)	16 (17.6%)	17 (13.0%)
	Week 26	n	47	40	39	87	126
		(-)	35 (74.5%)	35 (87.5%)	29 (74.4%)	70 (80.5%)	99 (78.6%)
		(+-)	0 (0.0%)	0 (0.0%)	3 (7.7%)	0 (0.0%)	3 (2.4%)
		(+)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	1 (0.8%)
		(2+)	1 (2.1%)	1 (2.5%)	2 (5.1%)	2 (2.3%)	4 (3.2%)
		(3+)	5 (10.6%)	2 (5.0%)	1 (2.6%)	7 (8.0%)	8 (6.3%)
		(4+)	6 (12.8%)	2 (5.0%)	3 (7.7%)	8 (9.2%)	11 (8.7%)
Urinalysis: Glucose	Week 52	n	43	39	38	82	120
		(-)	32 (74.4%)	34 (87.2%)	26 (68.4%)	66 (80.5%)	92 (76.7%)
		(+-)	1 (2.3%)	0 (0.0%)	2 (5.3%)	1 (1.2%)	3 (2.5%)
		(+)	0 (0.0%)	1 (2.6%)	1 (2.6%)	1 (1.2%)	2 (1.7%)
		(2+)	0 (0.0%)	1 (2.6%)	3 (7.9%)	1 (1.2%)	4 (3.3%)
		(3+)	2 (4.7%)	2 (5.1%)	2 (5.3%)	4 (4.9%)	6 (5.0%)
		(4+)	8 (18.6%)	1 (2.6%)	4 (10.5%)	9 (11.0%)	13 (10.8%)
	Week 52 / Early withdrawal	n	49	41	39	90	129
		(-)	35 (71.4%)	35 (85.4%)	27 (69.2%)	70 (77.8%)	97 (75.2%)
		(+-)	1 (2.0%)	0 (0.0%)	2 (5.1%)	1 (1.1%)	3 (2.3%)
		(+)	0 (0.0%)	1 (2.4%)	1 (2.6%)	1 (1.1%)	2 (1.6%)
		(2+)	0 (0.0%)	1 (2.4%)	3 (7.7%)	1 (1.1%)	4 (3.1%)
		(3+)	2 (4.1%)	2 (4.9%)	2 (5.1%)	4 (4.4%)	6 (4.7%)
		(4+)	11 (22.4%)	2 (4.9%)	4 (10.3%)	13 (14.4%)	17 (13.2%)
Urinalysis: Protein	Screening	n	49	42	40	91	131
		(-)	46 (93.9%)	39 (92.9%)	34 (85.0%)	85 (93.4%)	119 (90.8%)
		(+-)	1 (2.0%)	0 (0.0%)	4 (10.0%)	1 (1.1%)	5 (3.8%)
		(+)	2 (4.1%)	1 (2.4%)	0 (0.0%)	3 (3.3%)	3 (2.3%)
		(2+)	0 (0.0%)	2 (4.8%)	2 (5.0%)	2 (2.2%)	4 (3.1%)
		(3+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(4+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Week 26	n	47	40	39	87	126
		(-)	41 (87.2%)	36 (90.0%)	30 (76.9%)	77 (88.5%)	107 (84.9%)
		(+-)	3 (6.4%)	2 (5.0%)	4 (10.3%)	5 (5.7%)	9 (7.1%)
		(+)	3 (6.4%)	0 (0.0%)	4 (10.3%)	3 (3.4%)	7 (5.6%)
		(2+)	0 (0.0%)	1 (2.5%)	1 (2.6%)	1 (1.1%)	2 (1.6%)
		(3+)	0 (0.0%)	1 (2.5%)	0 (0.0%)	1 (1.1%)	1 (0.8%)

Parameter	Analysis Visit	Score	0.002% STN1012600 (Group 1) (N=49)	0.002% STN1012600 (Group 2) (N=42)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=40)	Mono-therapy (Group 1 + Group 2) (N=91)	Overall (N=131)
		(4+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Urinalysis: Protein	Week 52	n	43	39	38	82	120
		(-)	41 (95.3%)	34 (87.2%)	32 (84.2%)	75 (91.5%)	107 (89.2%)
		(+-)	2 (4.7%)	3 (7.7%)	4 (10.5%)	5 (6.1%)	9 (7.5%)
		(+)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	1 (0.8%)
		(2+)	0 (0.0%)	2 (5.1%)	1 (2.6%)	2 (2.4%)	3 (2.5%)
		(3+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(4+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Week 52 / Early withdrawal	n	49	41	39	90	129
		(-)	45 (91.8%)	36 (87.8%)	33 (84.6%)	81 (90.0%)	114 (88.4%)
		(+-)	4 (8.2%)	3 (7.3%)	4 (10.3%)	7 (7.8%)	11 (8.5%)
		(+)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	1 (0.8%)
		(2+)	0 (0.0%)	2 (4.9%)	1 (2.6%)	2 (2.2%)	3 (2.3%)
		(3+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(4+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Urinalysis: Urobilinogen	Screening	n	49	42	40	91	131
		(-)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(+-)	48 (98.0%)	42 (100.0%)	40 (100.0%)	90 (98.9%)	130 (99.2%)
		(+)	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
		(2+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(3+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(4+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Week 26	n	47	40	39	87	126
		(-)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(+-)	47 (100.0%)	40 (100.0%)	38 (97.4%)	87 (100.0%)	125 (99.2%)
		(+)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	1 (0.8%)
		(2+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(3+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(4+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Urinalysis: Urobilinogen	Week 52	n	43	39	38	82	120
		(-)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(+-)	43 (100.0%)	39 (100.0%)	37 (97.4%)	82 (100.0%)	119 (99.2%)
		(+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(2+)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	1 (0.8%)
		(3+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(4+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Week 52 / Early withdrawal	n	49	41	39	90	129
		(-)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(+-)	48 (98.0%)	41 (100.0%)	38 (97.4%)	89 (98.9%)	127 (98.4%)
		(+)	1 (2.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (0.8%)
		(2+)	0 (0.0%)	0 (0.0%)	1 (2.6%)	0 (0.0%)	1 (0.8%)
		(3+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		(4+)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Denominator is n for each visit.

Confidential

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.7.2

表 2.7.4.7-11. 併合解析: 男女別の有害事象一覧（男性）

System organ class Preferred term	Placebo to 0.003% P2* (N=5)	0.005% Latanoprost (N=73)	0.0005% STN1012600 (N=9)	0.001% STN1012600 (N=10)	0.002% STN1012600 (N=74)	0.003% STN1012600 (N=9)	STN1012600 Total** (N=107)
Subjects with any AE(s)	1 (20.0%)	27 (37.0%)	4 (44.4%)	3 (30.0%)	32 (43.2%)	6 (66.7%)	46 (43.0%)
Eye disorders	1 (20.0%)	25 (34.2%)	2 (22.2%)	3 (30.0%)	29 (39.2%)	4 (44.4%)	39 (36.4%)
Conjunctival hyperaemia	0 (0.0%)	13 (17.8%)	1 (11.1%)	0 (0.0%)	23 (31.1%)	1 (11.1%)	25 (23.4%)
Eye pruritus	0 (0.0%)	2 (2.7%)	0 (0.0%)	1 (10.0%)	2 (2.7%)	0 (0.0%)	3 (2.8%)
Punctate keratitis	0 (0.0%)	5 (6.8%)	0 (0.0%)	2 (20.0%)	1 (1.4%)	0 (0.0%)	3 (2.8%)
Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	2 (1.9%)
Eye irritation	0 (0.0%)	2 (2.7%)	0 (0.0%)	1 (10.0%)	1 (1.4%)	0 (0.0%)	2 (1.9%)
Foreign body sensation in eyes	0 (0.0%)	2 (2.7%)	1 (11.1%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	2 (1.9%)
Growth of eyelashes	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	2 (1.9%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Blepharitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Corneal hypertrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (0.9%)
Dry eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Eyelid oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (0.9%)
Eyelids pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Keratitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (0.9%)
Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
Vitreous opacities	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Blepharitis allergic	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctival telangiectasia	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pain	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid vellus hair changes	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Lacrimation increased	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Infections and infestations	0 (0.0%)	4 (5.5%)	2 (22.2%)	1 (10.0%)	4 (5.4%)	2 (22.2%)	9 (8.4%)
Nasopharyngitis	0 (0.0%)	1 (1.4%)	2 (22.2%)	1 (10.0%)	3 (4.1%)	1 (11.1%)	7 (6.5%)
COVID-19	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Cystitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (0.9%)
Corneal infection	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hordeolum	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Rhinitis	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Investigations	1 (20.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	3 (2.8%)
Blood potassium increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Blood triglycerides increased	0 (0.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)

Confidential

System organ class Preferred term	Placebo to 0.003% P2* (N=5)	0.005% Latanoprost (N=73)	0.0005% STN1012600 (N=9)	0.001% STN1012600 (N=10)	0.002% STN1012600 (N=74)	0.003% STN1012600 (N=9)	STN1012600 Total** (N=107)
Hepatic enzyme increased	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
Ear and labyrinth disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Vertigo	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Gastrointestinal disorders	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Nausea	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Pancreatitis	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Injury, poisoning and procedural complications	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (0.9%)
Radius fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (0.9%)
Musculoskeletal and connective tissue disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Back pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Nervous system disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Headache	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Renal and urinary disorders	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
Hypertonic bladder	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
General disorders and administration site conditions	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Malaise	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pyrexia	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Confidential

表 2.7.4.7-12. 併合解析: 男女別の有害事象一覧（女性）

System organ class Preferred term	Placebo to 0.003% P2* (N=6)	0.005% Latanoprost (N=111)	0.0005% STN1012600 (N=11)	0.001% STN1012600 (N=10)	0.002% STN1012600 (N=109)	0.003% STN1012600 (N=12)	STN1012600 Total** (N=148)
Subjects with any AE(s)	2 (33.3%)	50 (45.0%)	6 (54.5%)	5 (50.0%)	60 (55.0%)	9 (75.0%)	82 (55.4%)
Eye disorders	2 (33.3%)	33 (29.7%)	5 (45.5%)	4 (40.0%)	44 (40.4%)	7 (58.3%)	62 (41.9%)
Conjunctival hyperaemia	1 (16.7%)	12 (10.8%)	2 (18.2%)	2 (20.0%)	33 (30.3%)	3 (25.0%)	41 (27.7%)
Eye pruritus	0 (0.0%)	2 (1.8%)	1 (9.1%)	0 (0.0%)	2 (1.8%)	3 (25.0%)	6 (4.1%)
Punctate keratitis	0 (0.0%)	7 (6.3%)	1 (9.1%)	0 (0.0%)	4 (3.7%)	1 (8.3%)	6 (4.1%)
Dry eye	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	3 (2.8%)	1 (8.3%)	4 (2.7%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (3.7%)	0 (0.0%)	4 (2.7%)
Abnormal sensation in eye	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	2 (1.4%)
Conjunctival oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	2 (1.4%)
Conjunctivitis allergic	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (8.3%)	2 (1.4%)
Eye discharge	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	2 (1.4%)
Eye irritation	0 (0.0%)	6 (5.4%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	2 (1.4%)
Foreign body sensation in eyes	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (8.3%)	2 (1.4%)
Growth of eyelashes	0 (0.0%)	0 (0.0%)	1 (9.1%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	2 (1.4%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Cataract	1 (16.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.7%)
Chalazion	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.7%)
Conjunctival cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Conjunctival haemorrhage	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	1 (0.7%)
Keratitis	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Posterior capsule opacification	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Scintillating scotoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Vitreous detachment	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Vitreous floaters	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Asthenopia	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blepharitis	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blepharospasm	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pain	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Infections and infestations	0 (0.0%)	10 (9.0%)	1 (9.1%)	1 (10.0%)	8 (7.3%)	0 (0.0%)	10 (6.8%)
COVID-19	0 (0.0%)	5 (4.5%)	0 (0.0%)	0 (0.0%)	4 (3.7%)	0 (0.0%)	4 (2.7%)
Nasopharyngitis	0 (0.0%)	1 (0.9%)	1 (9.1%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	3 (2.0%)
Bronchitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Influenza	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	1 (0.7%)
Conjunctivitis bacterial	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

System organ class Preferred term	Placebo to 0.003% P2* (N=6)	0.005% Latanoprost (N=111)	0.0005% STN1012600 (N=11)	0.001% STN1012600 (N=10)	0.002% STN1012600 (N=109)	0.003% STN1012600 (N=12)	STN1012600 Total** (N=148)
Coronavirus infection	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Groin abscess	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hordeolum	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Post-acute COVID-19 syndrome	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Nervous system disorders	0 (0.0%)	3 (2.7%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	2 (16.7%)	4 (2.7%)
Headache	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	2 (1.4%)
Cervicobrachial syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Parkinson's disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Dizziness	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin and subcutaneous tissue disorders	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	3 (2.8%)	1 (8.3%)	4 (2.7%)
Eczema	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Hypertrichosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Urticaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Rash	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
General disorders and administration site conditions	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	3 (2.8%)	0 (0.0%)	3 (2.0%)
Peripheral swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Pyrexia	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Vaccination site pain	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Musculoskeletal and connective tissue disorders	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	3 (2.8%)	0 (0.0%)	3 (2.0%)
Back pain	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Pain in extremity	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Spinal stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Arthralgia	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Gastrointestinal disorders	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Abdominal pain upper	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Nausea	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Injury, poisoning and procedural complications	0 (0.0%)	5 (4.5%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Tooth fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Contusion	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Epicondylitis	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Fall	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

System organ class Preferred term	Placebo to 0.003% P2* (N=6)	0.005% Latanoprost (N=111)	0.0005% STN1012600 (N=11)	0.001% STN1012600 (N=10)	0.002% STN1012600 (N=109)	0.003% STN1012600 (N=12)	STN1012600 Total** (N=148)
Ligament sprain	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Spinal compression fracture	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Investigations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Eosinophil count increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Metabolism and nutrition disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Decreased appetite	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Respiratory, thoracic and mediastinal disorders	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Oropharyngeal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Cough	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Vascular disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Hypotension	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Ear and labyrinth disorders	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sudden hearing loss	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Breast cancer	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Product issues	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Device physical property issue	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Renal and urinary disorders	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pollakiuria	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

表 2.7.4.7-13. 併合解析: 男女別の副作用一覧（男性）

System organ class Preferred term	Placebo to 0.003% P2* (N=5)	0.005% Latanoprost (N=73)	0.0005% STN1012600 (N=9)	0.001% STN1012600 (N=10)	0.002% STN1012600 (N=74)	0.003% STN1012600 (N=9)	STN1012600 Total** (N=107)
Subjects with any ADR(s)	1 (20.0%)	19 (26.0%)	1 (11.1%)	2 (20.0%)	24 (32.4%)	0 (0.0%)	28 (26.2%)
Eye disorders	1 (20.0%)	19 (26.0%)	1 (11.1%)	2 (20.0%)	24 (32.4%)	0 (0.0%)	28 (26.2%)
Conjunctival hyperaemia	0 (0.0%)	11 (15.1%)	1 (11.1%)	0 (0.0%)	21 (28.4%)	0 (0.0%)	22 (20.6%)
Eye irritation	0 (0.0%)	2 (2.7%)	0 (0.0%)	1 (10.0%)	1 (1.4%)	0 (0.0%)	2 (1.9%)
Eye pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (10.0%)	1 (1.4%)	0 (0.0%)	2 (1.9%)
Growth of eyelashes	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	2 (1.9%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Dry eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Foreign body sensation in eyes	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (0.9%)
Punctate keratitis	0 (0.0%)	3 (4.1%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
Conjunctival telangiectasia	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pain	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid vellus hair changes	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Lacrimation increased	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Infections and infestations	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Corneal infection	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Confidential

表 2.7.4.7-14. 併合解析: 男女別の副作用一覧（女性）

System organ class Preferred term	Placebo to 0.003% P2* (N=6)	0.005% Latanoprost (N=111)	0.0005% STN1012600 (N=11)	0.001% STN1012600 (N=10)	0.002% STN1012600 (N=109)	0.003% STN1012600 (N=12)	STN1012600 Total** (N=148)
Subjects with any ADR(s)	1 (16.7%)	19 (17.1%)	4 (36.4%)	3 (30.0%)	39 (35.8%)	6 (50.0%)	53 (35.8%)
Eye disorders	1 (16.7%)	19 (17.1%)	4 (36.4%)	3 (30.0%)	38 (34.9%)	5 (41.7%)	51 (34.5%)
Conjunctival hyperaemia	1 (16.7%)	6 (5.4%)	2 (18.2%)	2 (20.0%)	31 (28.4%)	3 (25.0%)	39 (26.4%)
Eye pruritus	0 (0.0%)	1 (0.9%)	1 (9.1%)	0 (0.0%)	2 (1.8%)	3 (25.0%)	6 (4.1%)
Dry eye	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	3 (2.8%)	1 (8.3%)	4 (2.7%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (3.7%)	0 (0.0%)	4 (2.7%)
Punctate keratitis	0 (0.0%)	4 (3.6%)	1 (9.1%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	3 (2.0%)
Abnormal sensation in eye	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	2 (1.4%)
Conjunctival oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	2 (1.4%)
Eye irritation	0 (0.0%)	6 (5.4%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	0 (0.0%)	2 (1.4%)
Growth of eyelashes	0 (0.0%)	0 (0.0%)	1 (9.1%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	2 (1.4%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Conjunctival cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Conjunctivitis allergic	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Foreign body sensation in eyes	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Blepharitis	0 (0.0%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Keratitis	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Infections and infestations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.7%)
Skin and subcutaneous tissue disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)
Hypertrichosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (0.7%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

表 2.7.4.7-15. 101260006LT: 男女別の有害事象一覧（男性）

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=26)	0.002% STN1012600 (Group 2) (N=21)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=23)	Mono-therapy (Group 1 + Group 2) (N=47)	Overall (N=70)
Subjects with any AE(s)	25 (96.2%)	14 (66.7%)	22 (95.7%)	39 (83.0%)	61 (87.1%)
Eye disorders	20 (76.9%)	12 (57.1%)	15 (65.2%)	32 (68.1%)	47 (67.1%)
Conjunctival hyperaemia	10 (38.5%)	5 (23.8%)	8 (34.8%)	15 (31.9%)	23 (32.9%)
Growth of eyelashes	7 (26.9%)	8 (38.1%)	7 (30.4%)	15 (31.9%)	22 (31.4%)
Eyelash changes	7 (26.9%)	2 (9.5%)	3 (13.0%)	9 (19.1%)	12 (17.1%)
Eyelash thickening	5 (19.2%)	2 (9.5%)	1 (4.3%)	7 (14.9%)	8 (11.4%)
Eyelid vellus hair changes	4 (15.4%)	3 (14.3%)	1 (4.3%)	7 (14.9%)	8 (11.4%)
Blepharal pigmentation	3 (11.5%)	0 (0.0%)	2 (8.7%)	3 (6.4%)	5 (7.1%)
Conjunctivitis allergic	1 (3.8%)	1 (4.8%)	1 (4.3%)	2 (4.3%)	3 (4.3%)
Eyelash hyperpigmentation	1 (3.8%)	1 (4.8%)	1 (4.3%)	2 (4.3%)	3 (4.3%)
Conjunctival haemorrhage	1 (3.8%)	0 (0.0%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Conjunctival irritation	1 (3.8%)	0 (0.0%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Punctate keratitis	1 (3.8%)	0 (0.0%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Cataract	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Conjunctival deposit	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Corneal erosion	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Eye irritation	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Eye pruritus	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Eyelid oedema	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Iris hyperpigmentation	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Keratitis	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Meibomian gland dysfunction	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Pingueculitis	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Trichomegaly	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Infections and infestations	9 (34.6%)	3 (14.3%)	7 (30.4%)	12 (25.5%)	19 (27.1%)
Nasopharyngitis	5 (19.2%)	0 (0.0%)	0 (0.0%)	5 (10.6%)	5 (7.1%)
Coronavirus infection	2 (7.7%)	0 (0.0%)	1 (4.3%)	2 (4.3%)	3 (4.3%)
Gastroenteritis	0 (0.0%)	0 (0.0%)	2 (8.7%)	0 (0.0%)	2 (2.9%)
COVID-19	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Cellulitis	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Conjunctivitis	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Furuncle	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Gingivitis	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Herpes zoster	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Influenza	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Laryngopharyngitis	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Paronychia	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Periodontitis	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Pharyngitis	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Wound infection bacterial	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Gastrointestinal disorders	5 (19.2%)	1 (4.8%)	1 (4.3%)	6 (12.8%)	7 (10.0%)
Abdominal discomfort	2 (7.7%)	1 (4.8%)	0 (0.0%)	3 (6.4%)	3 (4.3%)
Large intestine polyp	1 (3.8%)	0 (0.0%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Anal pruritus	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Diarrhoea	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Nausea	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Skin and subcutaneous tissue disorders	1 (3.8%)	2 (9.5%)	3 (13.0%)	3 (6.4%)	6 (8.6%)
Eczema	0 (0.0%)	0 (0.0%)	2 (8.7%)	0 (0.0%)	2 (2.9%)
Hypertrichosis	1 (3.8%)	1 (4.8%)	0 (0.0%)	2 (4.3%)	2 (2.9%)

Confidential

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=26)	0.002% STN1012600 (Group 2) (N=21)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=23)	Mono-therapy (Group 1 + Group 2) (N=47)	Overall (N=70)
Acne	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Cold urticaria	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Respiratory, thoracic and mediastinal disorders	4 (15.4%)	1 (4.8%)	0 (0.0%)	5 (10.6%)	5 (7.1%)
Oropharyngeal pain	1 (3.8%)	1 (4.8%)	0 (0.0%)	2 (4.3%)	2 (2.9%)
Cough	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Epistaxis	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Rhinitis allergic	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Investigations	2 (7.7%)	1 (4.8%)	1 (4.3%)	3 (6.4%)	4 (5.7%)
Blood triglycerides increased	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Blood uric acid increased	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Gamma-glutamyltransferase increased	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Glucose urine present	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Intraocular pressure increased	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Musculoskeletal and connective tissue disorders	2 (7.7%)	1 (4.8%)	1 (4.3%)	3 (6.4%)	4 (5.7%)
Arthralgia	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Back pain	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Lumbar spinal stenosis	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Spondylolisthesis	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
General disorders and administration site conditions	2 (7.7%)	0 (0.0%)	0 (0.0%)	2 (4.3%)	2 (2.9%)
Injection site pain	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Pyrexia	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Hepatobiliary disorders	0 (0.0%)	1 (4.8%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Hepatic function abnormal	0 (0.0%)	1 (4.8%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Immune system disorders	1 (3.8%)	0 (0.0%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Seasonal allergy	1 (3.8%)	0 (0.0%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Vascular disorders	1 (3.8%)	1 (4.8%)	0 (0.0%)	2 (4.3%)	2 (2.9%)
Aneurysm	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Hypertension	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Cardiac disorders	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Angina unstable	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Injury, poisoning and procedural complications	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Epicondylitis	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Hand fracture	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Metabolism and nutrition disorders	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Hypokalaemia	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Bladder cancer	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=26)	0.002% STN1012600 (Group 2) (N=21)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=23)	Mono-therapy (Group 1 + Group 2) (N=47)	Overall (N=70)
Nervous system disorders	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Sciatica	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Psychiatric disorders	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Bipolar disorder	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.7.1

Confidential

表 2.7.4.7-16. 101260006LT: 男女別の有害事象一覧（女性）

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=23)	0.002% STN1012600 (Group 2) (N=21)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=17)	Mono-therapy (Group 1 + Group 2) (N=44)	Overall (N=61)
Subjects with any AE(s)	18 (78.3%)	18 (85.7%)	16 (94.1%)	36 (81.8%)	52 (85.2%)
Eye disorders	15 (65.2%)	14 (66.7%)	13 (76.5%)	29 (65.9%)	42 (68.9%)
Growth of eyelashes	4 (17.4%)	7 (33.3%)	10 (58.8%)	11 (25.0%)	21 (34.4%)
Conjunctival hyperaemia	5 (21.7%)	7 (33.3%)	5 (29.4%)	12 (27.3%)	17 (27.9%)
Eyelid vellus hair changes	0 (0.0%)	6 (28.6%)	5 (29.4%)	6 (13.6%)	11 (18.0%)
Blepharal pigmentation	1 (4.3%)	4 (19.0%)	1 (5.9%)	5 (11.4%)	6 (9.8%)
Eyelash changes	2 (8.7%)	4 (19.0%)	0 (0.0%)	6 (13.6%)	6 (9.8%)
Eyelash thickening	1 (4.3%)	3 (14.3%)	1 (5.9%)	4 (9.1%)	5 (8.2%)
Punctate keratitis	3 (13.0%)	1 (4.8%)	1 (5.9%)	4 (9.1%)	5 (8.2%)
Conjunctivitis allergic	2 (8.7%)	1 (4.8%)	1 (5.9%)	3 (6.8%)	4 (6.6%)
Dry eye	3 (13.0%)	0 (0.0%)	1 (5.9%)	3 (6.8%)	4 (6.6%)
Eyelash hyperpigmentation	0 (0.0%)	2 (9.5%)	1 (5.9%)	2 (4.5%)	3 (4.9%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	2 (11.8%)	0 (0.0%)	2 (3.3%)
Eye irritation	0 (0.0%)	0 (0.0%)	2 (11.8%)	0 (0.0%)	2 (3.3%)
Asthenopia	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Cataract	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Conjunctival haemorrhage	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Corneal disorder	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Diabetic retinopathy	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Keratitis	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Meibomian gland dysfunction	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Photopsia	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Trichiasis	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Infections and infestations	6 (26.1%)	6 (28.6%)	6 (35.3%)	12 (27.3%)	18 (29.5%)
Nasopharyngitis	2 (8.7%)	2 (9.5%)	1 (5.9%)	4 (9.1%)	5 (8.2%)
COVID-19	2 (8.7%)	0 (0.0%)	1 (5.9%)	2 (4.5%)	3 (4.9%)
Coronavirus infection	0 (0.0%)	2 (9.5%)	1 (5.9%)	2 (4.5%)	3 (4.9%)
Gastroenteritis	0 (0.0%)	2 (9.5%)	1 (5.9%)	2 (4.5%)	3 (4.9%)
Gingivitis	0 (0.0%)	2 (9.5%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Bronchitis	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Dermatophytosis of nail	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Oral candidiasis	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Oral herpes	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Periodontitis	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Pharyngitis	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Pneumonia	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Gastrointestinal disorders	5 (21.7%)	3 (14.3%)	0 (0.0%)	8 (18.2%)	8 (13.1%)
Dental caries	3 (13.0%)	1 (4.8%)	0 (0.0%)	4 (9.1%)	4 (6.6%)
Constipation	2 (8.7%)	0 (0.0%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Abdominal discomfort	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Anal fissure	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Diarrhoea	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Large intestine polyp	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Malocclusion	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Toothache	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Skin and subcutaneous tissue disorders	5 (21.7%)	1 (4.8%)	2 (11.8%)	6 (13.6%)	8 (13.1%)
Eczema	2 (8.7%)	1 (4.8%)	1 (5.9%)	3 (6.8%)	4 (6.6%)
Hypertrichosis	2 (8.7%)	0 (0.0%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Dermal cyst	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=23)	0.002% STN1012600 (Group 2) (N=21)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=17)	Mono-therapy (Group 1 + Group 2) (N=44)	Overall (N=61)
Miliaria	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Investigations	2 (8.7%)	2 (9.5%)	0 (0.0%)	4 (9.1%)	4 (6.6%)
Blood potassium increased	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Glucose urine present	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Intraocular pressure increased	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
White blood cell count increased	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Respiratory, thoracic and mediastinal disorders	3 (13.0%)	1 (4.8%)	0 (0.0%)	4 (9.1%)	4 (6.6%)
Cough	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Oropharyngeal pain	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Rhinitis allergic	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Rhinorrhoea	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
General disorders and administration site conditions	1 (4.3%)	2 (9.5%)	0 (0.0%)	3 (6.8%)	3 (4.9%)
Pyrexia	0 (0.0%)	2 (9.5%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Malaise	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Thirst	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Immune system disorders	2 (8.7%)	1 (4.8%)	0 (0.0%)	3 (6.8%)	3 (4.9%)
Seasonal allergy	1 (4.3%)	1 (4.8%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Allergy to arthropod sting	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Musculoskeletal and connective tissue disorders	1 (4.3%)	2 (9.5%)	0 (0.0%)	3 (6.8%)	3 (4.9%)
Arthralgia	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Back pain	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Periarthritis	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Injury, poisoning and procedural complications	1 (4.3%)	1 (4.8%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Contusion	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Thermal burn	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (4.3%)	1 (4.8%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Cholesteatoma	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Colon cancer	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Nervous system disorders	1 (4.3%)	1 (4.8%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Headache	1 (4.3%)	1 (4.8%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Cardiac disorders	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Supraventricular tachycardia	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Ear and labyrinth disorders	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Vertigo	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Metabolism and nutrition disorders	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Diabetes mellitus	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Renal and urinary disorders	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=23)	0.002% STN1012600 (Group 2) (N=21)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=17)	Mono-therapy (Group 1 + Group 2) (N=44)	Overall (N=61)
Urinary retention	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.7.3

Confidential

表 2.7.4.7-17. 101260006LT: 男女別の副作用一覧（男性）

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=26)	0.002% STN1012600 (Group 2) (N=21)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=23)	Mono-therapy (Group 1 + Group 2) (N=47)	Overall (N=70)
Subjects with any ADR(s)	19 (73.1%)	11 (52.4%)	14 (60.9%)	30 (63.8%)	44 (62.9%)
Eye disorders	19 (73.1%)	11 (52.4%)	14 (60.9%)	30 (63.8%)	44 (62.9%)
Conjunctival hyperaemia	10 (38.5%)	5 (23.8%)	7 (30.4%)	15 (31.9%)	22 (31.4%)
Growth of eyelashes	7 (26.9%)	8 (38.1%)	7 (30.4%)	15 (31.9%)	22 (31.4%)
Eyelash changes	7 (26.9%)	2 (9.5%)	3 (13.0%)	9 (19.1%)	12 (17.1%)
Eyelash thickening	5 (19.2%)	2 (9.5%)	1 (4.3%)	7 (14.9%)	8 (11.4%)
Eyelid vellus hair changes	4 (15.4%)	3 (14.3%)	1 (4.3%)	7 (14.9%)	8 (11.4%)
Blepharal pigmentation	3 (11.5%)	0 (0.0%)	2 (8.7%)	3 (6.4%)	5 (7.1%)
Eyelash hyperpigmentation	1 (3.8%)	1 (4.8%)	1 (4.3%)	2 (4.3%)	3 (4.3%)
Conjunctival irritation	1 (3.8%)	0 (0.0%)	1 (4.3%)	1 (2.1%)	2 (2.9%)
Eye irritation	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Eyelid oedema	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Iris hyperpigmentation	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Keratitis	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Punctate keratitis	0 (0.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.4%)
Trichomegaly	1 (3.8%)	0 (0.0%)	0 (0.0%)	1 (2.1%)	1 (1.4%)
Skin and subcutaneous tissue disorders	1 (3.8%)	1 (4.8%)	0 (0.0%)	2 (4.3%)	2 (2.9%)
Hypertrichosis	1 (3.8%)	1 (4.8%)	0 (0.0%)	2 (4.3%)	2 (2.9%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.7.2

Confidential

表 2.7.4.7-18. 101260006LT: 男女別の副作用一覧（女性）

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=23)	0.002% STN1012600 (Group 2) (N=21)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=17)	Mono-therapy (Group 1 + Group 2) (N=44)	Overall (N=61)
Subjects with any ADR(s)	10 (43.5%)	14 (66.7%)	12 (70.6%)	24 (54.5%)	36 (59.0%)
Eye disorders	9 (39.1%)	14 (66.7%)	12 (70.6%)	23 (52.3%)	35 (57.4%)
Growth of eyelashes	4 (17.4%)	7 (33.3%)	10 (58.8%)	11 (25.0%)	21 (34.4%)
Conjunctival hyperaemia	5 (21.7%)	7 (33.3%)	5 (29.4%)	12 (27.3%)	17 (27.9%)
Eyelid vellus hair changes	0 (0.0%)	6 (28.6%)	5 (29.4%)	6 (13.6%)	11 (18.0%)
Blepharal pigmentation	1 (4.3%)	4 (19.0%)	1 (5.9%)	5 (11.4%)	6 (9.8%)
Eyelash changes	2 (8.7%)	4 (19.0%)	0 (0.0%)	6 (13.6%)	6 (9.8%)
Eyelash thickening	1 (4.3%)	3 (14.3%)	1 (5.9%)	4 (9.1%)	5 (8.2%)
Eyelash hyperpigmentation	0 (0.0%)	2 (9.5%)	1 (5.9%)	2 (4.5%)	3 (4.9%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	2 (11.8%)	0 (0.0%)	2 (3.3%)
Eye irritation	0 (0.0%)	0 (0.0%)	2 (11.8%)	0 (0.0%)	2 (3.3%)
Punctate keratitis	1 (4.3%)	1 (4.8%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Corneal disorder	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Keratitis	0 (0.0%)	0 (0.0%)	1 (5.9%)	0 (0.0%)	1 (1.6%)
Photopsia	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Trichiasis	0 (0.0%)	1 (4.8%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Skin and subcutaneous tissue disorders	2 (8.7%)	0 (0.0%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Hypertrichosis	2 (8.7%)	0 (0.0%)	0 (0.0%)	2 (4.5%)	2 (3.3%)
Investigations	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
White blood cell count increased	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Nervous system disorders	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)
Headache	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	1 (1.6%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.7.4

Confidential

表 2.7.4.7-19. 併合解析: 年齢別の有害事象一覧（65 歳未満）

System organ class Preferred term	Placebo to 0.003% P2* (N=7)	0.005% Latanoprost (N=89)	0.0005% STN1012600 (N=9)	0.001% STN1012600 (N=9)	0.002% STN1012600 (N=90)	0.003% STN1012600 (N=13)	STN1012600 Total** (N=128)
Subjects with any AE(s)	3 (42.9%)	35 (39.3%)	5 (55.6%)	6 (66.7%)	50 (55.6%)	10 (76.9%)	74 (57.8%)
Eye disorders	3 (42.9%)	29 (32.6%)	4 (44.4%)	5 (55.6%)	43 (47.8%)	7 (53.8%)	62 (48.4%)
Conjunctival hyperaemia	1 (14.3%)	15 (16.9%)	2 (22.2%)	1 (11.1%)	37 (41.1%)	3 (23.1%)	44 (34.4%)
Punctate keratitis	0 (0.0%)	6 (6.7%)	0 (0.0%)	2 (22.2%)	4 (4.4%)	1 (7.7%)	7 (5.5%)
Dry eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.4%)	1 (7.7%)	5 (3.9%)
Eye pruritus	0 (0.0%)	2 (2.2%)	1 (11.1%)	1 (11.1%)	2 (2.2%)	1 (7.7%)	5 (3.9%)
Conjunctivitis allergic	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (7.7%)	2 (1.6%)
Foreign body sensation in eyes	0 (0.0%)	1 (1.1%)	1 (11.1%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	2 (1.6%)
Growth of eyelashes	1 (14.3%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.6%)
Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	2 (1.6%)
Abnormal sensation in eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Blepharitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Cataract	1 (14.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Conjunctival oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Eye irritation	0 (0.0%)	4 (4.5%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Eyelid oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Keratitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Scintillating scotoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Vitreous opacities	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Asthenopia	0 (0.0%)	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctival telangiectasia	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pain	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid vellus hair changes	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Lacrimation increased	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Infections and infestations	0 (0.0%)	10 (11.2%)	1 (11.1%)	2 (22.2%)	6 (6.7%)	1 (7.7%)	10 (7.8%)
Nasopharyngitis	0 (0.0%)	1 (1.1%)	1 (11.1%)	1 (11.1%)	3 (3.3%)	1 (7.7%)	6 (4.7%)
COVID-19	0 (0.0%)	5 (5.6%)	0 (0.0%)	0 (0.0%)	3 (3.3%)	0 (0.0%)	3 (2.3%)
Influenza	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Corneal infection	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Confidential

System organ class Preferred term	Placebo to 0.003% P2* (N=7)	0.005% Latanoprost (N=89)	0.0005% STN1012600 (N=9)	0.001% STN1012600 (N=9)	0.002% STN1012600 (N=90)	0.003% STN1012600 (N=13)	STN1012600 Total** (N=128)
Hordeolum	0 (0.0%)	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Post-acute COVID-19 syndrome	0 (0.0%)	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Rhinitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Investigations	1 (14.3%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	3 (2.3%)
Blood triglycerides increased	0 (0.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Eosinophil count increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Hepatic enzyme increased	1 (14.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
General disorders and administration site conditions	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	2 (1.6%)
Pyrexia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Vaccination site pain	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Nervous system disorders	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (7.7%)	2 (1.6%)
Cervicobrachial syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Headache	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Skin and subcutaneous tissue disorders	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (7.7%)	2 (1.6%)
Hypertrichosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Rash	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Ear and labyrinth disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Vertigo	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Gastrointestinal disorders	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Nausea	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Abdominal pain upper	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Musculoskeletal and connective tissue disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Back pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Renal and urinary disorders	1 (14.3%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Hypertonic bladder	1 (14.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Pollakiuria	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

System organ class Preferred term	Placebo to 0.003% P2* (N=7)	0.005% Latanoprost (N=89)	0.0005% STN1012600 (N=9)	0.001% STN1012600 (N=9)	0.002% STN1012600 (N=90)	0.003% STN1012600 (N=13)	STN1012600 Total** (N=128)
Respiratory, thoracic and mediastinal disorders	0 (0.0%)	2 (2.2%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Oropharyngeal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Cough	0 (0.0%)	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Injury, poisoning and procedural complications	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Epicondylitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

表 2.7.4.7-20. 併合解析: 年齢別の有害事象一覧（65 歳以上）

System organ class Preferred term	Placebo to 0.003% P2* (N=4)	0.005% Latanoprost (N=95)	0.0005% STN1012600 (N=11)	0.001% STN1012600 (N=11)	0.002% STN1012600 (N=93)	0.003% STN1012600 (N=8)	STN1012600 Total** (N=127)
Subjects with any AE(s)	0 (0.0%)	42 (44.2%)	5 (45.5%)	2 (18.2%)	42 (45.2%)	5 (62.5%)	54 (42.5%)
Eye disorders	0 (0.0%)	29 (30.5%)	3 (27.3%)	2 (18.2%)	30 (32.3%)	4 (50.0%)	39 (30.7%)
Conjunctival hyperaemia	0 (0.0%)	10 (10.5%)	1 (9.1%)	1 (9.1%)	19 (20.4%)	1 (12.5%)	22 (17.3%)
Eye pruritus	0 (0.0%)	2 (2.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	2 (25.0%)	4 (3.1%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.2%)	0 (0.0%)	3 (2.4%)
Eye irritation	0 (0.0%)	4 (4.2%)	0 (0.0%)	0 (0.0%)	3 (3.2%)	0 (0.0%)	3 (2.4%)
Conjunctival haemorrhage	0 (0.0%)	1 (1.1%)	1 (9.1%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	2 (1.6%)
Eye discharge	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	2 (1.6%)
Foreign body sensation in eyes	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (12.5%)	2 (1.6%)
Growth of eyelashes	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (9.1%)	1 (1.1%)	0 (0.0%)	2 (1.6%)
Punctate keratitis	0 (0.0%)	6 (6.3%)	1 (9.1%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	2 (1.6%)
Abnormal sensation in eye	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Chalazion	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Conjunctival cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Conjunctival oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Corneal hypertrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)
Eyelids pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Keratitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Posterior capsule opacification	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Vitreous detachment	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Vitreous floaters	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Blepharitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blepharitis allergic	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blepharospasm	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctivitis allergic	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dry eye	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pain	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Infections and infestations	0 (0.0%)	4 (4.2%)	2 (18.2%)	0 (0.0%)	6 (6.5%)	1 (12.5%)	9 (7.1%)
Nasopharyngitis	0 (0.0%)	1 (1.1%)	2 (18.2%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	4 (3.1%)
COVID-19	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	2 (1.6%)
Bronchitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Cystitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)
Conjunctivitis bacterial	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Coronavirus infection	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Groin abscess	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

System organ class Preferred term	Placebo to 0.003% P2* (N=4)	0.005% Latanoprost (N=95)	0.0005% STN1012600 (N=11)	0.001% STN1012600 (N=11)	0.002% STN1012600 (N=93)	0.003% STN1012600 (N=8)	STN1012600 Total** (N=127)
Influenza	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Musculoskeletal and connective tissue disorders	0 (0.0%)	2 (2.1%)	0 (0.0%)	0 (0.0%)	3 (3.2%)	0 (0.0%)	3 (2.4%)
Back pain	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Pain in extremity	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Spinal stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Arthralgia	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Nervous system disorders	0 (0.0%)	2 (2.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	1 (12.5%)	3 (2.4%)
Headache	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	2 (1.6%)
Parkinson's disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)
Dizziness	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Injury, poisoning and procedural complications	0 (0.0%)	4 (4.2%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	1 (12.5%)	2 (1.6%)
Radius fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)
Tooth fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Contusion	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Fall	0 (0.0%)	2 (2.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Ligament sprain	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Spinal compression fracture	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin and subcutaneous tissue disorders	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	2 (1.6%)
Eczema	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Urticaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Gastrointestinal disorders	0 (0.0%)	2 (2.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Abdominal pain upper	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Nausea	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pancreatitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
General disorders and administration site conditions	0 (0.0%)	2 (2.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Peripheral swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Malaise	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pyrexia	0 (0.0%)	2 (2.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Investigations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Blood potassium increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Metabolism and nutrition disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)
Decreased appetite	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)

System organ class Preferred term	Placebo to 0.003% P2* (N=4)	0.005% Latanoprost (N=95)	0.0005% STN1012600 (N=11)	0.001% STN1012600 (N=11)	0.002% STN1012600 (N=93)	0.003% STN1012600 (N=8)	STN1012600 Total** (N=127)
Vascular disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)
Hypotension	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)
Ear and labyrinth disorders	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sudden hearing loss	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Breast cancer	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Product issues	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Device physical property issue	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

表 2.7.4.7-21. 併合解析: 年齢別の副作用一覧（65 歳未満）

System organ class Preferred term	Placebo to 0.003% P2* (N=7)	0.005% Latanoprost (N=89)	0.0005% STN1012600 (N=9)	0.001% STN1012600 (N=9)	0.002% STN1012600 (N=90)	0.003% STN1012600 (N=13)	STN1012600 Total** (N=128)
Subjects with any ADR(s)	2 (28.6%)	20 (22.5%)	3 (33.3%)	3 (33.3%)	38 (42.2%)	4 (30.8%)	50 (39.1%)
Eye disorders	2 (28.6%)	20 (22.5%)	3 (33.3%)	3 (33.3%)	38 (42.2%)	3 (23.1%)	49 (38.3%)
Conjunctival hyperaemia	1 (14.3%)	10 (11.2%)	2 (22.2%)	1 (11.1%)	35 (38.9%)	2 (15.4%)	41 (32.0%)
Dry eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.4%)	1 (7.7%)	5 (3.9%)
Eye pruritus	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (11.1%)	1 (1.1%)	1 (7.7%)	4 (3.1%)
Growth of eyelashes	1 (14.3%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.6%)
Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	2 (1.6%)
Punctate keratitis	0 (0.0%)	3 (3.4%)	0 (0.0%)	1 (11.1%)	1 (1.1%)	0 (0.0%)	2 (1.6%)
Abnormal sensation in eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Conjunctival oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Conjunctivitis allergic	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Eye irritation	0 (0.0%)	4 (4.5%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Foreign body sensation in eyes	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Blepharitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjunctival telangiectasia	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eye pain	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Eyelid vellus hair changes	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Lacrimation increased	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Skin and subcutaneous tissue disorders	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Hypertrichosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	1 (0.8%)
Infections and infestations	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Corneal infection	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

表 2.7.4.7-22. 併合解析: 年齢別の副作用一覧（65 歳以上）

System organ class Preferred term	Placebo to 0.003% P2* (N=4)	0.005% Latanoprost (N=95)	0.0005% STN1012600 (N=11)	0.001% STN1012600 (N=11)	0.002% STN1012600 (N=93)	0.003% STN1012600 (N=8)	STN1012600 Total** (N=127)
Subjects with any ADR(s)	0 (0.0%)	18 (18.9%)	2 (18.2%)	2 (18.2%)	25 (26.9%)	2 (25.0%)	31 (24.4%)
Eye disorders	0 (0.0%)	18 (18.9%)	2 (18.2%)	2 (18.2%)	24 (25.8%)	2 (25.0%)	30 (23.6%)
Conjunctival hyperaemia	0 (0.0%)	7 (7.4%)	1 (9.1%)	1 (9.1%)	17 (18.3%)	1 (12.5%)	20 (15.7%)
Eye pruritus	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	2 (2.2%)	2 (25.0%)	4 (3.1%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.2%)	0 (0.0%)	3 (2.4%)
Eye irritation	0 (0.0%)	4 (4.2%)	0 (0.0%)	0 (0.0%)	3 (3.2%)	0 (0.0%)	3 (2.4%)
Growth of eyelashes	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (9.1%)	1 (1.1%)	0 (0.0%)	2 (1.6%)
Punctate keratitis	0 (0.0%)	4 (4.2%)	1 (9.1%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	2 (1.6%)
Abnormal sensation in eye	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Conjunctival cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Conjunctival oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Foreign body sensation in eyes	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (0.8%)
Blepharitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dry eye	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Keratitis	0 (0.0%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Infections and infestations	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)
Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.1%)	0 (0.0%)	1 (0.8%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

* Placebo to 0.003% arm received placebo by Week 6, then 0.003% STN1012600 from Week 6 to Month 3. "Placebo to 0.003% P2" shows AEs reported after the switch.

** STN1012600 Total summarizes columns "0.0005%", "0.001%", "0.002%", "0.003%" and "Placebo to 0.003% P2".

Confidential

表 2.7.4.7-23. 101260006LT: 年齢別の有害事象一覧（65 歳未満）

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=20)	0.002% STN1012600 (Group 2) (N=19)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=18)	Mono-therapy (Group 1 + Group 2) (N=39)	Overall (N=57)
Subjects with any AE(s)	18 (90.0%)	12 (63.2%)	18 (100.0%)	30 (76.9%)	48 (84.2%)
Eye disorders	18 (90.0%)	11 (57.9%)	16 (88.9%)	29 (74.4%)	45 (78.9%)
Conjunctival hyperaemia	9 (45.0%)	4 (21.1%)	6 (33.3%)	13 (33.3%)	19 (33.3%)
Growth of eyelashes	4 (20.0%)	6 (31.6%)	9 (50.0%)	10 (25.6%)	19 (33.3%)
Eyelash changes	3 (15.0%)	4 (21.1%)	3 (16.7%)	7 (17.9%)	10 (17.5%)
Eyelash thickening	3 (15.0%)	3 (15.8%)	1 (5.6%)	6 (15.4%)	7 (12.3%)
Conjunctivitis allergic	2 (10.0%)	1 (5.3%)	2 (11.1%)	3 (7.7%)	5 (8.8%)
Eyelid vellus hair changes	0 (0.0%)	3 (15.8%)	2 (11.1%)	3 (7.7%)	5 (8.8%)
Blepharal pigmentation	1 (5.0%)	1 (5.3%)	2 (11.1%)	2 (5.1%)	4 (7.0%)
Punctate keratitis	3 (15.0%)	1 (5.3%)	0 (0.0%)	4 (10.3%)	4 (7.0%)
Eye irritation	0 (0.0%)	0 (0.0%)	3 (16.7%)	0 (0.0%)	3 (5.3%)
Eyelash hyperpigmentation	0 (0.0%)	1 (5.3%)	1 (5.6%)	1 (2.6%)	2 (3.5%)
Keratitis	1 (5.0%)	0 (0.0%)	1 (5.6%)	1 (2.6%)	2 (3.5%)
Asthenopia	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Cataract	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (1.8%)
Corneal erosion	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Dry eye	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (1.8%)
Eyelid oedema	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Meibomian gland Dysfunction	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Trichomegaly	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Infections and infestations	7 (35.0%)	2 (10.5%)	5 (27.8%)	9 (23.1%)	14 (24.6%)
Nasopharyngitis	4 (20.0%)	1 (5.3%)	0 (0.0%)	5 (12.8%)	5 (8.8%)
COVID-19	1 (5.0%)	0 (0.0%)	1 (5.6%)	1 (2.6%)	2 (3.5%)
Coronavirus infection	0 (0.0%)	1 (5.3%)	1 (5.6%)	1 (2.6%)	2 (3.5%)
Gastroenteritis	0 (0.0%)	1 (5.3%)	1 (5.6%)	1 (2.6%)	2 (3.5%)
Dermatophytosis of nail	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (1.8%)
Influenza	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Laryngopharyngitis	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Paronychia	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (1.8%)
Pharyngitis	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (1.8%)
Gastrointestinal disorders	3 (15.0%)	2 (10.5%)	0 (0.0%)	5 (12.8%)	5 (8.8%)
Dental caries	2 (10.0%)	1 (5.3%)	0 (0.0%)	3 (7.7%)	3 (5.3%)
Abdominal discomfort	1 (5.0%)	1 (5.3%)	0 (0.0%)	2 (5.1%)	2 (3.5%)
Constipation	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Skin and subcutaneous tissue disorders	2 (10.0%)	1 (5.3%)	2 (11.1%)	3 (7.7%)	5 (8.8%)
Acne	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Dermal cyst	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Eczema	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (1.8%)
Hypertrichosis	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Miliaria	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (1.8%)
Immune system disorders	2 (10.0%)	1 (5.3%)	1 (5.6%)	3 (7.7%)	4 (7.0%)
Seasonal allergy	2 (10.0%)	1 (5.3%)	1 (5.6%)	3 (7.7%)	4 (7.0%)
Respiratory, thoracic and mediastinal disorders	2 (10.0%)	2 (10.5%)	0 (0.0%)	4 (10.3%)	4 (7.0%)
Oropharyngeal pain	1 (5.0%)	2 (10.5%)	0 (0.0%)	3 (7.7%)	3 (5.3%)
Rhinitis allergic	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=20)	0.002% STN1012600 (Group 2) (N=19)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=18)	Mono-therapy (Group 1 + Group 2) (N=39)	Overall (N=57)
General disorders and administration site conditions	1 (5.0%)	2 (10.5%)	0 (0.0%)	3 (7.7%)	3 (5.3%)
Pyrexia	0 (0.0%)	2 (10.5%)	0 (0.0%)	2 (5.1%)	2 (3.5%)
Malaise	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Thirst	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Investigations	2 (10.0%)	1 (5.3%)	0 (0.0%)	3 (7.7%)	3 (5.3%)
Blood triglycerides increased	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Blood uric acid increased	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Glucose urine present	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
White blood cell count Increased	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Cardiac disorders	1 (5.0%)	1 (5.3%)	0 (0.0%)	2 (5.1%)	2 (3.5%)
Angina unstable	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Supraventricular tachycardia	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Injury, poisoning and procedural complications	1 (5.0%)	1 (5.3%)	0 (0.0%)	2 (5.1%)	2 (3.5%)
Epicondylitis	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Hand fracture	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Thermal burn	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Musculoskeletal and connective tissue disorders	1 (5.0%)	1 (5.3%)	0 (0.0%)	2 (5.1%)	2 (3.5%)
Back pain	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Periarthritis	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Nervous system disorders	1 (5.0%)	1 (5.3%)	0 (0.0%)	2 (5.1%)	2 (3.5%)
Headache	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Sciatica	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Hepatobiliary disorders	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Hepatic function abnormal	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Cholesteatoma	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Psychiatric disorders	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Bipolar disorder	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Renal and urinary disorders	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Urinary retention	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.7.5

Confidential

表 2.7.4.7-24. 101260006LT: 年齢別の有害事象一覧（65 歳以上）

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=29)	0.002% STN1012600 (Group 2) (N=23)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=22)	Mono-therapy (Group 1 + Group 2) (N=52)	Overall (N=74)
Subjects with any AE(s)	25 (86.2%)	20 (87.0%)	20 (90.9%)	45 (86.5%)	65 (87.8%)
Eye disorders	17 (58.6%)	15 (65.2%)	12 (54.5%)	32 (61.5%)	44 (59.5%)
Growth of eyelashes	7 (24.1%)	9 (39.1%)	8 (36.4%)	16 (30.8%)	24 (32.4%)
Conjunctival hyperaemia	6 (20.7%)	8 (34.8%)	7 (31.8%)	14 (26.9%)	21 (28.4%)
Eyelid vellus hair changes	4 (13.8%)	6 (26.1%)	4 (18.2%)	10 (19.2%)	14 (18.9%)
Eyelash changes	6 (20.7%)	2 (8.7%)	0 (0.0%)	8 (15.4%)	8 (10.8%)
Blepharal pigmentation	3 (10.3%)	3 (13.0%)	1 (4.5%)	6 (11.5%)	7 (9.5%)
Eyelash thickening	3 (10.3%)	2 (8.7%)	1 (4.5%)	5 (9.6%)	6 (8.1%)
Eyelash hyperpigmentation	1 (3.4%)	2 (8.7%)	1 (4.5%)	3 (5.8%)	4 (5.4%)
Dry eye	3 (10.3%)	0 (0.0%)	0 (0.0%)	3 (5.8%)	3 (4.1%)
Punctate keratitis	1 (3.4%)	0 (0.0%)	2 (9.1%)	1 (1.9%)	3 (4.1%)
Conjunctival haemorrhage	1 (3.4%)	1 (4.3%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Conjunctival irritation	1 (3.4%)	0 (0.0%)	1 (4.5%)	1 (1.9%)	2 (2.7%)
Conjunctivitis allergic	1 (3.4%)	1 (4.3%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	2 (9.1%)	0 (0.0%)	2 (2.7%)
Cataract	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Conjunctival deposit	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Corneal disorder	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Diabetic retinopathy	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Eye pruritus	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Iris hyperpigmentation	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Meibomian gland Dysfunction	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Photopsia	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Pingueculitis	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Trichiasis	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Infections and infestations	8 (27.6%)	7 (30.4%)	8 (36.4%)	15 (28.8%)	23 (31.1%)
Nasopharyngitis	3 (10.3%)	1 (4.3%)	1 (4.5%)	4 (7.7%)	5 (6.8%)
Coronavirus infection	2 (6.9%)	1 (4.3%)	1 (4.5%)	3 (5.8%)	4 (5.4%)
Gastroenteritis	0 (0.0%)	1 (4.3%)	2 (9.1%)	1 (1.9%)	3 (4.1%)
Gingivitis	0 (0.0%)	2 (8.7%)	1 (4.5%)	2 (3.8%)	3 (4.1%)
COVID-19	1 (3.4%)	0 (0.0%)	1 (4.5%)	1 (1.9%)	2 (2.7%)
Periodontitis	2 (6.9%)	0 (0.0%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Bronchitis	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Cellulitis	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Conjunctivitis	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Furuncle	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Herpes zoster	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Oral candidiasis	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Oral herpes	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Pharyngitis	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Pneumonia	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Wound infection bacterial	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Gastrointestinal disorders	7 (24.1%)	2 (8.7%)	1 (4.5%)	9 (17.3%)	10 (13.5%)
Large intestine polyp	1 (3.4%)	1 (4.3%)	1 (4.5%)	2 (3.8%)	3 (4.1%)
Abdominal discomfort	1 (3.4%)	1 (4.3%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Diarrhoea	2 (6.9%)	0 (0.0%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Anal fissure	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Anal pruritus	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Constipation	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Dental caries	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Malocclusion	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=29)	0.002% STN1012600 (Group 2) (N=23)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=22)	Mono-therapy (Group 1 + Group 2) (N=52)	Overall (N=74)
Nausea	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Toothache	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Skin and subcutaneous tissue disorders	4 (13.8%)	2 (8.7%)	3 (13.6%)	6 (11.5%)	9 (12.2%)
Eczema	2 (6.9%)	1 (4.3%)	2 (9.1%)	3 (5.8%)	5 (6.8%)
Hypertrichosis	2 (6.9%)	1 (4.3%)	0 (0.0%)	3 (5.8%)	3 (4.1%)
Cold urticaria	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Investigations	2 (6.9%)	2 (8.7%)	1 (4.5%)	4 (7.7%)	5 (6.8%)
Intraocular pressure increased	1 (3.4%)	1 (4.3%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Blood potassium increased	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Gamma-glutamyltransferase increased	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Glucose urine present	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Musculoskeletal and connective tissue disorders	2 (6.9%)	2 (8.7%)	1 (4.5%)	4 (7.7%)	5 (6.8%)
Arthralgia	1 (3.4%)	1 (4.3%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Back pain	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Lumbar spinal stenosis	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Spondylolisthesis	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Respiratory, thoracic and mediastinal disorders	5 (17.2%)	0 (0.0%)	0 (0.0%)	5 (9.6%)	5 (6.8%)
Cough	2 (6.9%)	0 (0.0%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Epistaxis	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Rhinitis allergic	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Rhinorrhoea	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
General disorders and administration site conditions	2 (6.9%)	0 (0.0%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Injection site pain	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Pyrexia	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Metabolism and nutrition disorders	1 (3.4%)	0 (0.0%)	1 (4.5%)	1 (1.9%)	2 (2.7%)
Diabetes mellitus	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Hypokalaemia	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0%)	1 (4.3%)	1 (4.5%)	1 (1.9%)	2 (2.7%)
Bladder cancer	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Colon cancer	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Vascular disorders	1 (3.4%)	1 (4.3%)	0 (0.0%)	2 (3.8%)	2 (2.7%)
Aneurysm	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Hypertension	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Ear and labyrinth disorders	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Vertigo	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Hepatobiliary disorders	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Hepatic function abnormal	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Immune system disorders	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=29)	0.002% STN1012600 (Group 2) (N=23)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=22)	Mono-therapy (Group 1 + Group 2) (N=52)	Overall (N=74)
Allergy to arthropod sting	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Injury, poisoning and procedural complications	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Contusion	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Nervous system disorders	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Headache	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.7.7

Confidential

表 2.7.4.7-25. 101260006LT: 年齢別の副作用一覧（65 歳未満）

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=20)	0.002% STN1012600 (Group 2) (N=19)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=18)	Mono-therapy (Group 1 + Group 2) (N=39)	Overall (N=57)
Subjects with any ADR(s)	15 (75.0%)	10 (52.6%)	15 (83.3%)	25 (64.1%)	40 (70.2%)
Eye disorders	14 (70.0%)	10 (52.6%)	15 (83.3%)	24 (61.5%)	39 (68.4%)
Conjunctival hyperaemia	9 (45.0%)	4 (21.1%)	6 (33.3%)	13 (33.3%)	19 (33.3%)
Growth of eyelashes	4 (20.0%)	6 (31.6%)	9 (50.0%)	10 (25.6%)	19 (33.3%)
Eyelash changes	3 (15.0%)	4 (21.1%)	3 (16.7%)	7 (17.9%)	10 (17.5%)
Eyelash thickening	3 (15.0%)	3 (15.8%)	1 (5.6%)	6 (15.4%)	7 (12.3%)
Eyelid vellus hair changes	0 (0.0%)	3 (15.8%)	2 (11.1%)	3 (7.7%)	5 (8.8%)
Blepharal pigmentation	1 (5.0%)	1 (5.3%)	2 (11.1%)	2 (5.1%)	4 (7.0%)
Eye irritation	0 (0.0%)	0 (0.0%)	3 (16.7%)	0 (0.0%)	3 (5.3%)
Eyelash hyperpigmentation	0 (0.0%)	1 (5.3%)	1 (5.6%)	1 (2.6%)	2 (3.5%)
Keratitis	1 (5.0%)	0 (0.0%)	1 (5.6%)	1 (2.6%)	2 (3.5%)
Punctate keratitis	1 (5.0%)	1 (5.3%)	0 (0.0%)	2 (5.1%)	2 (3.5%)
Eyelid oedema	0 (0.0%)	1 (5.3%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Trichomegaly	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Investigations	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
White blood cell count increased	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Skin and subcutaneous tissue disorders	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)
Hypertrichosis	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (2.6%)	1 (1.8%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.7.6

Confidential

表 2.7.4.7-26. 101260006LT: 年齢別の副作用一覧（65 歳以上）

System organ class Preferred term	0.002% STN1012600 (Group 1) (N=29)	0.002% STN1012600 (Group 2) (N=23)	0.002% STN1012600 + 0.5% Timolol (Group 3) (N=22)	Mono-therapy (Group 1 + Group 2) (N=52)	Overall (N=74)
Subjects with any ADR(s)	14 (48.3%)	15 (65.2%)	11 (50.0%)	29 (55.8%)	40 (54.1%)
Eye disorders	14 (48.3%)	15 (65.2%)	11 (50.0%)	29 (55.8%)	40 (54.1%)
Growth of eyelashes	7 (24.1%)	9 (39.1%)	8 (36.4%)	16 (30.8%)	24 (32.4%)
Conjunctival hyperaemia	6 (20.7%)	8 (34.8%)	6 (27.3%)	14 (26.9%)	20 (27.0%)
Eyelid vellus hair changes	4 (13.8%)	6 (26.1%)	4 (18.2%)	10 (19.2%)	14 (18.9%)
Eyelash changes	6 (20.7%)	2 (8.7%)	0 (0.0%)	8 (15.4%)	8 (10.8%)
Blepharal pigmentation	3 (10.3%)	3 (13.0%)	1 (4.5%)	6 (11.5%)	7 (9.5%)
Eyelash thickening	3 (10.3%)	2 (8.7%)	1 (4.5%)	5 (9.6%)	6 (8.1%)
Eyelash hyperpigmentation	1 (3.4%)	2 (8.7%)	1 (4.5%)	3 (5.8%)	4 (5.4%)
Conjunctival irritation	1 (3.4%)	0 (0.0%)	1 (4.5%)	1 (1.9%)	2 (2.7%)
Erythema of eyelid	0 (0.0%)	0 (0.0%)	2 (9.1%)	0 (0.0%)	2 (2.7%)
Corneal disorder	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Iris hyperpigmentation	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Photopsia	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Punctate keratitis	0 (0.0%)	0 (0.0%)	1 (4.5%)	0 (0.0%)	1 (1.4%)
Trichiasis	0 (0.0%)	1 (4.3%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Skin and subcutaneous tissue disorders	2 (6.9%)	1 (4.3%)	0 (0.0%)	3 (5.8%)	3 (4.1%)
Hypertrichosis	2 (6.9%)	1 (4.3%)	0 (0.0%)	3 (5.8%)	3 (4.1%)
Nervous system disorders	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)
Headache	1 (3.4%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.4%)

Any subject who experienced multiple events within a system organ class or preferred term was counted only once for that system organ class or preferred term.

Subjects are classified by actual treatment received.

Cross Reference: 添付資料 5.3.5.2-1 Table 14.3.1.7.8

Confidential

目次

2.7.5 参考文献.....2

Confidential

2.7.5 参考文献

(1) Hammid A, Fallon JK, Lassila T, Vieiro P, Balla A, Gonzalez F, et al. Activity and expression of carboxylesterases and arylacetamide deacetylase in human ocular tissues. Drug Met Dispos. 2022;50:1483-1492.

(2) Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47:S6-S12.

(3) Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: From molecular structure to function. Drug Met Dispos. 2002;30:488-93.

(4) Dahlin A, Geier E, Stocker SL, Cropp CD, Grigorenko E, Bloomer M, et al. Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye Substructures. Mol Pharm. 2013;10:650-663.

(5) 参天製薬株式会社. エイベリス®点眼液 0.002%/ エイベリス®ミニ点眼液 0.002% 医薬品インタビューフォーム. 2022 年 5 月改訂（第 7 版）

(6) 塩川美菜子、井上賢治、富田剛司. 多施設における緑内障実態調査 2012 年版 －薬物治療－. あたらしい眼科. 2013; 30(6): 851-6.

(7) Weinreb RN, Kaufman PL. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2009;50(4):1497-1505.